index	id1	id2	is_in_same_sent	min_sents_window	sentence	in_neighbors	label
34153873	3630	D003920	False	1	The KAG motif of HLA-DRB1 ( beta71 , beta74 , beta86 ) predicts seroconversion and development of type 1 @DiseaseTgt$ . BACKGROUND : HLA-DR4 , a common antigen of HLA-DRB1 , has multiple subtypes that are strongly associated with risk of type 1 @DiseaseTgt$ ( T1D ) ; however , some are risk neutral or resistant . The pathobiological mechanism of HLA-DR4 subtypes remains to be elucidated . METHODS : We used a population-based case-control study of T1D ( 962 patients and 636 controls ) to decipher genetic associations of HLA-DR4 subtypes and specific residues with susceptibility to T1D . Using a birth cohort of 7865 children with periodically measured islet autoantibodies ( GADA , IAA or IA-2A ) , we proposed to validate discovered genetic associations with a totally different study design and time-to-seroconversions prior to clinical onset of T1D . A novel analytic strategy hierarchically organized the HLA-DRB1 alleles by sequence similarity and identified critical amino acid residues by minimizing local genomic architecture and higher-order interactions . FINDINGS : Three amino acid residues of HLA-DRB1 ( beta71 , beta74 , beta86 ) were found to be predictive of T1D risk in the population-based study . The " KAG " motif , corresponding to HLA-DRB1x04:01 , was most strongly associated with T1D risk ( [O]dds [R]atio=3.64 , p = 3.19 x 10 - 64 ) . Three less frequent motifs ( " EAV " , OR = 2.55 , p = 0.025 ; " RAG " , OR = 1.93 , p = 0.043 ; and " RAV " , OR = 1.56 , p = 0.003 ) were associated with T1D risk , while two motifs ( " REG " and " REV " ) were equally protective ( OR = 0.11 , p = 4.23 x 10 - 4 ) . In an independent birth cohort of HLA-DR3 and HLA-DR4 subjects , those having the " KAG " motif had increased risk for time-to-seroconversion ( Hazard Ratio = 1.74 , p = 6.51 x 10 - 14 ) after adjusting potential confounders . INTERPRETATIONS : DNA sequence variation in HLA-DRB1 at positions beta71 , beta74 , and beta86 are non-conservative ( beta74 A E , beta71 E vs K vs R and beta86 G vs V ) . They result in substantial differences in peptide antigen anchor pocket preferences at p1 , p4 and potentially neighboring regions such as pocket p7 . Differential peptide antigen binding is likely to be affected . These sequence substitutions may account for most of the HLA-DR4 contribution to T1D risk as illustrated in two HLA-peptide model complexes of the T1D autoantigens @GeneSrc$ and GAD65 . FUNDING : National Institute of @DiseaseTgt$ and Digestive and Kidney Diseases and the Swedish Child @DiseaseTgt$ Foundation and the Swedish Research Council .	2 2 12 4 2 6 2 6 6 6 6 6 12 12 13 13 19 19 19 13 12 21 21 31 23 27 27 23 29 27 23 21 33 31 37 37 37 33 39 37 43 43 43 39 45 43 45 31 52 52 52 52 53 31 53 53 21 59 59 63 62 62 59 63 66 66 63 63 71 68 71 71 75 75 75 71 77 75 80 80 77 80 83 80 80 86 71 88 86 91 91 88 91 94 91 96 88 98 96 71 121 103 103 100 106 106 103 111 109 111 111 100 113 111 113 113 113 113 113 121 121 121 123 121 123 126 124 132 132 130 132 132 126 132 123 134 138 138 123 140 138 121 145 145 145 147 147 147 150 150 147 153 153 147 147 147 159 159 159 155 161 155 164 164 161 164 164 164 147 185 169 174 174 174 185 176 174 178 176 178 178 178 178 178 185 185 188 188 185 191 191 188 195 195 195 188 185 201 201 201 201 210 201 201 205 203 201 210 209 210 210 213 213 210 219 219 219 219 219 213 221 219 224 224 219 219 210 230 229 230 237 233 233 230 233 233 230 237 237 241 241 237 241 241 245 241 245 245 241 241 249 241 253 241 253 241 241 258 241 258 241 237 237 262 266 266 237 266 266 270 237 273 273 270 237 289 277 289 280 280 277 280 280 284 280 284 280 289 289 237 292 292 289 292 292 296 292 298 296 301 301 296 292 237 308 308 308 308 323 310 308 310 310 310 323 323 315 321 321 321 321 316 323 323 323 326 324 334 329 334 329 330 334 334 326 336 334 339 339 334 334 342 323 344 342 323 346 346 350 350 362 352 350 354 350 354 355 354 354 354 354 362 346 366 366 366 346 366 369 366 369 369 371 371 373 373 366 376 366 366 346 382 382 385 385 382 391 391 391 391 391 385 393 391 393 393 393 398 393 393 403 400 403 399 382 408 408 408 410 410 410 413 413 410 410 417 417 419 419 419 421 419 425 425 425 421 428 428 425 430 419 435 435 435 435 430 438 438 435 438 439 440 440 419 444 444 447 444 449 447 449 447 451 454 451 454 460 458 460 460 454 460 465 465 465 460 444	0
34153873	2572	D003920	False	1	The KAG motif of HLA-DRB1 ( beta71 , beta74 , beta86 ) predicts seroconversion and development of type 1 @DiseaseTgt$ . BACKGROUND : HLA-DR4 , a common antigen of HLA-DRB1 , has multiple subtypes that are strongly associated with risk of type 1 @DiseaseTgt$ ( T1D ) ; however , some are risk neutral or resistant . The pathobiological mechanism of HLA-DR4 subtypes remains to be elucidated . METHODS : We used a population-based case-control study of T1D ( 962 patients and 636 controls ) to decipher genetic associations of HLA-DR4 subtypes and specific residues with susceptibility to T1D . Using a birth cohort of 7865 children with periodically measured islet autoantibodies ( GADA , IAA or IA-2A ) , we proposed to validate discovered genetic associations with a totally different study design and time-to-seroconversions prior to clinical onset of T1D . A novel analytic strategy hierarchically organized the HLA-DRB1 alleles by sequence similarity and identified critical amino acid residues by minimizing local genomic architecture and higher-order interactions . FINDINGS : Three amino acid residues of HLA-DRB1 ( beta71 , beta74 , beta86 ) were found to be predictive of T1D risk in the population-based study . The " KAG " motif , corresponding to HLA-DRB1x04:01 , was most strongly associated with T1D risk ( [O]dds [R]atio=3.64 , p = 3.19 x 10 - 64 ) . Three less frequent motifs ( " EAV " , OR = 2.55 , p = 0.025 ; " RAG " , OR = 1.93 , p = 0.043 ; and " RAV " , OR = 1.56 , p = 0.003 ) were associated with T1D risk , while two motifs ( " REG " and " REV " ) were equally protective ( OR = 0.11 , p = 4.23 x 10 - 4 ) . In an independent birth cohort of HLA-DR3 and HLA-DR4 subjects , those having the " KAG " motif had increased risk for time-to-seroconversion ( Hazard Ratio = 1.74 , p = 6.51 x 10 - 14 ) after adjusting potential confounders . INTERPRETATIONS : DNA sequence variation in HLA-DRB1 at positions beta71 , beta74 , and beta86 are non-conservative ( beta74 A E , beta71 E vs K vs R and beta86 G vs V ) . They result in substantial differences in peptide antigen anchor pocket preferences at p1 , p4 and potentially neighboring regions such as pocket p7 . Differential peptide antigen binding is likely to be affected . These sequence substitutions may account for most of the HLA-DR4 contribution to T1D risk as illustrated in two HLA-peptide model complexes of the T1D autoantigens preproinsulin and @GeneSrc$ . FUNDING : National Institute of @DiseaseTgt$ and Digestive and Kidney Diseases and the Swedish Child @DiseaseTgt$ Foundation and the Swedish Research Council .	2 2 12 4 2 6 2 6 6 6 6 6 12 12 13 13 19 19 19 13 12 21 21 31 23 27 27 23 29 27 23 21 33 31 37 37 37 33 39 37 43 43 43 39 45 43 45 31 52 52 52 52 53 31 53 53 21 59 59 63 62 62 59 63 66 66 63 63 71 68 71 71 75 75 75 71 77 75 80 80 77 80 83 80 80 86 71 88 86 91 91 88 91 94 91 96 88 98 96 71 121 103 103 100 106 106 103 111 109 111 111 100 113 111 113 113 113 113 113 121 121 121 123 121 123 126 124 132 132 130 132 132 126 132 123 134 138 138 123 140 138 121 145 145 145 147 147 147 150 150 147 153 153 147 147 147 159 159 159 155 161 155 164 164 161 164 164 164 147 185 169 174 174 174 185 176 174 178 176 178 178 178 178 178 185 185 188 188 185 191 191 188 195 195 195 188 185 201 201 201 201 210 201 201 205 203 201 210 209 210 210 213 213 210 219 219 219 219 219 213 221 219 224 224 219 219 210 230 229 230 237 233 233 230 233 233 230 237 237 241 241 237 241 241 245 241 245 245 241 241 249 241 253 241 253 241 241 258 241 258 241 237 237 262 266 266 237 266 266 270 237 273 273 270 237 289 277 289 280 280 277 280 280 284 280 284 280 289 289 237 292 292 289 292 292 296 292 298 296 301 301 296 292 237 308 308 308 308 323 310 308 310 310 310 323 323 315 321 321 321 321 316 323 323 323 326 324 334 329 334 329 330 334 334 326 336 334 339 339 334 334 342 323 344 342 323 346 346 350 350 362 352 350 354 350 354 355 354 354 354 354 362 346 366 366 366 346 366 369 366 369 369 371 371 373 373 366 376 366 366 346 382 382 385 385 382 391 391 391 391 391 385 393 391 393 393 393 398 393 393 403 400 403 399 382 408 408 408 410 410 410 413 413 410 410 417 417 419 419 419 421 419 425 425 425 421 428 428 425 430 419 435 435 435 435 430 438 438 435 438 439 440 440 419 444 444 447 444 449 447 449 447 451 454 451 454 460 458 460 460 454 460 465 465 465 460 444	0
34153873	3123	D007674	False	1	The KAG motif of @GeneSrc$ ( beta71 , beta74 , beta86 ) predicts seroconversion and development of type 1 diabetes . BACKGROUND : HLA-DR4 , a common antigen of @GeneSrc$ , has multiple subtypes that are strongly associated with risk of type 1 diabetes ( T1D ) ; however , some are risk neutral or resistant . The pathobiological mechanism of HLA-DR4 subtypes remains to be elucidated . METHODS : We used a population-based case-control study of T1D ( 962 patients and 636 controls ) to decipher genetic associations of HLA-DR4 subtypes and specific residues with susceptibility to T1D . Using a birth cohort of 7865 children with periodically measured islet autoantibodies ( GADA , IAA or IA-2A ) , we proposed to validate discovered genetic associations with a totally different study design and time-to-seroconversions prior to clinical onset of T1D . A novel analytic strategy hierarchically organized the @GeneSrc$ alleles by sequence similarity and identified critical amino acid residues by minimizing local genomic architecture and higher-order interactions . FINDINGS : Three amino acid residues of @GeneSrc$ ( beta71 , beta74 , beta86 ) were found to be predictive of T1D risk in the population-based study . The " KAG " motif , corresponding to @GeneSrc$ , was most strongly associated with T1D risk ( [O]dds [R]atio=3.64 , p = 3.19 x 10 - 64 ) . Three less frequent motifs ( " EAV " , OR = 2.55 , p = 0.025 ; " RAG " , OR = 1.93 , p = 0.043 ; and " RAV " , OR = 1.56 , p = 0.003 ) were associated with T1D risk , while two motifs ( " REG " and " REV " ) were equally protective ( OR = 0.11 , p = 4.23 x 10 - 4 ) . In an independent birth cohort of HLA-DR3 and HLA-DR4 subjects , those having the " KAG " motif had increased risk for time-to-seroconversion ( Hazard Ratio = 1.74 , p = 6.51 x 10 - 14 ) after adjusting potential confounders . INTERPRETATIONS : DNA sequence variation in @GeneSrc$ at positions beta71 , beta74 , and beta86 are non-conservative ( beta74 A E , beta71 E vs K vs R and beta86 G vs V ) . They result in substantial differences in peptide antigen anchor pocket preferences at p1 , p4 and potentially neighboring regions such as pocket p7 . Differential peptide antigen binding is likely to be affected . These sequence substitutions may account for most of the HLA-DR4 contribution to T1D risk as illustrated in two @GeneSrc$ model complexes of the T1D autoantigens preproinsulin and GAD65 . FUNDING : National Institute of Diabetes and Digestive and @DiseaseTgt$ and the Swedish Child Diabetes Foundation and the Swedish Research Council .	2 2 12 4 2 6 2 6 6 6 6 6 12 12 13 13 19 19 19 13 12 21 21 31 23 27 27 23 29 27 23 21 33 31 37 37 37 33 39 37 43 43 43 39 45 43 45 31 52 52 52 52 53 31 53 53 21 59 59 63 62 62 59 63 66 66 63 63 71 68 71 71 75 75 75 71 77 75 80 80 77 80 83 80 80 86 71 88 86 91 91 88 91 94 91 96 88 98 96 71 121 103 103 100 106 106 103 111 109 111 111 100 113 111 113 113 113 113 113 121 121 121 123 121 123 126 124 132 132 130 132 132 126 132 123 134 138 138 123 140 138 121 145 145 145 147 147 147 150 150 147 153 153 147 147 147 159 159 159 155 161 155 164 164 161 164 164 164 147 185 169 174 174 174 185 176 174 178 176 178 178 178 178 178 185 185 188 188 185 191 191 188 195 195 195 188 185 201 201 201 201 210 201 201 205 203 201 210 209 210 210 213 213 210 219 219 219 219 219 213 221 219 224 224 219 219 210 230 229 230 237 233 233 230 233 233 230 237 237 241 241 237 241 241 245 241 245 245 241 241 249 241 253 241 253 241 241 258 241 258 241 237 237 262 266 266 237 266 266 270 237 273 273 270 237 289 277 289 280 280 277 280 280 284 280 284 280 289 289 237 292 292 289 292 292 296 292 298 296 301 301 296 292 237 308 308 308 308 323 310 308 310 310 310 323 323 315 321 321 321 321 316 323 323 323 326 324 334 329 334 329 330 334 334 326 336 334 339 339 334 334 342 323 344 342 323 346 346 350 350 362 352 350 354 350 354 355 354 354 354 354 362 346 366 366 366 346 366 369 366 369 369 371 371 373 373 366 376 366 366 346 382 382 385 385 382 391 391 391 391 391 385 393 391 393 393 393 398 393 393 403 400 403 399 382 408 408 408 410 410 410 413 413 410 410 417 417 419 419 419 421 419 425 425 425 421 428 428 425 430 419 435 435 435 435 430 438 438 435 438 439 440 440 419 444 444 447 444 449 447 449 447 451 453|451 453 459 457 459 459 453 459 464 464 464 459 444	0
34153873	3123	D003920	True	0	The KAG motif of @GeneSrc$ ( beta71 , beta74 , beta86 ) predicts seroconversion and development of type 1 @DiseaseTgt$ . BACKGROUND : HLA-DR4 , a common antigen of @GeneSrc$ , has multiple subtypes that are strongly associated with risk of type 1 @DiseaseTgt$ ( T1D ) ; however , some are risk neutral or resistant . The pathobiological mechanism of HLA-DR4 subtypes remains to be elucidated . METHODS : We used a population-based case-control study of T1D ( 962 patients and 636 controls ) to decipher genetic associations of HLA-DR4 subtypes and specific residues with susceptibility to T1D . Using a birth cohort of 7865 children with periodically measured islet autoantibodies ( GADA , IAA or IA-2A ) , we proposed to validate discovered genetic associations with a totally different study design and time-to-seroconversions prior to clinical onset of T1D . A novel analytic strategy hierarchically organized the @GeneSrc$ alleles by sequence similarity and identified critical amino acid residues by minimizing local genomic architecture and higher-order interactions . FINDINGS : Three amino acid residues of @GeneSrc$ ( beta71 , beta74 , beta86 ) were found to be predictive of T1D risk in the population-based study . The " KAG " motif , corresponding to @GeneSrc$ , was most strongly associated with T1D risk ( [O]dds [R]atio=3.64 , p = 3.19 x 10 - 64 ) . Three less frequent motifs ( " EAV " , OR = 2.55 , p = 0.025 ; " RAG " , OR = 1.93 , p = 0.043 ; and " RAV " , OR = 1.56 , p = 0.003 ) were associated with T1D risk , while two motifs ( " REG " and " REV " ) were equally protective ( OR = 0.11 , p = 4.23 x 10 - 4 ) . In an independent birth cohort of HLA-DR3 and HLA-DR4 subjects , those having the " KAG " motif had increased risk for time-to-seroconversion ( Hazard Ratio = 1.74 , p = 6.51 x 10 - 14 ) after adjusting potential confounders . INTERPRETATIONS : DNA sequence variation in @GeneSrc$ at positions beta71 , beta74 , and beta86 are non-conservative ( beta74 A E , beta71 E vs K vs R and beta86 G vs V ) . They result in substantial differences in peptide antigen anchor pocket preferences at p1 , p4 and potentially neighboring regions such as pocket p7 . Differential peptide antigen binding is likely to be affected . These sequence substitutions may account for most of the HLA-DR4 contribution to T1D risk as illustrated in two @GeneSrc$ model complexes of the T1D autoantigens preproinsulin and GAD65 . FUNDING : National Institute of @DiseaseTgt$ and Digestive and Kidney Diseases and the Swedish Child @DiseaseTgt$ Foundation and the Swedish Research Council .	2 2 12 4 2 6 2 6 6 6 6 6 12 12 13 13 19 19 19 13 12 21 21 31 23 27 27 23 29 27 23 21 33 31 37 37 37 33 39 37 43 43 43 39 45 43 45 31 52 52 52 52 53 31 53 53 21 59 59 63 62 62 59 63 66 66 63 63 71 68 71 71 75 75 75 71 77 75 80 80 77 80 83 80 80 86 71 88 86 91 91 88 91 94 91 96 88 98 96 71 121 103 103 100 106 106 103 111 109 111 111 100 113 111 113 113 113 113 113 121 121 121 123 121 123 126 124 132 132 130 132 132 126 132 123 134 138 138 123 140 138 121 145 145 145 147 147 147 150 150 147 153 153 147 147 147 159 159 159 155 161 155 164 164 161 164 164 164 147 185 169 174 174 174 185 176 174 178 176 178 178 178 178 178 185 185 188 188 185 191 191 188 195 195 195 188 185 201 201 201 201 210 201 201 205 203 201 210 209 210 210 213 213 210 219 219 219 219 219 213 221 219 224 224 219 219 210 230 229 230 237 233 233 230 233 233 230 237 237 241 241 237 241 241 245 241 245 245 241 241 249 241 253 241 253 241 241 258 241 258 241 237 237 262 266 266 237 266 266 270 237 273 273 270 237 289 277 289 280 280 277 280 280 284 280 284 280 289 289 237 292 292 289 292 292 296 292 298 296 301 301 296 292 237 308 308 308 308 323 310 308 310 310 310 323 323 315 321 321 321 321 316 323 323 323 326 324 334 329 334 329 330 334 334 326 336 334 339 339 334 334 342 323 344 342 323 346 346 350 350 362 352 350 354 350 354 355 354 354 354 354 362 346 366 366 366 346 366 369 366 369 369 371 371 373 373 366 376 366 366 346 382 382 385 385 382 391 391 391 391 391 385 393 391 393 393 393 398 393 393 403 400 403 399 382 408 408 408 410 410 410 413 413 410 410 417 417 419 419 419 421 419 425 425 425 421 428 428 425 430 419 435 435 435 435 430 438 438 435 438 439 440 440 419 444 444 447 444 449 447 449 447 451 454 451 454 460 458 460 460 454 460 465 465 465 460 444	0
28733970	29058	D030342	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and @GeneSrc$ . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	79608	D020734	False	4	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . @GeneSrc$ mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	0
28733970	79608	D010300	False	2	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . @GeneSrc$ mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	23317	D010302	False	1	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are @GeneSrc$ , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	5420	D030342	False	2	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . @GeneSrc$ mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	79608	D030342	False	1	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . @GeneSrc$ mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	54832	D010302	False	4	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , @GeneSrc$ , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	8867	D010300	False	1	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include @GeneSrc$ , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	5420	D010302	False	6	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . @GeneSrc$ mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	8867	D010302	False	4	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include @GeneSrc$ , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	9829	D030342	True	0	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , @GeneSrc$ , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	23317	D030342	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are @GeneSrc$ , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	8867	D020734	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include @GeneSrc$ , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	1
28733970	51142	D010302	False	1	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , @GeneSrc$ , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	29058	D020734	False	6	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and @GeneSrc$ . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	0
28733970	29058	D010300	True	0	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and @GeneSrc$ . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	116442	D030342	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in @GeneSrc$ cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	391356	D020734	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and @GeneSrc$ . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	1
28733970	54832	D020734	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , @GeneSrc$ , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	1
28733970	23317	D010300	True	0	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are @GeneSrc$ , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	116442	D010302	False	7	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in @GeneSrc$ cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	391356	D030342	True	0	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , VPS13C , and @GeneSrc$ . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	51142	D030342	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , @GeneSrc$ , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	9829	D010302	False	4	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , @GeneSrc$ , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	8867	D030342	True	0	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include @GeneSrc$ , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	23317	D020734	False	6	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are @GeneSrc$ , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	0
28733970	9829	D020734	False	3	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , @GeneSrc$ , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	1
28733970	391356	D010300	False	1	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and @GeneSrc$ . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	54832	D030342	True	0	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for @DiseaseTgt$ include SYNJ1 , DNAJC6 , @GeneSrc$ , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 112 111 109|111 112 112 113 113 113 113 113 113 113 112 134 125 125 122 127 125 127 130 127 130 134 134 134 137 137 134 134 134 141 149 143 141 143 148 148 148 143 134 149 149 153 155 155 155 159 159 159 155 155 155 163 164 155 167 167 164 155 172 171 169 172 176 176 176 172 172 188 184 184 184 184 184 178 188 188 188 188 190 188 195 195 195 193 188 188 198 206 202 202 202 198 202 202 202 206 208 210 210 206 206 206 214 215 220 218 218 215 220 206 220 206	0
28733970	5420	D010300	True	0	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . @GeneSrc$ mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	79608	D010302	False	3	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . @GeneSrc$ mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	116442	D020734	True	0	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in @GeneSrc$ cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	1
28733970	54832	D010300	False	1	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , @GeneSrc$ , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	116442	D010300	False	1	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in @GeneSrc$ cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	5420	D020734	False	1	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . @GeneSrc$ mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	0
28733970	51142	D020734	False	6	New Genes Causing Hereditary Parkinson 's Disease or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , @GeneSrc$ , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked @DiseaseTgt$ . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical @DiseaseTgt$ , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 177 177 174|177 174 189 185 185 185 185 185 179 189 189 189 189 191 189 196 196 196 194 189 189 199 207 203 203 203 199 203 203 203 207 209 210 207|210 207 207 214 215 220 218 218 215 220 207 220 207	0
28733970	391356	D010302	False	4	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and @GeneSrc$ . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	29058	D010302	False	1	New Genes Causing Hereditary Parkinson 's Disease or @DiseaseTgt$ . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing Parkinson 's disease or @DiseaseTgt$ have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant Parkinson 's disease are DNAJC13 , CHCHD2 , and @GeneSrc$ . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset PD , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive PD , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant PD genes have generally been found in medium- to late-onset Parkinson 's disease . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause PD .	1 1 1 4 6 4 2 6 6 1 19 12 10 10 15 16 10 19 19 19 19 22 20 22 22 26 22 26 30 28 27 30 30 35 35 19 37 35 35 19 19 42 45 42 42 40 50 50 50 50 45 19 53 56 56 56 56 56 62 62 62 60 57 64 56 64 64 64 64 64 56 81 81 74 81 78 78 78 74 81 81 81 81 81 85 81 85 85 90 90 81 90 93 96 96 96 96 99 99 96 96 102 103 96 106 106 103 96 109 114 113 113 113 109 114 114 115 115 115 115 115 115 115 114 136 127 127 124 129 127 129 132 129 132 136 136 136 139 139 136 136 136 143 151 145 143 145 150 150 150 145 136 151 151 155 157 157 157 161 161 161 157 157 157 165 166 157 169 169 166 157 174 173 171 174 178 178 178 174 174 190 186 186 186 186 186 180 190 190 190 190 192 190 197 197 197 195 190 190 200 208 204 204 204 200 204 204 204 208 210 212 212 208 208 208 216 217 222 220 220 217 222 208 222 208	0
28733970	51142	D010300	True	0	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , @GeneSrc$ , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , DNAJC6 , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
28733970	9829	D010300	False	1	New Genes Causing @DiseaseTgt$ or Parkinsonism . PURPOSE OF REVIEW : This article reviews was to review genes where putative or confirmed pathogenic mutations causing @DiseaseTgt$ or Parkinsonism have been identified since 2012 , and summarizes the clinical and pathological picture of the associated disease subtypes . RECENT FINDINGS : Newly reported genes for dominant @DiseaseTgt$ are DNAJC13 , CHCHD2 , and TMEM230 . However , the evidence for a disease-causing role is not conclusive , and further genetic and functional studies are warranted . RIC3 mutations have been reported from one family but not yet encountered in other patients . New genes for autosomal recessive disease include SYNJ1 , @GeneSrc$ , VPS13C , and PTRHD1 . Deletions of a region on chromosome 22 ( 22q11.2del ) are also associated with early-onset @DiseaseTgt$ , but the mode of inheritance and the underlying causative gene remain unclear . PODXL mutations were reported in autosomal recessive @DiseaseTgt$ , but their roles remain to be confirmed . Mutations in RAB39B cause an X-linked Parkinsonian disorder . Mutations in the new dominant @DiseaseTgt$ genes have generally been found in medium- to late-onset @DiseaseTgt$ . Many mutations in the new recessive and X-chromosomal genes cause severe atypical juvenile Parkinsonism , but less devastating mutations in these genes may cause @DiseaseTgt$ .	1 1 1 2|3 3 3 1 16 9 7 7 12 13 7 16 16 16 16 19 17 19 19 23 19 23 24|25 25 25 30 30 16 32 30 30 16 16 37 40 37 37 35 45 45 45 45 40 16 48 51 51 51 51 51 55 55 55|52 57 51 57 57 57 57 57 51 74 74 67 74 71 71 71 67 74 74 74 74 74 78 74 78 78 83 83 74 83 86 89 89 89 89 92 92 89 89 95 96 89 99 99 96 89 102 107 106 106 106 102 107 107 108 108 108 108 108 108 108 107 129 120 120 117 122 120 122 125 122 125 129 129 129 132 132 129 129 129 136 144 138 136 138 143 143 143 138 129 144 144 148 150 150 150 154 154 154 150 150 150 158 159 150 162 162 159 150 167 166 164 167 171 171 171 167 167 183 179 179 179 179 179 173 183 183 183 183 185 183 188 188 183|188 183 191 199 195 195 195 191 195 195 195 199 201 203 203 199 199 199 207 208 213 211 211 208 213 199 213 199	0
31226929	6323	D008881	False	1	Advances in genetics of @DiseaseTgt$ . BACKGROUND : @DiseaseTgt$ is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of @DiseaseTgt$ , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in @DiseaseTgt$ etiology . FINDINGS : @DiseaseTgt$ is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , ATP1A2 and @GeneSrc$ - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic @DiseaseTgt$ , hemiplegic @DiseaseTgt$ and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common @DiseaseTgt$ forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of @DiseaseTgt$ leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with @DiseaseTgt$ pathophysiology . CONCLUSIONS : The complexity of @DiseaseTgt$ is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning @DiseaseTgt$ will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for @DiseaseTgt$ sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 173 173 170 139 203 178 178 175 178 181 179 181 184 181 178 178 188 178 190 188 190 194 194 190 194 194 199 199 194 175 203 203 203 205 203 205 208 205 208 211 208 214 214 203 203 217 219 219 219 221 219 226 226 225 226 221 226 226 226 234 232 234 234 221 234 237 234 234 234 241 239 241 219 243 243 247 245 250 250 247 219 257 257 257 257 257 268 268 262 262 262 268 264 262 264 268 268 268 270 268 273 273 270 273 268 268 278 276 284 281 284 281 281 278 268 292 289 289 286 291 289 292 295 295 292 298 298 295 298 301 299 301 304 301 292 292 308 292 308 311 309 311 314 311 292 317 319 319 319 321 319 323 321 323 326 323 329 329 326 319 319 340 335 335 332 335 338 335 340 319 340 343 341 346 346 341 340 348 348 351 355 353 351|353 355 348 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	6323	D051271	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , ATP1A2 and @GeneSrc$ - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with @DiseaseTgt$ . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 172 172|170 139 202 177 177 174 177 180 178 180 183 180 177 177 187 177 189 187 189 193 193 189 193 193 198 198 193 174 202 202 202 204 202 204 207 204 207 210 207 213 213 202 202 216 218 218 218 220 218 225 225 224 225 220 225 225 225 233 231 233 233 220 233 236 233 233 233 240 238 240 218 242 242 246 244 249 249 246 218 256 256 256 256 256 267 267 261 261 261 267 263 261 263 267 267 267 269 267 272 272 269 272 267 267 277 275 283 280 283 280 280 277 267 291 288 288 285 290 288 291 294 294 291 297 297 294 297 300 298 300 303 300 291 291 307 291 307 310 308 310 313 310 291 316 318 318 318 320 318 322 320 322 325 322 328 328 325 318 318 339 334 334 331 334 337 334 339 318 339 342 340 345 345 340 339 347 347 350 355 353 353 350 355 347 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	773	D000275	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - @GeneSrc$ , ATP1A2 and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading @DiseaseTgt$ , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 173 173 170 139 203 178 178 175 178 181 179 181 184 181 178 178 188 178 190 188 190 194 194 190 194 194 199 199 194 175 203 203 203 205 203 205 208 205 208 211 208 214 214 203 203 217 219 219 219 221 219 226 226 225 226 221 226 226 226 234 232 234 234 221 234 237 234 234 234 241 239 241 219 243 243 247 245 250 250 247 219 257 257 257 257 257 268 268 262 262 262 268 264 262 264 268 268 268 270 268 273 273 270 273 268 268 278 276 284 281 284 281 281 278 268 292 289 289 286 291 289 292 295 295 292 298 298 295 298 301 299 301 304 301 292 292 308 292 308 311 309 311 314 311 292 317 319 319 319 321 319 323 321 323 326 323 329 329 326 319 319 340 335 335 332 335 338 335 340 319 340 343 341 346 346 341 340 348 348 351 356 354 354 351 356 348 360 360 360 356 356 364 364 372 368 368 368 364 368 369 372 372 374 372 374 378 378 375 378 378 374 383 374 385 383 385 385 390 390 385 372	0
31226929	6323	D013901	False	4	Advances in genetics of migraine . BACKGROUND : Migraine is a complex @DiseaseTgt$ with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , ATP1A2 and @GeneSrc$ - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 12 12 12 12 6|12 17 17 17 15 12 12 20 20 23 23 20 25 23 25 20 29 27 31 32 33 20 20 44 38 38 35 38 42 42 39 44 20 44 51 51 51 51 51 45 20 54 55 55 55 60 60 60 56 63 63 60 63 63 68 68 63 68 71 68 68 75 75 72 55 81 81 81 81 81 85 85 85 81 85 85 89 87 91 89 91 89 87 96 94 98 96 98 81 102 108 108 108 108 108 108 108 108 111 109 115 115 115 111 115 115 117 117 117 117 117 124 115 126 124 126 129 126 108 132 138 137 137 134 134 132 138 145 145 145 141 145 145 138 149 149 149 145 149 152 149 149 155 145 157 159 159 155 162 162 159 162 163 166 138 166 169 167 172 172 169 138 202 177 177 174 177 180 178 180 183 180 177 177 187 177 189 187 189 193 193 189 193 193 198 198 193 174 202 202 202 204 202 204 207 204 207 210 207 213 213 202 202 216 218 218 218 220 218 225 225 224 225 220 225 225 225 233 231 233 233 220 233 236 233 233 233 240 238 240 218 242 242 246 244 249 249 246 218 256 256 256 256 256 267 267 261 261 261 267 263 261 263 267 267 267 269 267 272 272 269 272 267 267 277 275 283 280 283 280 280 277 267 291 288 288 285 290 288 291 294 294 291 297 297 294 297 300 298 300 303 300 291 291 307 291 307 310 308 310 313 310 291 316 318 318 318 320 318 322 320 322 325 322 328 328 325 318 318 339 334 334 331 334 337 334 339 318 339 342 340 345 345 340 339 347 347 350 355 353 353 350 355 347 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	6323	D020325	True	0	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . @DiseaseTgt$ is a rare monogenic @DiseaseTgt$ subtype caused by mutations in three main genes - CACNA1A , ATP1A2 and @GeneSrc$ - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 95|88 97 95 97 82 100|106 106 106 106 106 106 106 106 109 107 113 113 113 109 113 113 115 115 115 115 115 122 113 124 122 124 127 124 106 130 136 135 135 132 132 130 136 143 143 143 139 143 143 136 147 147 147 143 147 150 147 147 153 143 155 157 157 153 160 160 157 160 161 164 136 164 167 165 170 170 167 136 200 175 175 172 175 178 176 178 181 178 175 175 185 175 187 185 187 191 191 187 191 191 196 196 191 172 200 200 200 202 200 202 205 202 205 208 205 211 211 200 200 214 216 216 216 218 216 223 223 222 223 218 223 223 223 231 229 231 231 218 231 234 231 231 231 238 236 238 216 240 240 244 242 247 247 244 216 254 254 254 254 254 265 265 259 259 259 265 261 259 261 265 265 265 267 265 270 270 267 270 265 265 275 273 281 278 281 278 278 275 265 289 286 286 283 288 286 289 292 292 289 295 295 292 295 298 296 298 301 298 289 289 305 289 305 308 306 308 311 308 289 314 316 316 316 318 316 320 318 320 323 320 326 326 323 316 316 337 332 332 329 332 335 332 337 316 337 340 338 343 343 338 337 345 345 348 353 351 351 348 353 345 357 357 357 353 353 361 361 369 365 365 365 361 365 366 369 369 371 369 371 375 375 372 375 375 371 380 371 382 380 382 382 387 387 382 369	1
31226929	477	D013901	False	4	Advances in genetics of migraine . BACKGROUND : Migraine is a complex @DiseaseTgt$ with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , @GeneSrc$ and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 12 12 12 12 6|12 17 17 17 15 12 12 20 20 23 23 20 25 23 25 20 29 27 31 32 33 20 20 44 38 38 35 38 42 42 39 44 20 44 51 51 51 51 51 45 20 54 55 55 55 60 60 60 56 63 63 60 63 63 68 68 63 68 71 68 68 75 75 72 55 81 81 81 81 81 85 85 85 81 85 85 89 87 91 89 91 89 87 96 94 98 96 98 81 102 108 108 108 108 108 108 108 108 111 109 115 115 115 111 115 115 117 117 117 117 117 124 115 126 124 126 129 126 108 132 138 137 137 134 134 132 138 145 145 145 141 145 145 138 149 149 149 145 149 152 149 149 155 145 157 159 159 155 162 162 159 162 163 166 138 166 169 167 172 172 169 138 202 177 177 174 177 180 178 180 183 180 177 177 187 177 189 187 189 193 193 189 193 193 198 198 193 174 202 202 202 204 202 204 207 204 207 210 207 213 213 202 202 216 218 218 218 220 218 225 225 224 225 220 225 225 225 233 231 233 233 220 233 236 233 233 233 240 238 240 218 242 242 246 244 249 249 246 218 256 256 256 256 256 267 267 261 261 261 267 263 261 263 267 267 267 269 267 272 272 269 272 267 267 277 275 283 280 283 280 280 277 267 291 288 288 285 290 288 291 294 294 291 297 297 294 297 300 298 300 303 300 291 291 307 291 307 310 308 310 313 310 291 316 318 318 318 320 318 322 320 322 325 322 328 328 325 318 318 339 334 334 331 334 337 334 339 318 339 342 340 345 345 340 339 347 347 350 355 353 353 350 355 347 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	477	D000275	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , @GeneSrc$ and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading @DiseaseTgt$ , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 173 173 170 139 203 178 178 175 178 181 179 181 184 181 178 178 188 178 190 188 190 194 194 190 194 194 199 199 194 175 203 203 203 205 203 205 208 205 208 211 208 214 214 203 203 217 219 219 219 221 219 226 226 225 226 221 226 226 226 234 232 234 234 221 234 237 234 234 234 241 239 241 219 243 243 247 245 250 250 247 219 257 257 257 257 257 268 268 262 262 262 268 264 262 264 268 268 268 270 268 273 273 270 273 268 268 278 276 284 281 284 281 281 278 268 292 289 289 286 291 289 292 295 295 292 298 298 295 298 301 299 301 304 301 292 292 308 292 308 311 309 311 314 311 292 317 319 319 319 321 319 323 321 323 326 323 329 329 326 319 319 340 335 335 332 335 338 335 340 319 340 343 341 346 346 341 340 348 348 351 356 354 354 351 356 348 360 360 360 356 356 364 364 372 368 368 368 364 368 369 372 372 374 372 374 378 378 375 378 378 374 383 374 385 383 385 385 390 390 385 372	0
31226929	477	D051271	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , @GeneSrc$ and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with @DiseaseTgt$ . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 172 172|170 139 202 177 177 174 177 180 178 180 183 180 177 177 187 177 189 187 189 193 193 189 193 193 198 198 193 174 202 202 202 204 202 204 207 204 207 210 207 213 213 202 202 216 218 218 218 220 218 225 225 224 225 220 225 225 225 233 231 233 233 220 233 236 233 233 233 240 238 240 218 242 242 246 244 249 249 246 218 256 256 256 256 256 267 267 261 261 261 267 263 261 263 267 267 267 269 267 272 272 269 272 267 267 277 275 283 280 283 280 280 277 267 291 288 288 285 290 288 291 294 294 291 297 297 294 297 300 298 300 303 300 291 291 307 291 307 310 308 310 313 310 291 316 318 318 318 320 318 322 320 322 325 322 328 328 325 318 318 339 334 334 331 334 337 334 339 318 339 342 340 345 345 340 339 347 347 350 355 353 353 350 355 347 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	6323	D000275	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , ATP1A2 and @GeneSrc$ - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading @DiseaseTgt$ , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 173 173 170 139 203 178 178 175 178 181 179 181 184 181 178 178 188 178 190 188 190 194 194 190 194 194 199 199 194 175 203 203 203 205 203 205 208 205 208 211 208 214 214 203 203 217 219 219 219 221 219 226 226 225 226 221 226 226 226 234 232 234 234 221 234 237 234 234 234 241 239 241 219 243 243 247 245 250 250 247 219 257 257 257 257 257 268 268 262 262 262 268 264 262 264 268 268 268 270 268 273 273 270 273 268 268 278 276 284 281 284 281 281 278 268 292 289 289 286 291 289 292 295 295 292 298 298 295 298 301 299 301 304 301 292 292 308 292 308 311 309 311 314 311 292 317 319 319 319 321 319 323 321 323 326 323 329 329 326 319 319 340 335 335 332 335 338 335 340 319 340 343 341 346 346 341 340 348 348 351 356 354 354 351 356 348 360 360 360 356 356 364 364 372 368 368 368 364 368 369 372 372 374 372 374 378 378 375 378 378 374 383 374 385 383 385 385 390 390 385 372	0
31226929	477	D008881	False	1	Advances in genetics of @DiseaseTgt$ . BACKGROUND : @DiseaseTgt$ is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of @DiseaseTgt$ , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in @DiseaseTgt$ etiology . FINDINGS : @DiseaseTgt$ is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , @GeneSrc$ and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic @DiseaseTgt$ , hemiplegic @DiseaseTgt$ and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common @DiseaseTgt$ forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of @DiseaseTgt$ leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with @DiseaseTgt$ pathophysiology . CONCLUSIONS : The complexity of @DiseaseTgt$ is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning @DiseaseTgt$ will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for @DiseaseTgt$ sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 173 173 170 139 203 178 178 175 178 181 179 181 184 181 178 178 188 178 190 188 190 194 194 190 194 194 199 199 194 175 203 203 203 205 203 205 208 205 208 211 208 214 214 203 203 217 219 219 219 221 219 226 226 225 226 221 226 226 226 234 232 234 234 221 234 237 234 234 234 241 239 241 219 243 243 247 245 250 250 247 219 257 257 257 257 257 268 268 262 262 262 268 264 262 264 268 268 268 270 268 273 273 270 273 268 268 278 276 284 281 284 281 281 278 268 292 289 289 286 291 289 292 295 295 292 298 298 295 298 301 299 301 304 301 292 292 308 292 308 311 309 311 314 311 292 317 319 319 319 321 319 323 321 323 326 323 329 329 326 319 319 340 335 335 332 335 338 335 340 319 340 343 341 346 346 341 340 348 348 351 355 353 351|353 355 348 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	773	D020325	True	0	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . @DiseaseTgt$ is a rare monogenic @DiseaseTgt$ subtype caused by mutations in three main genes - @GeneSrc$ , ATP1A2 and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 95|88 97 95 97 82 100|106 106 106 106 106 106 106 106 109 107 113 113 113 109 113 113 115 115 115 115 115 122 113 124 122 124 127 124 106 130 136 135 135 132 132 130 136 143 143 143 139 143 143 136 147 147 147 143 147 150 147 147 153 143 155 157 157 153 160 160 157 160 161 164 136 164 167 165 170 170 167 136 200 175 175 172 175 178 176 178 181 178 175 175 185 175 187 185 187 191 191 187 191 191 196 196 191 172 200 200 200 202 200 202 205 202 205 208 205 211 211 200 200 214 216 216 216 218 216 223 223 222 223 218 223 223 223 231 229 231 231 218 231 234 231 231 231 238 236 238 216 240 240 244 242 247 247 244 216 254 254 254 254 254 265 265 259 259 259 265 261 259 261 265 265 265 267 265 270 270 267 270 265 265 275 273 281 278 281 278 278 275 265 289 286 286 283 288 286 289 292 292 289 295 295 292 295 298 296 298 301 298 289 289 305 289 305 308 306 308 311 308 289 314 316 316 316 318 316 320 318 320 323 320 326 326 323 316 316 337 332 332 329 332 335 332 337 316 337 340 338 343 343 338 337 345 345 348 353 351 351 348 353 345 357 357 357 353 353 361 361 369 365 365 365 361 365 366 369 369 371 369 371 375 375 372 375 375 371 380 371 382 380 382 382 387 387 382 369	1
31226929	773	D008881	False	1	Advances in genetics of @DiseaseTgt$ . BACKGROUND : @DiseaseTgt$ is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of @DiseaseTgt$ , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in @DiseaseTgt$ etiology . FINDINGS : @DiseaseTgt$ is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - @GeneSrc$ , ATP1A2 and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic @DiseaseTgt$ , hemiplegic @DiseaseTgt$ and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common @DiseaseTgt$ forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of @DiseaseTgt$ leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with @DiseaseTgt$ pathophysiology . CONCLUSIONS : The complexity of @DiseaseTgt$ is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning @DiseaseTgt$ will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for @DiseaseTgt$ sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 173 173 170 139 203 178 178 175 178 181 179 181 184 181 178 178 188 178 190 188 190 194 194 190 194 194 199 199 194 175 203 203 203 205 203 205 208 205 208 211 208 214 214 203 203 217 219 219 219 221 219 226 226 225 226 221 226 226 226 234 232 234 234 221 234 237 234 234 234 241 239 241 219 243 243 247 245 250 250 247 219 257 257 257 257 257 268 268 262 262 262 268 264 262 264 268 268 268 270 268 273 273 270 273 268 268 278 276 284 281 284 281 281 278 268 292 289 289 286 291 289 292 295 295 292 298 298 295 298 301 299 301 304 301 292 292 308 292 308 311 309 311 314 311 292 317 319 319 319 321 319 323 321 323 326 323 329 329 326 319 319 340 335 335 332 335 338 335 340 319 340 343 341 346 346 341 340 348 348 351 355 353 351|353 355 348 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	477	D020325	True	0	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . @DiseaseTgt$ is a rare monogenic @DiseaseTgt$ subtype caused by mutations in three main genes - CACNA1A , @GeneSrc$ and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 95|88 97 95 97 82 100|106 106 106 106 106 106 106 106 109 107 113 113 113 109 113 113 115 115 115 115 115 122 113 124 122 124 127 124 106 130 136 135 135 132 132 130 136 143 143 143 139 143 143 136 147 147 147 143 147 150 147 147 153 143 155 157 157 153 160 160 157 160 161 164 136 164 167 165 170 170 167 136 200 175 175 172 175 178 176 178 181 178 175 175 185 175 187 185 187 191 191 187 191 191 196 196 191 172 200 200 200 202 200 202 205 202 205 208 205 211 211 200 200 214 216 216 216 218 216 223 223 222 223 218 223 223 223 231 229 231 231 218 231 234 231 231 231 238 236 238 216 240 240 244 242 247 247 244 216 254 254 254 254 254 265 265 259 259 259 265 261 259 261 265 265 265 267 265 270 270 267 270 265 265 275 273 281 278 281 278 278 275 265 289 286 286 283 288 286 289 292 292 289 295 295 292 295 298 296 298 301 298 289 289 305 289 305 308 306 308 311 308 289 314 316 316 316 318 316 320 318 320 323 320 326 326 323 316 316 337 332 332 329 332 335 332 337 316 337 340 338 343 343 338 337 345 345 348 353 351 351 348 353 345 357 357 357 353 353 361 361 369 365 365 365 361 365 366 369 369 371 369 371 375 375 372 375 375 371 380 371 382 380 382 382 387 387 382 369	1
31226929	477	D020326	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , @DiseaseTgt$ ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , @GeneSrc$ and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86|88 90 88 90 88 88 95 93 97 95 97 82 101 107 107 107 107 107 107 107 107 110 108 114 114 114 110 114 114 116 116 116 116 116 123 114 125 123 125 128 125 107 131 137 136 136 133 133 131 137 144 144 144 140 144 144 137 148 148 148 144 148 151 148 148 154 144 156 158 158 154 161 161 158 161 162 165 137 165 168 166 171 171 168 137 201 176 176 173 176 179 177 179 182 179 176 176 186 176 188 186 188 192 192 188 192 192 197 197 192 173 201 201 201 203 201 203 206 203 206 209 206 212 212 201 201 215 217 217 217 219 217 224 224 223 224 219 224 224 224 232 230 232 232 219 232 235 232 232 232 239 237 239 217 241 241 245 243 248 248 245 217 255 255 255 255 255 266 266 260 260 260 266 262 260 262 266 266 266 268 266 271 271 268 271 266 266 276 274 282 279 282 279 279 276 266 290 287 287 284 289 287 290 293 293 290 296 296 293 296 299 297 299 302 299 290 290 306 290 306 309 307 309 312 309 290 315 317 317 317 319 317 321 319 321 324 321 327 327 324 317 317 338 333 333 330 333 336 333 338 317 338 341 339 344 344 339 338 346 346 349 354 352 352 349 354 346 358 358 358 354 354 362 362 370 366 366 366 362 366 367 370 370 372 370 372 376 376 373 376 376 372 381 372 383 381 383 383 388 388 383 370	0
31226929	773	D020326	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , @DiseaseTgt$ ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - @GeneSrc$ , ATP1A2 and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86|88 90 88 90 88 88 95 93 97 95 97 82 101 107 107 107 107 107 107 107 107 110 108 114 114 114 110 114 114 116 116 116 116 116 123 114 125 123 125 128 125 107 131 137 136 136 133 133 131 137 144 144 144 140 144 144 137 148 148 148 144 148 151 148 148 154 144 156 158 158 154 161 161 158 161 162 165 137 165 168 166 171 171 168 137 201 176 176 173 176 179 177 179 182 179 176 176 186 176 188 186 188 192 192 188 192 192 197 197 192 173 201 201 201 203 201 203 206 203 206 209 206 212 212 201 201 215 217 217 217 219 217 224 224 223 224 219 224 224 224 232 230 232 232 219 232 235 232 232 232 239 237 239 217 241 241 245 243 248 248 245 217 255 255 255 255 255 266 266 260 260 260 266 262 260 262 266 266 266 268 266 271 271 268 271 266 266 276 274 282 279 282 279 279 276 266 290 287 287 284 289 287 290 293 293 290 296 296 293 296 299 297 299 302 299 290 290 306 290 306 309 307 309 312 309 290 315 317 317 317 319 317 321 319 321 324 321 327 327 324 317 317 338 333 333 330 333 336 333 338 317 338 341 339 344 344 339 338 346 346 349 354 352 352 349 354 346 358 358 358 354 354 362 362 370 366 366 366 362 366 367 370 370 372 370 372 376 376 373 376 376 372 381 372 383 381 383 383 388 388 383 370	0
31226929	773	D013901	False	4	Advances in genetics of migraine . BACKGROUND : Migraine is a complex @DiseaseTgt$ with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - @GeneSrc$ , ATP1A2 and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 12 12 12 12 6|12 17 17 17 15 12 12 20 20 23 23 20 25 23 25 20 29 27 31 32 33 20 20 44 38 38 35 38 42 42 39 44 20 44 51 51 51 51 51 45 20 54 55 55 55 60 60 60 56 63 63 60 63 63 68 68 63 68 71 68 68 75 75 72 55 81 81 81 81 81 85 85 85 81 85 85 89 87 91 89 91 89 87 96 94 98 96 98 81 102 108 108 108 108 108 108 108 108 111 109 115 115 115 111 115 115 117 117 117 117 117 124 115 126 124 126 129 126 108 132 138 137 137 134 134 132 138 145 145 145 141 145 145 138 149 149 149 145 149 152 149 149 155 145 157 159 159 155 162 162 159 162 163 166 138 166 169 167 172 172 169 138 202 177 177 174 177 180 178 180 183 180 177 177 187 177 189 187 189 193 193 189 193 193 198 198 193 174 202 202 202 204 202 204 207 204 207 210 207 213 213 202 202 216 218 218 218 220 218 225 225 224 225 220 225 225 225 233 231 233 233 220 233 236 233 233 233 240 238 240 218 242 242 246 244 249 249 246 218 256 256 256 256 256 267 267 261 261 261 267 263 261 263 267 267 267 269 267 272 272 269 272 267 267 277 275 283 280 283 280 280 277 267 291 288 288 285 290 288 291 294 294 291 297 297 294 297 300 298 300 303 300 291 291 307 291 307 310 308 310 313 310 291 316 318 318 318 320 318 322 320 322 325 322 328 328 325 318 318 339 334 334 331 334 337 334 339 318 339 342 340 345 345 340 339 347 347 350 355 353 353 350 355 347 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
31226929	6323	D020326	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , @DiseaseTgt$ ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - CACNA1A , ATP1A2 and @GeneSrc$ - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with aura symptoms . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86|88 90 88 90 88 88 95 93 97 95 97 82 101 107 107 107 107 107 107 107 107 110 108 114 114 114 110 114 114 116 116 116 116 116 123 114 125 123 125 128 125 107 131 137 136 136 133 133 131 137 144 144 144 140 144 144 137 148 148 148 144 148 151 148 148 154 144 156 158 158 154 161 161 158 161 162 165 137 165 168 166 171 171 168 137 201 176 176 173 176 179 177 179 182 179 176 176 186 176 188 186 188 192 192 188 192 192 197 197 192 173 201 201 201 203 201 203 206 203 206 209 206 212 212 201 201 215 217 217 217 219 217 224 224 223 224 219 224 224 224 232 230 232 232 219 232 235 232 232 232 239 237 239 217 241 241 245 243 248 248 245 217 255 255 255 255 255 266 266 260 260 260 266 262 260 262 266 266 266 268 266 271 271 268 271 266 266 276 274 282 279 282 279 279 276 266 290 287 287 284 289 287 290 293 293 290 296 296 293 296 299 297 299 302 299 290 290 306 290 306 309 307 309 312 309 290 315 317 317 317 319 317 321 319 321 324 321 327 327 324 317 317 338 333 333 330 333 336 333 338 317 338 341 339 344 344 339 338 346 346 349 354 352 352 349 354 346 358 358 358 354 354 362 362 370 366 366 366 362 366 367 370 370 372 370 372 376 376 373 376 376 372 381 372 383 381 383 383 388 388 383 370	0
31226929	773	D051271	False	1	Advances in genetics of migraine . BACKGROUND : Migraine is a complex neurovascular disorder with a strong genetic component . There are rare monogenic forms of migraine , as well as more common polygenic forms ; research into the genes involved in both types has provided insights into the many contributing genetic factors . This review summarises advances that have been made in the knowledge and understanding of the genes and genetic variations implicated in migraine etiology . FINDINGS : Migraine is characterised into two main types , migraine without aura ( MO ) and migraine with aura ( MA ) . Hemiplegic migraine is a rare monogenic MA subtype caused by mutations in three main genes - @GeneSrc$ , ATP1A2 and SCN1A - which encode ion channel and transport proteins . Functional studies in cellular and animal models show that , in general , mutations result in impaired glutamatergic neurotransmission and cortical hyperexcitability , which make the brain more susceptible to cortical spreading depression , a phenomenon thought to coincide with @DiseaseTgt$ . Variants in other genes encoding ion channels and solute carriers , or with roles in regulating neurotransmitters at neuronal synapses , or in vascular function , can also cause monogenic migraine , hemiplegic migraine and related disorders with overlapping symptoms . Next-generation sequencing will accelerate the finding of new potentially causal variants and genes , with high-throughput bioinformatics analysis methods and functional analysis pipelines important in prioritising , confirming and understanding the mechanisms of disease-causing variants . With respect to common migraine forms , large genome-wide association studies ( GWAS ) have greatly expanded our knowledge of the genes involved , emphasizing the role of both neuronal and vascular pathways . Dissecting the genetic architecture of migraine leads to greater understanding of what underpins relationships between subtypes and comorbid disorders , and may have utility in diagnosis or tailoring treatments . Further work is required to identify causal polymorphisms and the mechanism of their effect , and studies of gene expression and epigenetic factors will help bridge the genetics with migraine pathophysiology . CONCLUSIONS : The complexity of migraine disorders is mirrored by their genetic complexity . A comprehensive knowledge of the genetic factors underpinning migraine will lead to improved understanding of molecular mechanisms and pathogenesis , to enable better diagnosis and treatments for migraine sufferers .	0 2 0 4 2 0 6 6 13 13 13 13 13 6 18 18 18 16 13 13 21 21 24 24 21 26 24 26 21 30 28 32 33 34 21 21 45 39 39 36 39 43 43 40 45 21 45 52 52 52 52 52 46 21 55 56 56 56 61 61 61 57 64 64 61 64 64 69 69 64 69 72 69 69 76 76 73 56 82 82 82 82 82 86 86 86 82 86 86 90 88 92 90 92 90 88 97 95 99 97 99 82 103 109 109 109 109 109 109 109 109 112 110 116 116 116 112 116 116 118 118 118 118 118 125 116 127 125 127 130 127 109 133 139 138 138 135 135 133 139 146 146 146 142 146 146 139 150 150 150 146 150 153 150 150 156 146 158 160 160 156 163 163 160 163 164 167 139 167 170 168 172 172|170 139 202 177 177 174 177 180 178 180 183 180 177 177 187 177 189 187 189 193 193 189 193 193 198 198 193 174 202 202 202 204 202 204 207 204 207 210 207 213 213 202 202 216 218 218 218 220 218 225 225 224 225 220 225 225 225 233 231 233 233 220 233 236 233 233 233 240 238 240 218 242 242 246 244 249 249 246 218 256 256 256 256 256 267 267 261 261 261 267 263 261 263 267 267 267 269 267 272 272 269 272 267 267 277 275 283 280 283 280 280 277 267 291 288 288 285 290 288 291 294 294 291 297 297 294 297 300 298 300 303 300 291 291 307 291 307 310 308 310 313 310 291 316 318 318 318 320 318 322 320 322 325 322 328 328 325 318 318 339 334 334 331 334 337 334 339 318 339 342 340 345 345 340 339 347 347 350 355 353 353 350 355 347 359 359 359 355 355 363 363 371 367 367 367 363 367 368 371 371 373 371 373 377 377 374 377 377 373 382 373 384 382 384 384 389 389 384 371	0
34716609	215	D003141	True	0	@GeneSrc$ and X-linked adrenoleukodystrophy : @DiseaseTgt$ with a markedly variable phenotype showing conserved neurobiology in animal models . X-linked adrenoleukodystrophy ( X-ALD ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . X-ALD is the most common peroxisomal inborn error of metabolism and confers a high degree of morbidity and mortality . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive demyelination , while in others only dying-back axonopathy or even isolated adrenal insufficiency is seen , without genotype-phenotype correlation . X-ALD 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased glial death , and axonal damage . Most strikingly , however , cerebral invasion of leukocytes and demyelination were not observed in any animal model for X-ALD , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for ALD .	0 0 3 0 0 0|5 10 10 9 10 5 10 13 11 16 16 13 0 19 27 21 19 21 27 27 26 27 27 27 31 31 28 36 36 36 36 31 38 36 38 27 43 43 27 47 47 47 43 27 56 56 56 53 56 56 56 56 58 56 56 56 63 63 60 65 63 65 65 56 75 75 72 75 74 72 75 78 78 75 81 81 78 86 86 86 86 81 81 89 81 75 103 93 103 95 96 93 96 99 101 101 96 103 75 103 107 107 103 75 112 109 112 115 115 115 115 117 115 119 115 115 122 115 126 126 126 122 130 129 130 126 133 133 130 115 137 137 138 139 139 139 143 143 140 139 153 153 149 149 153 152 152 149 153 155 153 155 153 157 162 162 162 158 153 165 169 168 168 165 169 172 172 169 175 175 172 169 169 179 182 182 182 177 182 185 182 182 189 189 182 182 182 193 182 169 196 208 208 208 208 201 208 203 201 201 201 208 208 208 212 212 212 208 214 212 208 208 219 219 216 225 225 225 225 225 219 208 228 229 229 233 233 233 229 235 229 239 238 239 229 242 242 239 239 239 246 239 248 246 251 251 248 253 251 255 253 258 258 255 260 258 229	0
34716609	215	D003643	False	1	@GeneSrc$ and X-linked adrenoleukodystrophy : A disease with a markedly variable phenotype showing conserved neurobiology in animal models . X-linked adrenoleukodystrophy ( X-ALD ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . X-ALD is the most common peroxisomal inborn error of metabolism and confers a high degree of morbidity and @DiseaseTgt$ . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive demyelination , while in others only dying-back axonopathy or even isolated adrenal insufficiency is seen , without genotype-phenotype correlation . X-ALD 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased @DiseaseTgt$ , and axonal damage . Most strikingly , however , cerebral invasion of leukocytes and demyelination were not observed in any animal model for X-ALD , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for ALD .	0 0 3 0 0 6 0 11 11 10 11 6 11 14 12 17 17 14 0 20 28 22 20 22 28 28 27 28 28 28 32 32 29 37 37 37 37 32 39 37 39 28 44 44 28 48 48 48 44 28 57 57 57 54 57 57 57 57 59 57 57 57 64 64 61 66 64 66 66 57 76 76 73 76 75 73 76 79 79 76 82 82 79 87 87 87 87 82 82 90 82 76 104 94 104 96 97 94 97 100 102 102 97 104 76 104 108 108 104 76 113 110 113 116 116 116 116 118 116 120 116 116 123 116 127 127 127 123 131 130 131 127 134 134 131 116 138 138 139 140 140 140 144 144 141 140 154 154 150 150 154 153 153 150 154 156 154 156 154 158 163 163 163 159 154 166 170 169 169 166 170 173 173 170 176 176 173 170 170 180 183 183 183 178 183 186 183 183 189 189|183 183 183 193 183 170 196 208 208 208 208 201 208 203 201 201 201 208 208 208 212 212 212 208 214 212 208 208 219 219 216 225 225 225 225 225 219 208 228 229 229 233 233 233 229 235 229 239 238 239 229 242 242 239 239 239 246 239 248 246 251 251 248 253 251 255 253 258 258 255 260 258 229	0
34716609	215	D000309	False	2	@GeneSrc$ and X-linked adrenoleukodystrophy : A disease with a markedly variable phenotype showing conserved neurobiology in animal models . X-linked adrenoleukodystrophy ( X-ALD ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . X-ALD is the most common peroxisomal inborn error of metabolism and confers a high degree of morbidity and mortality . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive demyelination , while in others only dying-back axonopathy or even isolated @DiseaseTgt$ is seen , without genotype-phenotype correlation . X-ALD 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased glial death , and axonal damage . Most strikingly , however , cerebral invasion of leukocytes and demyelination were not observed in any animal model for X-ALD , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for ALD .	0 0 3 0 0 6 0 11 11 10 11 6 11 14 12 17 17 14 0 20 28 22 20 22 28 28 27 28 28 28 32 32 29 37 37 37 37 32 39 37 39 28 44 44 28 48 48 48 44 28 57 57 57 54 57 57 57 57 59 57 57 57 64 64 61 66 64 66 66 57 76 76 73 76 75 73 76 79 79 76 82 82 79 87 87 87 87 82 82 90 82 76 103 94 103 96 97 94 97 100 101 97|101 103 76 103 107 107 103 76 112 109 112 115 115 115 115 117 115 119 115 115 122 115 126 126 126 122 130 129 130 126 133 133 130 115 137 137 138 139 139 139 143 143 140 139 153 153 149 149 153 152 152 149 153 155 153 155 153 157 162 162 162 158 153 165 169 168 168 165 169 172 172 169 175 175 172 169 169 179 182 182 182 177 182 185 182 182 189 189 182 182 182 193 182 169 196 208 208 208 208 201 208 203 201 201 201 208 208 208 212 212 212 208 214 212 208 208 219 219 216 225 225 225 225 225 219 208 228 229 229 233 233 233 229 235 229 239 238 239 229 242 242 239 239 239 246 239 248 246 251 251 248 253 251 255 253 258 258 255 260 258 229	0
34716609	215	D016472	False	2	@GeneSrc$ and X-linked adrenoleukodystrophy : A disease with a markedly variable phenotype showing conserved neurobiology in animal models . X-linked adrenoleukodystrophy ( X-ALD ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . X-ALD is the most common peroxisomal inborn error of metabolism and confers a high degree of morbidity and mortality . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive demyelination , while in others only @DiseaseTgt$ or even isolated adrenal insufficiency is seen , without genotype-phenotype correlation . X-ALD 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased glial death , and axonal damage . Most strikingly , however , cerebral invasion of leukocytes and demyelination were not observed in any animal model for X-ALD , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for ALD .	0 0 3 0 0 6 0 11 11 10 11 6 11 14 12 17 17 14 0 20 28 22 20 22 28 28 27 28 28 28 32 32 29 37 37 37 37 32 39 37 39 28 44 44 28 48 48 48 44 28 57 57 57 54 57 57 57 57 59 57 57 57 64 64 61 66 64 66 66 57 76 76 73 76 75 73 76 79 79 76 82 82 79 87 87 87 87 82 82 90 82 76 103 94 103 96 94|96 96 99 101 101 96 103 76 103 107 107 103 76 112 109 112 115 115 115 115 117 115 119 115 115 122 115 126 126 126 122 130 129 130 126 133 133 130 115 137 137 138 139 139 139 143 143 140 139 153 153 149 149 153 152 152 149 153 155 153 155 153 157 162 162 162 158 153 165 169 168 168 165 169 172 172 169 175 175 172 169 169 179 182 182 182 177 182 185 182 182 189 189 182 182 182 193 182 169 196 208 208 208 208 201 208 203 201 201 201 208 208 208 212 212 212 208 214 212 208 208 219 219 216 225 225 225 225 225 219 208 228 229 229 233 233 233 229 235 229 239 238 239 229 242 242 239 239 239 246 239 248 246 251 251 248 253 251 255 253 258 258 255 260 258 229	0
34716609	215	D001480	False	6	@GeneSrc$ and X-linked adrenoleukodystrophy : A disease with a markedly variable phenotype showing conserved neurobiology in animal models . X-linked adrenoleukodystrophy ( X-ALD ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . X-ALD is the most common peroxisomal inborn error of metabolism and confers a high degree of morbidity and mortality . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive demyelination , while in others only dying-back axonopathy or even isolated adrenal insufficiency is seen , without genotype-phenotype correlation . X-ALD 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased glial death , and @DiseaseTgt$ . Most strikingly , however , cerebral invasion of leukocytes and demyelination were not observed in any animal model for X-ALD , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for ALD .	0 0 3 0 0 6 0 11 11 10 11 6 11 14 12 17 17 14 0 20 28 22 20 22 28 28 27 28 28 28 32 32 29 37 37 37 37 32 39 37 39 28 44 44 28 48 48 48 44 28 57 57 57 54 57 57 57 57 59 57 57 57 64 64 61 66 64 66 66 57 76 76 73 76 75 73 76 79 79 76 82 82 79 87 87 87 87 82 82 90 82 76 104 94 104 96 97 94 97 100 102 102 97 104 76 104 108 108 104 76 113 110 113 116 116 116 116 118 116 120 116 116 123 116 127 127 127 123 131 130 131 127 134 134 131 116 138 138 139 140 140 140 144 144 141 140 154 154 150 150 154 153 153 150 154 156 154 156 154 158 163 163 163 159 154 166 170 169 169 166 170 173 173 170 176 176 173 170 170 180 183 183 183 178 183 186 183 183 190 190 183 183 183 183|193 170 196 208 208 208 208 201 208 203 201 201 201 208 208 208 212 212 212 208 214 212 208 208 219 219 216 225 225 225 225 225 219 208 228 229 229 233 233 233 229 235 229 239 238 239 229 242 242 239 239 239 246 239 248 246 251 251 248 253 251 255 253 258 258 255 260 258 229	0
34716609	215	D008661	False	1	@GeneSrc$ and X-linked adrenoleukodystrophy : A disease with a markedly variable phenotype showing conserved neurobiology in animal models . X-linked adrenoleukodystrophy ( X-ALD ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . X-ALD is the most common @DiseaseTgt$ and confers a high degree of morbidity and mortality . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive demyelination , while in others only dying-back axonopathy or even isolated adrenal insufficiency is seen , without genotype-phenotype correlation . X-ALD 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased glial death , and axonal damage . Most strikingly , however , cerebral invasion of leukocytes and demyelination were not observed in any animal model for X-ALD , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for ALD .	0 0 3 0 0 6 0 11 11 10 11 6 11 14 12 17 17 14 0 20 28 22 20 22 28 28 27 28 28 28 32 32 29 37 37 37 37 32 39 37 39 28 44 44 28 48 48 48 44 28 55 55 55 54 55 55 55 55 60 60 57 62 60 62 62 55 72 72 69 72 71 69 72 75 75 72 78 78 75 83 83 83 83 78 78 86 78 72 100 90 100 92 93 90 93 96 98 98 93 100 72 100 104 104 100 72 109 106 109 112 112 112 112 114 112 116 112 112 119 112 123 123 123 119 127 126 127 123 130 130 127 112 134 134 135 136 136 136 140 140 137 136 150 150 146 146 150 149 149 146 150 152 150 152 150 154 159 159 159 155 150 162 166 165 165 162 166 169 169 166 172 172 169 166 166 176 179 179 179 174 179 182 179 179 186 186 179 179 179 190 179 166 193 205 205 205 205 198 205 200 198 198 198 205 205 205 209 209 209 205 211 209 205 205 216 216 213 222 222 222 222 222 216 205 225 226 226 230 230 230 226 232 226 236 235 236 226 239 239 236 236 236 243 236 245 243 248 248 245 250 248 252 250 255 255 252 257 255 226	0
34716609	215	D000326	True	0	@GeneSrc$ and @DiseaseTgt$ : A disease with a markedly variable phenotype showing conserved neurobiology in animal models . @DiseaseTgt$ ( @DiseaseTgt$ ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . @DiseaseTgt$ is the most common peroxisomal inborn error of metabolism and confers a high degree of morbidity and mortality . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive demyelination , while in others only dying-back axonopathy or even isolated adrenal insufficiency is seen , without genotype-phenotype correlation . @DiseaseTgt$ 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased glial death , and axonal damage . Most strikingly , however , cerebral invasion of leukocytes and demyelination were not observed in any animal model for @DiseaseTgt$ , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for @DiseaseTgt$ .	0 0 0|2 0 5 0 10 10 9 10 5 10 13 11 16 16 13 0 18|26 20 18 20 26 26 25 26 26 26 30 30 27 35 35 35 35 30 37 35 37 26 42 42 26 46 46 46 42 26 55 55 55 52 55 55 55 55 57 55 55 55 62 62 59 64 62 64 64 55 74 74 71 74 73 71 74 77 77 74 80 80 77 85 85 85 85 80 80 88 80 74 102 92 102 94 95 92 95 98 100 100 95 102 74 102 106 106 102 74 111 108 111 114 114 114 114 116 114 118 114 114 121 114 125 125 125 121 129 128 129 125 132 132 129 114 136 136 137 138 138 138 142 142 139 138 152 152 148 148 152 151 151 148 152 154 152 154 152 156 161 161 161 157 152 164 168 167 167 164 168 171 171 168 174 174 171 168 168 178 181 181 181 176 181 184 181 181 188 188 181 181 181 192 181 168 195 207 207 207 207 200 207 202 200 200 200 207 207 207 211 211 211 207 213 211 207 207 218 218 215 224 224 224 224 224 218 207 227 228 228 232 232 232 228 234 228 238 237 238 228 241 241 238 238 238 245 238 247 245 250 250 247 252 250 254 252 257 257 254 259 257 228	1
34716609	215	D003711	False	2	@GeneSrc$ and X-linked adrenoleukodystrophy : A disease with a markedly variable phenotype showing conserved neurobiology in animal models . X-linked adrenoleukodystrophy ( X-ALD ) is a phenotypically heterogeneous disorder involving defective peroxisomal beta-oxidation of very long-chain fatty acids ( VLCFAs ) , due to mutation in the @GeneSrc$ gene . X-ALD is the most common peroxisomal inborn error of metabolism and confers a high degree of morbidity and mortality . Remarkably , a subset of patients exhibit a cerebral form with inflammatory invasion of the central nervous system and extensive @DiseaseTgt$ , while in others only dying-back axonopathy or even isolated adrenal insufficiency is seen , without genotype-phenotype correlation . X-ALD 's biochemical signature is marked elevation of VLCFAs in blood , a finding that has been utilized for massive newborn screening for early diagnosis . Investigational gene therapy approaches hold promises for improved outcomes . However , the pathophysiological mechanisms of the disease remain poorly understood , limiting investigation of targeted therapeutic options . Animal models for the disease recapitulate the biochemical signature of VLCFA accumulation and demonstrate mitochondrially generated reactive oxygen species , oxidative damage , increased glial death , and axonal damage . Most strikingly , however , cerebral invasion of leukocytes and @DiseaseTgt$ were not observed in any animal model for X-ALD , reflecting upon pathological processes that are yet to be discovered . This review summarizes the current disease models in animals , the lessons learned from these models , and the gaps that remained to be filled in order to assist in therapeutic investigations for ALD .	0 0 3 0 0 6 0 11 11 10 11 6 11 14 12 17 17 14 0 20 28 22 20 22 28 28 27 28 28 28 32 32 29 37 37 37 37 32 39 37 39 28 44 44 28 48 48 48 44 28 57 57 57 54 57 57 57 57 59 57 57 57 64 64 61 66 64 66 66 57 76 76 73 76 75 73 76 79 79 76 82 82 79 87 87 87 87 82 82 90 82 76 104 94 104 96 97 94 97 100 102 102 97 104 76 104 108 108 104 76 113 110 113 116 116 116 116 118 116 120 116 116 123 116 127 127 127 123 131 130 131 127 134 134 131 116 138 138 139 140 140 140 144 144 141 140 154 154 150 150 154 153 153 150 154 156 154 156 154 158 163 163 163 159 154 166 170 169 169 166 170 173 173 170 176 176 173 170 170 180 183 183 183 178 183 186 183 183 190 190 183 183 183 194 183 170 197 209 209 209 209 202 209 204 202 202 202 209 209 209 213 213 213 209 215 213 209 209 220 220 217 226 226 226 226 226 220 209 229 230 230 234 234 234 230 236 230 240 239 240 230 243 243 240 240 240 247 240 249 247 252 252 249 254 252 256 254 259 259 256 261 259 230	0
36348357	348	D000544	True	0	@GeneSrc$ in @DiseaseTgt$ : pathophysiology and therapeutic strategies . @DiseaseTgt$ ( @DiseaseTgt$ ) is the most common cause of dementia worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the @GeneSrc$ ( @GeneSrc$ ) gene remains the strongest and most prevalent , impacting more than half of all @DiseaseTgt$ cases . While the epsilon4 allele of the @GeneSrc$ gene significantly increases @DiseaseTgt$ risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three @GeneSrc$ protein isoforms that differ at two amino acid positions . The primary physiological function of @GeneSrc$ is to mediate lipid transport in the brain and periphery ; however , additional functions of @GeneSrc$ in diverse biological functions have been recognized . Pathogenically , @GeneSrc$ seeds amyloid-beta ( Abeta ) plaques in the brain with @GeneSrc$ driving earlier and more abundant amyloids . @GeneSrc$ isoforms also have differential effects on multiple Abeta-related or Abeta-independent pathways . The complexity of @GeneSrc$ biology and pathobiology presents challenges to designing effective @GeneSrc$ therapeutic strategies . This review examines the key pathobiological pathways of @GeneSrc$ and related targeting strategies with a specific focus on the latest technological advances and tools .	0 2 0|2 0 0 4 7 4 0 9|17 11 9 11 17 17 16 17 17 19 17 17 17 17 24 27 27 27 17 31 28 31 27 27 36 36 36 49 40 40 40 36 40 49 48 48 48 48 48 49 49 51 49 51 54 51 51 49 59 59 56 63 63 63 59 49 74 68 68 74 72 72 72 68 74 82 76 74 82 80 80 82 82 82 82 88 88 88 86 83 82 92 92 93 93 97 97 97 93 99 97 104 104 104 104 99 93 109 108 109 112 111 109 112 114 112 116 114 119 119 116 119 119 114 135 135 126 135 128 126 132 132 132 126 135 135 114 112 156 156 140 156 140 143 141 143 140 148 148 140 150 148 150 151 152 155 152 156 156 159 161 161 161 163 161 166 166 161 166 166 166 161 172 178 175 175 172 175 175 178 178 181 178 185 182 182 181 178 188 189 189 193 193 193 189 195 193 195 195 195 195 203 203 203 189 208 208 208 208 203 208 208 189	0
36348357	348	D003704	False	1	@GeneSrc$ in Alzheimer 's disease : pathophysiology and therapeutic strategies . Alzheimer 's disease ( AD ) is the most common cause of @DiseaseTgt$ worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the @GeneSrc$ ( @GeneSrc$ ) gene remains the strongest and most prevalent , impacting more than half of all AD cases . While the epsilon4 allele of the @GeneSrc$ gene significantly increases AD risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three @GeneSrc$ protein isoforms that differ at two amino acid positions . The primary physiological function of @GeneSrc$ is to mediate lipid transport in the brain and periphery ; however , additional functions of @GeneSrc$ in diverse biological functions have been recognized . Pathogenically , @GeneSrc$ seeds amyloid-beta ( Abeta ) plaques in the brain with @GeneSrc$ driving earlier and more abundant amyloids . @GeneSrc$ isoforms also have differential effects on multiple Abeta-related or Abeta-independent pathways . The complexity of @GeneSrc$ biology and pathobiology presents challenges to designing effective @GeneSrc$ therapeutic strategies . This review examines the key pathobiological pathways of @GeneSrc$ and related targeting strategies with a specific focus on the latest technological advances and tools .	0 4 4 4 0 0 0 6 9 6 0 13 13 21 15 13 15 21 21 20 21 21 23 21 21 21 21 28 31 31 31 21 35 32 35 31 31 40 40 40 53 44 44 44 40 44 53 52 52 52 52 52 53 53 55 53 55 58 55 55 53 63 63 60 67 67 67 63 53 78 72 72 78 76 76 76 72 78 86 80 78 86 84 84 86 86 86 86 92 92 92 90 87 86 96 96 97 97 101 101 101 97 103 101 108 108 108 108 103 97 113 112 113 116 115 113 116 118 116 120 118 123 123 120 123 123 118 139 139 130 139 132 130 136 136 136 130 139 139 118 116 160 160 144 160 144 147 145 147 144 152 152 144 154 152 154 155 156 159 156 160 160 163 165 165 165 167 165 170 170 165 170 170 170 165 176 182 179 179 176 179 179 182 182 185 182 189 186 186 185 182 192 193 193 197 197 197 193 199 197 199 199 199 199 207 207 207 193 212 212 212 212 207 212 212 193	0
36348357	351	D000544	False	3	ApoE in @DiseaseTgt$ : pathophysiology and therapeutic strategies . @DiseaseTgt$ ( @DiseaseTgt$ ) is the most common cause of dementia worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the apolipoprotein E ( APOE ) gene remains the strongest and most prevalent , impacting more than half of all @DiseaseTgt$ cases . While the epsilon4 allele of the APOE gene significantly increases @DiseaseTgt$ risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three apoE protein isoforms that differ at two amino acid positions . The primary physiological function of apoE is to mediate lipid transport in the brain and periphery ; however , additional functions of apoE in diverse biological functions have been recognized . Pathogenically , apoE seeds @GeneSrc$ ( @GeneSrc$ ) plaques in the brain with apoE4 driving earlier and more abundant amyloids . ApoE isoforms also have differential effects on multiple @GeneSrc$ or @GeneSrc$ pathways . The complexity of apoE biology and pathobiology presents challenges to designing effective apoE-targeted therapeutic strategies . This review examines the key pathobiological pathways of apoE and related targeting strategies with a specific focus on the latest technological advances and tools .	0 2 0|2 0 0 4 7 4 0 9|17 11 9 11 17 17 16 17 17 19 17 17 17 17 24 27 27 27 17 31 28 31 27 27 36 36 36 50 40 40 40 36 40 50 49 49 49 49 49 49 50 50 52 50 52 55 52 52 50 60 60 57 64 64 64 60 50 75 69 69 75 73 73 73 69 75 83 77 75 83 81 81 83 83 83 83 89 89 89 87 84 83 93 93 94 94 98 98 98 94 100 98 105 105 105 105 100 94 110 109 110 113 112 110 113 115 113 117 115 120 120 117 120 120 115 136 136 127 136 129 127 133 133 133 127 136 136 115 113 157 157 141 157 141 144 142 144 141 149 149 141 151 149 151 152 153 156 153 157 157 160 162 162 162 164 162 167 167 162 167 167 167 162 173 179 176 176 173 176 176 179 179 182 179 186 183 183 182 179 189 190 190 194 194 194 190 196 194 196 196 196 196 204 204 204 190 209 209 209 209 204 209 209 190	0
36348357	351	D003704	False	5	ApoE in Alzheimer 's disease : pathophysiology and therapeutic strategies . Alzheimer 's disease ( AD ) is the most common cause of @DiseaseTgt$ worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the apolipoprotein E ( APOE ) gene remains the strongest and most prevalent , impacting more than half of all AD cases . While the epsilon4 allele of the APOE gene significantly increases AD risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three apoE protein isoforms that differ at two amino acid positions . The primary physiological function of apoE is to mediate lipid transport in the brain and periphery ; however , additional functions of apoE in diverse biological functions have been recognized . Pathogenically , apoE seeds @GeneSrc$ ( @GeneSrc$ ) plaques in the brain with apoE4 driving earlier and more abundant amyloids . ApoE isoforms also have differential effects on multiple @GeneSrc$ or @GeneSrc$ pathways . The complexity of apoE biology and pathobiology presents challenges to designing effective apoE-targeted therapeutic strategies . This review examines the key pathobiological pathways of apoE and related targeting strategies with a specific focus on the latest technological advances and tools .	0 4 4 4 0 0 0 6 9 6 0 13 13 21 15 13 15 21 21 20 21 21 23 21 21 21 21 28 31 31 31 21 35 32 35 31 31 40 40 40 54 44 44 44 40 44 54 53 53 53 53 53 53 54 54 56 54 56 59 56 56 54 64 64 61 68 68 68 64 54 79 73 73 79 77 77 77 73 79 87 81 79 87 85 85 87 87 87 87 93 93 93 91 88 87 97 97 98 98 102 102 102 98 104 102 109 109 109 109 104 98 114 113 114 117 116 114 117 119 117 121 119 124 124 121 124 124 119 140 140 131 140 133 131 137 137 137 131 140 140 119 117 161 161 145 161 145 148 146 148 145 153 153 145 155 153 155 156 157 160 157 161 161 164 166 166 166 168 166 171 171 166 171 171 171 166 177 183 180 180 177 180 180 183 183 186 183 190 187 187 186 183 193 194 194 198 198 198 194 200 198 200 200 200 200 208 208 208 194 213 213 213 213 208 213 213 194	0
35986530	57526	D012640	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	57526	D020521	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	1000	D004827	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6324	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6323	D008881	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	2566	D004827	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	2566	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6326	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	57526	D030342	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6324	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6324	D004827	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	57526	D004827	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	1
35986530	1000	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	1000	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	1000	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	2566	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	1000	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6326	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6324	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6812	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6812	D004827	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6326	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6812	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6323	D000544	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6326	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6326	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6326	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6812	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6812	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	57526	D000544	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	1000	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6326	D004827	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6812	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6324	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6323	D030342	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	2566	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	57526	D008881	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6324	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6323	D012640	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6323	D009422	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	1000	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6323	D004827	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	1
35986530	57526	D000069279	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6324	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6326	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6324	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6323	D020521	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	1000	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6812	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	348980	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	348980	D004827	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 66 66 50 50 72 72 72 72 72 76 76 74 72 80 80 80 72 82 80 72 85 90 90 90 89 90 90 90 95 94 95 90 98 98 95 90 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	348980	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6323	D000069279	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6812	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	57526	D009422	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
36153580	4137	D010300	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and @DiseaseTgt$ , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 236|238 238 242 242 238 238 238 238 248 248 238 238 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	4137	D019636	False	2	APOE in the bullseye of @DiseaseTgt$ : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other @DiseaseTgt$ characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 5 3|5 0 0 11 11 11 7 16 16 13 16 7 16 19 16 0 28 28 28 25 28 25 25 28 31 31 28 28 34 34 38 38 38 34 38 38 40 38 38 38 38 38 38 50 50 38 52 50 54 34 60 60 58 60 60 54 63 63 60 68 68 68 68 63 70 68 70 34 75 75 75 78 78 75 80 78 75 75 85 85 75 85 88 85 93 93 93 93 85 75 96 97 97 102 100 102 102 97 105 105 102 105 106 107 111 111 108 113 111 120 120 119 116 119 120 102 122 120 122 122 97 97 97 129 127 129 129 97 134 135 135 141 141 140 138 141 135 143 141 146 146 143 146 152 148 152 152 143 152 156 156 152 158 156 160 156 160 160 160 163 160 160 160 169 156 169 172 169 172 175 172 175 175 175 156 181 156 135 184 184 186 184 186 189 187 189 194 194 194 190 194 198 196 194 198 198 198 198 202 205 198 205 208 198 208 211 198 215 215 215 198 184 218 256 222 222 222 218 225 225 225|218 225 229 229 226 225 218 231 234 218 234 238 236 234 238 242 242 238 238 238 238 248 248 238 238 234 252 234 218 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	4137	D009103	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and @DiseaseTgt$ , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 257 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 236|253 219 257 257 257 257 263 263 262 263 263 267 266 267 263 267 272 272 272 268 272 275 273 272 278 272 280 278 280 280 280 285 263 288 288 285 291 291 288 295 295 295 291 263	0
36153580	348	D010300	True	0	@GeneSrc$ in the bullseye of neurodegenerative diseases : impact of the @GeneSrc$ genotype in Alzheimer 's disease pathology and brain diseases . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the @GeneSrc$ genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and @DiseaseTgt$ , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 236|238 238 242 242 238 238 238 238 248 248 238 238 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	351	D019636	False	2	APOE in the bullseye of @DiseaseTgt$ : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other @DiseaseTgt$ characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 5 3|5 0 0 11 11 11 7 16 16 13 16 7 16 19 16 0 28 28 28 25 28 25 25 28 31 31 28 28 34 34 38 38 38 34 38 38 40 38 38 38 38 38 38 50 50 38 52 50 54 34 60 60 58 60 60 54 63 63 60 68 68 68 68 63 70 68 70 34 75 75 75 78 78 75 80 78 75 75 85 85 75 85 88 85 93 93 93 93 85 75 96 97 97 102 100 102 102 97 105 105 102 105 106 107 111 111 108 113 111 120 120 119 116 119 120 102 122 120 122 122 97 97 97 129 127 129 129 97 134 135 135 141 141 140 138 141 135 143 141 146 146 143 146 152 148 152 152 143 152 156 156 152 158 156 160 156 160 160 160 163 160 160 160 169 156 169 172 169 172 175 172 175 175 175 156 181 156 135 184 184 186 184 186 189 187 189 194 194 194 190 194 198 196 194 198 198 198 198 202 205 198 205 208 198 208 211 198 215 215 215 198 184 218 256 222 222 222 218 225 225 225|218 225 229 229 226 225 218 231 234 218 234 238 236 234 238 242 242 238 238 238 238 248 248 238 238 234 252 234 218 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	351	D010300	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and @DiseaseTgt$ , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 236|238 238 242 242 238 238 238 238 248 248 238 238 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	348	D000690	True	0	@GeneSrc$ in the bullseye of neurodegenerative diseases : impact of the @GeneSrc$ genotype in Alzheimer 's disease pathology and brain diseases . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the @GeneSrc$ genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , @DiseaseTgt$ , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 248|240 240 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	351	D000070642	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , @DiseaseTgt$ , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 242|240 240 240 240 248 248 240 240 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	351	D020521	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , @DiseaseTgt$ , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 258 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 254 236 219 258 258 258 258 264 264 263 264 264 268 267 268 264 268 273 273 273 269 273 276 274 273 279 273 281 279 281 281 281 286 264 289 289 286 292 292 289 296 296 296 292 264	0
36153580	351	D000690	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , @DiseaseTgt$ , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 248|240 240 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	4137	D020521	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , @DiseaseTgt$ , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 258 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 254 236 219 258 258 258 258 264 264 263 264 264 268 267 268 264 268 273 273 273 269 273 276 274 273 279 273 281 279 281 281 281 286 264 289 289 286 292 292 289 296 296 296 292 264	0
36153580	4137	D007249	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt @DiseaseTgt$ , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 258 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 254 236 219 258 258 258 258 264 264 263 264 264 268 267 268 264 268 273 273 273 269 273 276 274 273 279 273 281 279 281 281 281 286 264 289 289 286 292 292 289 296 296 296 292 264	0
36153580	348	D000070642	True	0	@GeneSrc$ in the bullseye of neurodegenerative diseases : impact of the @GeneSrc$ genotype in Alzheimer 's disease pathology and brain diseases . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the @GeneSrc$ genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , @DiseaseTgt$ , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 242|240 240 240 240 248 248 240 240 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	348	D020521	True	0	@GeneSrc$ in the bullseye of neurodegenerative diseases : impact of the @GeneSrc$ genotype in Alzheimer 's disease pathology and brain diseases . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the @GeneSrc$ genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , @DiseaseTgt$ , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 258 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 254 236 219 258 258 258 258 264 264 263 264 264 268 267 268 264 268 273 273 273 269 273 276 274 273 279 273 281 279 281 281 281 286 264 289 289 286 292 292 289 296 296 296 292 264	0
36153580	4137	D000070642	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , @DiseaseTgt$ , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 242|240 240 240 240 248 248 240 240 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	4137	D000544	True	0	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in @DiseaseTgt$ . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset @DiseaseTgt$ ( @DiseaseTgt$ ) . Neuroinflammation has become the third hallmark of @DiseaseTgt$ , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of @DiseaseTgt$ pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting @DiseaseTgt$ pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the @DiseaseTgt$ field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on @DiseaseTgt$ and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 14 8|14 0 23 23 23 20 23 20 20 23 26 26 23 23 29 29 33 33 33 29 33 33 35 33 33 33 33 33 33 45 45 33 47 45 49 29 55 55 53 55 55 49 58 58 55 61 61 61|58 63 61 63 29 68 68 68 71 71 68 73 71 68 68 78 78 68 78 81 78 86 86 86 86 78 68 89 90 90 95 93 95 95 90 98 98 95 98 99 100 104 104 101 106 104 113 113 112 109 112 113 95 115 113 115 115 90 90 90 122 120 122 122 90 127 128 128 134 134 133 131 134 128 136 134 139 139 136 139 145 141 145 145 136 145 149 149 145 151 149 153 149 153 153 153 156 153 153 153 162 149 162 165 162 165 168 165 168 168 168 149 174 149 128 177 177 179 177 179 182 180 182 187 187 187 183 187 191 189 187 191 191 191 191 195 198 191 198 201 191 201 204 191 208 208 208 191 177 211 250 215 215 215 211 219 219 219 211 219 223 223 220 219 211 225 228 211 228 232 230 228 232 236 236 232 232 232 232 242 242 232 232 228 246 228 211 250 250 250 250 256 256 255 256 256 260 259 260 256 260 265 265 265 261 265 268 266 265 271 265 273 271 273 273 273 278 256 281 281 278 284 284 281 288 288 288 284 256	0
36153580	348	D007249	True	0	@GeneSrc$ in the bullseye of neurodegenerative diseases : impact of the @GeneSrc$ genotype in Alzheimer 's disease pathology and brain diseases . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the @GeneSrc$ genotype in other neurodegenerative diseases characterized by overt @DiseaseTgt$ , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 258 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 254 236 219 258 258 258 258 264 264 263 264 264 268 267 268 264 268 273 273 273 269 273 276 274 273 279 273 281 279 281 281 281 286 264 289 289 286 292 292 289 296 296 296 292 264	0
36153580	351	D009103	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and @DiseaseTgt$ , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 257 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 236|253 219 257 257 257 257 263 263 262 263 263 267 266 267 263 267 272 272 272 268 272 275 273 272 278 272 280 278 280 280 280 285 263 288 288 285 291 291 288 295 295 295 291 263	0
36153580	348	D000544	True	0	@GeneSrc$ in the bullseye of neurodegenerative diseases : impact of the @GeneSrc$ genotype in @DiseaseTgt$ . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset @DiseaseTgt$ ( @DiseaseTgt$ ) . Neuroinflammation has become the third hallmark of @DiseaseTgt$ , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of @DiseaseTgt$ pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting @DiseaseTgt$ pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the @DiseaseTgt$ field . The impact of the @GeneSrc$ genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on @DiseaseTgt$ and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 6 6 3 0 0 12 12 12 8 14 8|14 0 23 23 23 20 23 20 20 23 26 26 23 23 29 29 33 33 33 29 33 33 35 33 33 33 33 33 33 45 45 33 47 45 49 29 55 55 53 55 55 49 58 58 55 61 61 61|58 63 61 63 29 68 68 68 71 71 68 73 71 68 68 78 78 68 78 81 78 86 86 86 86 78 68 89 90 90 95 93 95 95 90 98 98 95 98 99 100 104 104 101 106 104 113 113 112 109 112 113 95 115 113 115 115 90 90 90 122 120 122 122 90 127 128 128 134 134 133 131 134 128 136 134 139 139 136 139 145 141 145 145 136 145 149 149 145 151 149 153 149 153 153 153 156 153 153 153 162 149 162 165 162 165 168 165 168 168 168 149 174 149 128 177 177 179 177 179 182 180 182 187 187 187 183 187 191 189 187 191 191 191 191 195 198 191 198 201 191 201 204 191 208 208 208 191 177 211 250 215 215 215 211 219 219 219 211 219 223 223 220 219 211 225 228 211 228 232 230 228 232 236 236 232 232 232 232 242 242 232 232 228 246 228 211 250 250 250 250 256 256 255 256 256 260 259 260 256 260 265 265 265 261 265 268 266 265 271 265 273 271 273 273 273 278 256 281 281 278 284 284 281 288 288 288 284 256	1
36153580	348	D009103	True	0	@GeneSrc$ in the bullseye of neurodegenerative diseases : impact of the @GeneSrc$ genotype in Alzheimer 's disease pathology and brain diseases . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the @GeneSrc$ genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and @DiseaseTgt$ , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 257 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 236|253 219 257 257 257 257 263 263 262 263 263 267 266 267 263 267 272 272 272 268 272 275 273 272 278 272 280 278 280 280 280 285 263 288 288 285 291 291 288 295 295 295 291 263	0
36153580	351	D000544	True	0	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in @DiseaseTgt$ . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset @DiseaseTgt$ ( @DiseaseTgt$ ) . Neuroinflammation has become the third hallmark of @DiseaseTgt$ , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of @DiseaseTgt$ pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting @DiseaseTgt$ pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the @DiseaseTgt$ field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on @DiseaseTgt$ and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 14 8|14 0 23 23 23 20 23 20 20 23 26 26 23 23 29 29 33 33 33 29 33 33 35 33 33 33 33 33 33 45 45 33 47 45 49 29 55 55 53 55 55 49 58 58 55 61 61 61|58 63 61 63 29 68 68 68 71 71 68 73 71 68 68 78 78 68 78 81 78 86 86 86 86 78 68 89 90 90 95 93 95 95 90 98 98 95 98 99 100 104 104 101 106 104 113 113 112 109 112 113 95 115 113 115 115 90 90 90 122 120 122 122 90 127 128 128 134 134 133 131 134 128 136 134 139 139 136 139 145 141 145 145 136 145 149 149 145 151 149 153 149 153 153 153 156 153 153 153 162 149 162 165 162 165 168 165 168 168 168 149 174 149 128 177 177 179 177 179 182 180 182 187 187 187 183 187 191 189 187 191 191 191 191 195 198 191 198 201 191 201 204 191 208 208 208 191 177 211 250 215 215 215 211 219 219 219 211 219 223 223 220 219 211 225 228 211 228 232 230 228 232 236 236 232 232 232 232 242 242 232 232 228 246 228 211 250 250 250 250 256 256 255 256 256 260 259 260 256 260 265 265 265 261 265 268 266 265 271 265 273 271 273 273 273 278 256 281 281 278 284 284 281 288 288 288 284 256	0
36153580	4137	D000690	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , @GeneSrc$ pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , @DiseaseTgt$ , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 256 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 248|240 240 236 252 236 219 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	348	D019636	True	0	@GeneSrc$ in the bullseye of @DiseaseTgt$ : impact of the @GeneSrc$ genotype in Alzheimer 's disease pathology and brain diseases . @GeneSrc$ is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , @GeneSrc$ , @GeneSrc$ , and @GeneSrc$ , and the genetic expression of @GeneSrc$ is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with Amyloid-beta plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning @GeneSrc$ Starting from the evolution of @GeneSrc$ to how @GeneSrc$ 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how @GeneSrc$ 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of @GeneSrc$ on astrocytic and microglial function and microglial dynamics , synaptic function , amyloid-beta load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the @GeneSrc$ genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the @GeneSrc$ genotype in other @DiseaseTgt$ characterized by overt inflammation , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the @GeneSrc$ genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the @GeneSrc$ field .	0 3 3 0 5 3|5 0 0 11 11 11 7 16 16 13 16 7 16 19 16 0 28 28 28 25 28 25 25 28 31 31 28 28 34 34 38 38 38 34 38 38 40 38 38 38 38 38 38 50 50 38 52 50 54 34 60 60 58 60 60 54 63 63 60 68 68 68 68 63 70 68 70 34 75 75 75 78 78 75 80 78 75 75 85 85 75 85 88 85 93 93 93 93 85 75 96 97 97 102 100 102 102 97 105 105 102 105 106 107 111 111 108 113 111 120 120 119 116 119 120 102 122 120 122 122 97 97 97 129 127 129 129 97 134 135 135 141 141 140 138 141 135 143 141 146 146 143 146 152 148 152 152 143 152 156 156 152 158 156 160 156 160 160 160 163 160 160 160 169 156 169 172 169 172 175 172 175 175 175 156 181 156 135 184 184 186 184 186 189 187 189 194 194 194 190 194 198 196 194 198 198 198 198 202 205 198 205 208 198 208 211 198 215 215 215 198 184 218 256 222 222 222 218 225 225 225|218 225 229 229 226 225 218 231 234 218 234 238 236 234 238 242 242 238 238 238 238 248 248 238 238 234 252 234 218 256 256 256 256 262 262 261 262 262 266 265 266 262 266 271 271 271 267 271 274 272 271 277 271 279 277 279 279 279 284 262 287 287 284 290 290 287 294 294 294 290 262	0
36153580	351	D007249	False	2	APOE in the bullseye of neurodegenerative diseases : impact of the APOE genotype in Alzheimer 's disease pathology and brain diseases . ApoE is the major lipid and cholesterol carrier in the CNS . There are three major human polymorphisms , apoE2 , apoE3 , and apoE4 , and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer 's disease ( AD ) . Neuroinflammation has become the third hallmark of AD , together with @GeneSrc$ plaques and neurofibrillary tangles of hyperphosphorylated aggregated tau protein . This review aims to broadly and extensively describe the differential aspects concerning apoE. Starting from the evolution of apoE to how APOE 's single-nucleotide polymorphisms affect its structure , function , and involvement during health and disease . This review reflects on how APOE 's polymorphisms impact critical aspects of AD pathology , such as the neuroinflammatory response , particularly the effect of APOE on astrocytic and microglial function and microglial dynamics , synaptic function , @GeneSrc$ load , tau pathology , autophagy , and cell-cell communication . We discuss influential factors affecting AD pathology combined with the APOE genotype , such as sex , age , diet , physical exercise , current therapies and clinical trials in the AD field . The impact of the APOE genotype in other neurodegenerative diseases characterized by overt @DiseaseTgt$ , e.g. , alpha- synucleinopathies and Parkinson 's disease , traumatic brain injury , stroke , amyotrophic lateral sclerosis , and multiple sclerosis , is also addressed . Therefore , this review gathers the most relevant findings related to the APOE genotype up to date and its implications on AD and CNS pathologies to provide a deeper understanding of the knowledge in the APOE field .	0 3 3 0 6 6 3 0 0 12 12 12 8 17 17 14 17 8 17 20 17 0 29 29 29 26 29 26 26 29 32 32 29 29 35 35 39 39 39 35 39 39 41 39 39 39 39 39 39 51 51 39 53 51 55 35 61 61 59 61 61 55 64 64 61 69 69 69 69 64 71 69 71 35 76 76 76 79 79 76 81 79 76 76 86 86 76 86 89 86 94 94 94 94 86 76 97 98 98 103 101 103 103 98 106 106 103 106 107 108 112 112 109 114 112 121 121 120 117 120 121 103 123 121 123 123 98 98 98 130 128 130 130 98 135 136 136 142 142 141 139 142 136 144 142 147 147 144 147 153 149 153 153 144 153 157 157 153 159 157 161 157 161 161 161 164 161 161 161 170 157 170 173 170 173 176 173 176 176 176 157 182 157 136 185 185 187 185 187 190 188 190 195 195 195 191 195 199 197 195 199 199 199 199 203 206 199 206 209 199 209 212 199 216 216 216 199 185 219 258 223 223 223 219 227 227 227 219 227 231 231 228 227 219 233 236 219 236 240 238 236 240 244 244 240 240 240 240 250 250 240 240 236 254 236 219 258 258 258 258 264 264 263 264 264 268 267 268 264 268 273 273 273 269 273 276 274 273 279 273 281 279 281 281 281 286 264 289 289 286 292 292 289 296 296 296 292 264	0
31909500	215	D000326	True	0	@DiseaseTgt$ : Pathology , pathophysiology , diagnostic testing , newborn screening and therapies . @DiseaseTgt$ ( @DiseaseTgt$ ) is a rare X-linked disease caused by a mutation of the peroxisomal @GeneSrc$ gene . This review summarizes our current understanding of the pathogenic cell- and tissue-specific roles of lipid species in the context of experimental therapeutic strategies and provides an overview of critical historical developments , therapeutic trials and the advent of newborn screening in the USA . In @DiseaseTgt$ , very long-chain fatty acid ( VLCFA ) chain length-dependent dysregulation of endoplasmic reticulum stress and mitochondrial radical generating systems inducing cell death pathways has been shown , providing the rationale for therapeutic moiety-specific VLCFA reduction and antioxidant strategies . The continuing increase in newborn screening programs and promising results from ongoing and recent therapeutic investigations provide hope for @DiseaseTgt$ .	0 0 0 2 2 4 7 2 7 10 7 10 10 0 22 16 14 16 22 22 22 20 22 22 26 26 23 31 31 31 31 26 22 34 35 35 38 38 35 42 42 42 38 42 42 42 48 48 45 51 51 35 55 55 53 51 35 35 59 57 63 63 63 59 63 66 57 66 69 66 72 72 69 75 75 72 35 78 89 78 81 82 89 82 88 88 88 88 89 105 93 93 93 89 93 96 93 98 93 98 102 102 99 105 105 105 105 105 109 107 114 114 111 114 109 114 117 114 105 121 121 135 125 125 125 121 121 128 121 134 134 130 130 130 128 135 135 138 136 135	1
31909500	215	D000079225	False	2	X-linked adrenoleukodystrophy : Pathology , pathophysiology , diagnostic testing , newborn screening and therapies . Adrenoleukodystrophy ( ALD ) is a rare X-linked disease caused by a mutation of the peroxisomal @GeneSrc$ gene . This review summarizes our current understanding of the pathogenic cell- and tissue-specific roles of lipid species in the context of experimental therapeutic strategies and provides an overview of critical historical developments , therapeutic trials and the advent of newborn screening in the USA . In ALD , very long-chain fatty acid ( VLCFA ) chain length-dependent dysregulation of endoplasmic reticulum @DiseaseTgt$ and mitochondrial radical generating systems inducing cell death pathways has been shown , providing the rationale for therapeutic moiety-specific VLCFA reduction and antioxidant strategies . The continuing increase in newborn screening programs and promising results from ongoing and recent therapeutic investigations provide hope for ALD .	1 1 1 1 3 3 5 8 3 8 11 8 11 11 1 23 17 15 17 23 23 23 21 23 23 27 27 24 32 32 32 32 27 23 35 36 36 39 39 36 43 43 43 39 43 43 43 49 49 46 52 52 36 56 56 54 52 36 36 60 58 64 64 64 60 64 67 58 67 70 67 73 73 70 76 76 73 36 79 90 79 82 83 90 83 89 89 89 89 90 106 94 94 94 90 94 97 94 99 94 99 103 103 100 106 106 106 106 106 110 108 115 115 112 115 110 115 118 115 106 122 122 136 126 126 126 122 122 129 122 135 135 131 131 131 129 136 136 139 137 136	0
31909500	215	D040181	True	0	X-linked adrenoleukodystrophy : Pathology , pathophysiology , diagnostic testing , newborn screening and therapies . Adrenoleukodystrophy ( ALD ) is a rare @DiseaseTgt$ caused by a mutation of the peroxisomal @GeneSrc$ gene . This review summarizes our current understanding of the pathogenic cell- and tissue-specific roles of lipid species in the context of experimental therapeutic strategies and provides an overview of critical historical developments , therapeutic trials and the advent of newborn screening in the USA . In ALD , very long-chain fatty acid ( VLCFA ) chain length-dependent dysregulation of endoplasmic reticulum stress and mitochondrial radical generating systems inducing cell death pathways has been shown , providing the rationale for therapeutic moiety-specific VLCFA reduction and antioxidant strategies . The continuing increase in newborn screening programs and promising results from ongoing and recent therapeutic investigations provide hope for ALD .	1 1 1 1 3 3 5 8 3 8 11 8 11 11 1 22 17 15 17 22 22 22 21|22 22 26 26 23 31 31 31 31 26 22 34 35 35 38 38 35 42 42 42 38 42 42 42 48 48 45 51 51 35 55 55 53 51 35 35 59 57 63 63 63 59 63 66 57 66 69 66 72 72 69 75 75 72 35 78 89 78 81 82 89 82 88 88 88 88 89 105 93 93 93 89 93 96 93 98 93 98 102 102 99 105 105 105 105 105 109 107 114 114 111 114 109 114 117 114 105 121 121 135 125 125 125 121 121 128 121 134 134 130 130 130 128 135 135 138 136 135	0
34916831	467	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , @GeneSrc$ . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	1843	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , @GeneSrc$ , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	467	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , @GeneSrc$ . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	1277	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , @GeneSrc$ , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	3687	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , @GeneSrc$ , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	3687	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , @GeneSrc$ , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	1993	D020181	True	0	Identification of @GeneSrc$ Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the @GeneSrc$ genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 @GeneSrc$ genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	894	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , @GeneSrc$ , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	374	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including @GeneSrc$ , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	6696	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , @GeneSrc$ , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	2920	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , @GeneSrc$ , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	1843	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , @GeneSrc$ , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	894	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , @GeneSrc$ , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	2920	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , @GeneSrc$ , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	6696	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , @GeneSrc$ , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	374	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including @GeneSrc$ , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	59	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , @GeneSrc$ , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	1993	D000544	True	0	Identification of @GeneSrc$ Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the @GeneSrc$ genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 @GeneSrc$ genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	6319	D020181	False	9	Identification of Hub Genes in Patients with Alzheimer Disease and @DiseaseTgt$ Integrated Bioinformatics Analysis . Background : @DiseaseTgt$ ( OSA ) is associated with an increased risk of Alzheimer 's disease ( AD ) . This study aimed to identify the key common genes in AD and OSA and explore molecular mechanism value in AD . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to AD and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with AD and OSA by WGCNA , respectively . A total of 33 common genes were screened in AD and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , @GeneSrc$ , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to AD and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of AD at the transcriptome level .	0 3 3 0 5 3 8 8 5 8 8|10|3 13 13 10 0 22 15 15|17 19 17 19 22 22 26 26 26 22 30 30 30 26 32 30 32 22 36 37 37 39 37 43 43 43 39 45 43 45 45 39 39 52 52 49 54 49 37 64 56 59 60 56 60 60 64 64 72 72 72 72 72 72 72 64 64 64 64 80 80 80 80 89 82 80 82 80 87 87 80 89 89 91 89 93 94 91 96 94 96 96 100 98 100 100 89 105 106 139 106 109 107 111 109 111 109 115 109 117 115 117 117 121 119 121 117 106 106 129 129 129 106 131 129 131 129 136 136 133 139 139 139 143 143 143 139 139 151 151 149 149 151 151 151 155 155 155 151 155 159 159 156 162 162 159 151 174 164 167 174 167 170 167 174 174 174 174 176 174 176 176 180 174 174 174 174 185 191 189 189 189 185 191 191 193 191 193 193 197 191 191 201 201 202 202 207 207 207 207 202 210 210 207 213 213 210 213 213 202 219 219 233 233 225 225 224 225 233 228 228 225 230 228 228 233 233 237 237 237 233 237 240 237 240 240 240 240 240 240 240 240 240 240 240 240 252 252 252 240 240 240 233 264 264 263 264 264 267 267 264 270 270 264 273 273 270 275 270 275 275 264 281 281 283 283 283 286 286 283 288 283 291 291 288 294 294 291 298 298 298 294 300 298 304 304 304 298 283	0
34916831	59	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , SCD , @GeneSrc$ , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	6319	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , COL1A1 , @GeneSrc$ , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
34916831	1277	D000544	False	1	Identification of Hub Genes in Patients with @DiseaseTgt$ and Obstructive Sleep Apnea Syndrome Using Integrated Bioinformatics Analysis . Background : Obstructive sleep apnea syndrome ( OSA ) is associated with an increased risk of @DiseaseTgt$ ( @DiseaseTgt$ ) . This study aimed to identify the key common genes in @DiseaseTgt$ and OSA and explore molecular mechanism value in @DiseaseTgt$ . Methods : Expression profiles GSE5281 and GSE135917 were acquired from Gene Expression Omnibus ( GEO ) database , respectively . Weighted gene co-expression network analysis ( WGCNA ) and R 4.0.2 software were used for identifying differentially expressed genes ( DEGs ) related to @DiseaseTgt$ and OSA . Function enrichment analyses using Gene Ontology ( GO ) and Kyoto Encyclopedia of Genes and Genomes ( KEGG ) pathway , and the protein-protein interaction network ( PPI ) using the STRING database were subsequently performed on the shared DEGs . Finally , the hub genes were screened from the PPI network using the MCC algorithm of CytoHubba plugin . Results : Seven modules and four modules were the most significant with @DiseaseTgt$ and OSA by WGCNA , respectively . A total of 33 common genes were screened in @DiseaseTgt$ and OSA by VENN . Functional enrichment analysis indicated that DEGs were mainly involved in cellular response to oxidative stress , neuroinflammation . Among these DEGs , the top 10 hub genes ( high scores in cytoHubba ) were selected in the PPI network , including AREG , SPP1 , CXCL2 , ITGAX , DUSP1 , @GeneSrc$ , SCD , ACTA2 , CCND2 , ATF3 . Conclusion : This study presented ten target genes on the basis of common genes to @DiseaseTgt$ and OSA . These candidate genes may provide a novel perspective to explore the underlying mechanism that OSA leads to an increased risk of @DiseaseTgt$ at the transcriptome level .	0 3 3 0 5 3 7 5|7 7 12 12 12 7 3 16 16 13 0 28 18 23 23 23 18 25 23 25 28 28 32 32 32 28 34 34|32 36 34 36 28 40 41 41 43 41 47 47 47 43 49 47 49 49 43 43 56 56 53 58 53 41 68 60 63 64 60 64 64 68 68 76 76 76 76 76 76 76 68 68 68 68 84 84 84 84 93 86 84 86 84 91 91 84 93 93 95 93 97 98 95 100 98 100 100 104 102 104 104 93 109 110 143 110 113 111 115 113 115 113 119 113 121 119 121 121 125 123 125 121 110 110 133 133 133 110 135 133 135 133 140 140 137 143 143 143 147 147 147 143 143 155 155 153 153 155 155 155 159 159 159 155 159 163 163 160 166 166 163 155 178 168 171 178 171 174 171 178 178 178 178 180 178 180 180 184 178 178 178 178 189 195 193 193 193 189 195 195 197 195 197 197 201 195 195 205 205 206 206 211 211 211 211 206 214 214 211 217 217 214 217 217 206 223 223 237 237 229 229 228 229 237 232 232 229 234 232 232 237 237 241 241 241 237 241 244 241 244 244 244 244 244 244 244 244 244 244 244 244 256 256 256 244 244 244 237 268 268 267 268 268 271 271 268 274 274 268 277 277 274 279 274 279 279 268 285 285 287 287 287 290 290 287 292 287 295 295 292 298 298 295 302 302 302 298 304 302 308 308 308 302 287	0
26593886	5309	D020271	False	7	From eyeless to @DiseaseTgt$ . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. @GeneSrc$ ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 3 1|3 1 6 9 9 9 9 12 12 9 16 16 16 12 19 19 16 21 19 21 24 21 21 19 29 29 19 31 29 33 31 33 31 38 38 35 43 43 43 43 38 46 46 43 46 50 50 46 9 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	1414	D000853	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between @DiseaseTgt$ and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or @DiseaseTgt$ are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. @GeneSrc$ , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 89 87|89 89 92 89 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 258 258 244 247 247 247 242 247 251 251 247 255 255 253 251|253|255 258 258 240 261 261 258 261 261 265 263 265 261 258 258 272 272 258 274 272 277 277 274 277 272 282 282 272 284 282 284 287 284 287 287 284 239	0
26593886	351	D000853	False	1	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( @GeneSrc$ ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between @DiseaseTgt$ and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or @DiseaseTgt$ are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 89 87|89 89 92 89 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 258 258 244 247 247 247 242 247 251 251 247 255 255 253 251|253|255 258 258 240 261 261 258 261 261 265 263 265 261 258 258 272 272 258 274 272 277 277 274 277 272 282 282 272 284 282 284 287 284 287 287 284 239	0
26593886	351	D009422	False	1	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( @GeneSrc$ ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and @DiseaseTgt$ . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in @DiseaseTgt$ ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 90|92 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 283 274|283 283 286 283 286 286 283 239	0
26593886	351	D002386	True	0	From eyeless to neurological diseases . Age-related @DiseaseTgt$ are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( @GeneSrc$ ) leading to the hypothesis that @DiseaseTgt$ could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 275 275 261 277 275 280 280 277 280 275 285 285 275 287 285 287 290 287 290 290 287 240	0
26593886	1415	D020271	False	7	From eyeless to @DiseaseTgt$ . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , @GeneSrc$ ) .	1 1 3 1|3 1 6 9 9 9 9 12 12 9 16 16 16 12 19 19 16 21 19 21 24 21 21 19 29 29 19 31 29 33 31 33 31 38 38 35 43 43 43 43 38 46 46 43 46 50 50 46 9 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	1414	D002386	False	6	From eyeless to neurological diseases . Age-related @DiseaseTgt$ are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that @DiseaseTgt$ could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. @GeneSrc$ , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 275 275 261 277 275 280 280 277 280 275 285 285 275 287 285 287 290 287 290 290 287 240	0
26593886	43812	D020271	True	0	From @GeneSrc$ to @DiseaseTgt$ . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila @GeneSrc$ gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 3 1|3 1 6 9 9 9 9 12 12 9 16 16 16 12 19 19 16 21 19 21 24 21 21 19 29 29 19 31 29 33 31 33 31 38 38 35 43 43 43 43 38 46 46 43 46 50 50 46 9 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	5080	D020271	False	4	From eyeless to @DiseaseTgt$ . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian @GeneSrc$ gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that @GeneSrc$ is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( @GeneSrc$ ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 3 1|3 1 6 9 9 9 9 12 12 9 16 16 16 12 19 19 16 21 19 21 24 21 21 19 29 29 19 31 29 33 31 33 31 38 38 35 43 43 43 43 38 46 46 43 46 50 50 46 9 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	351	D019636	False	6	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( @GeneSrc$ ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in @DiseaseTgt$ ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 274 274|261 277 277 274 277 274 282 282 274 284 282 284 287 284 287 287 284 240	0
26593886	5080	D000853	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between @DiseaseTgt$ and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian @GeneSrc$ gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that @GeneSrc$ is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or @DiseaseTgt$ are also involved in regenerative processes and neurogenesis ( @GeneSrc$ ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 89 87|89 89 92 89 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 258 258 244 247 247 247 242 247 251 251 247 255 255 253 251|253|255 258 258 240 261 261 258 261 261 265 263 265 261 258 258 272 272 258 274 272 277 277 274 277 272 282 282 272 284 282 284 287 284 287 287 284 239	1
26593886	1415	D019636	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in @DiseaseTgt$ ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , @GeneSrc$ ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 274 274|261 277 277 274 277 274 282 282 274 284 282 284 287 284 287 287 284 240	0
26593886	5309	D000853	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between @DiseaseTgt$ and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or @DiseaseTgt$ are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. @GeneSrc$ ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 89 87|89 89 92 89 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 258 258 244 247 247 247 242 247 251 251 247 255 255 253 251|253|255 258 258 240 261 261 258 261 261 265 263 265 261 258 258 272 272 258 274 272 277 277 274 277 272 282 282 272 284 282 284 287 284 287 287 284 239	0
26593886	1414	D000544	False	6	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for @DiseaseTgt$ . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. @GeneSrc$ , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 50 47|50 10 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	5309	D009422	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and @DiseaseTgt$ . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. @GeneSrc$ ) or in @DiseaseTgt$ ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 90|92 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 283 274|283 283 286 283 286 286 283 239	0
26593886	43812	D002386	False	1	From @GeneSrc$ to neurological diseases . Age-related @DiseaseTgt$ are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that @DiseaseTgt$ could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila @GeneSrc$ gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 275 275 261 277 275 280 280 277 280 275 285 285 275 287 285 287 290 287 290 290 287 240	0
26593886	351	D020271	False	1	From eyeless to @DiseaseTgt$ . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( @GeneSrc$ ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 3 1|3 1 6 9 9 9 9 12 12 9 16 16 16 12 19 19 16 21 19 21 24 21 21 19 29 29 19 31 29 33 31 33 31 38 38 35 43 43 43 43 38 46 46 43 46 50 50 46 9 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	1414	D009422	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and @DiseaseTgt$ . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in @DiseaseTgt$ ( e.g. @GeneSrc$ , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 90|92 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 283 274|283 283 286 283 286 286 283 239	1
26593886	5080	D019636	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian @GeneSrc$ gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that @GeneSrc$ is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( @GeneSrc$ ) , but also in @DiseaseTgt$ ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 274 274|261 277 277 274 277 274 282 282 274 284 282 284 287 284 287 287 284 240	0
26593886	1415	D002386	False	6	From eyeless to neurological diseases . Age-related @DiseaseTgt$ are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that @DiseaseTgt$ could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , @GeneSrc$ ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 275 275 261 277 275 280 280 277 280 275 285 285 275 287 285 287 290 287 290 290 287 240	0
26593886	5309	D000544	False	6	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for @DiseaseTgt$ . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. @GeneSrc$ ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 50 47|50 10 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	5080	D000544	False	3	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for @DiseaseTgt$ . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian @GeneSrc$ gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that @GeneSrc$ is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( @GeneSrc$ ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 50 47|50 10 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	5309	D019636	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in @DiseaseTgt$ ( e.g. @GeneSrc$ ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 274 274|261 277 277 274 277 274 282 282 274 284 282 284 287 284 287 287 284 240	1
26593886	1415	D009422	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and @DiseaseTgt$ . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in @DiseaseTgt$ ( e.g. Crybb1 , @GeneSrc$ ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 90|92 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 283 274|283 283 286 283 286 286 283 239	1
26593886	43812	D019636	False	3	From @GeneSrc$ to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila @GeneSrc$ gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in @DiseaseTgt$ ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 274 274|261 277 277 274 277 274 282 282 274 284 282 284 287 284 287 287 284 240	0
26593886	1415	D000853	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between @DiseaseTgt$ and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or @DiseaseTgt$ are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , @GeneSrc$ ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 89 87|89 89 92 89 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 258 258 244 247 247 247 242 247 251 251 247 255 255 253 251|253|255 258 258 240 261 261 258 261 261 265 263 265 261 258 258 272 272 258 274 272 277 277 274 277 272 282 282 272 284 282 284 287 284 287 287 284 239	0
26593886	43812	D000544	False	1	From @GeneSrc$ to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for @DiseaseTgt$ . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila @GeneSrc$ gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 50 47|50 10 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	5309	D002386	False	6	From eyeless to neurological diseases . Age-related @DiseaseTgt$ are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that @DiseaseTgt$ could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. @GeneSrc$ ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 275 275 261 277 275 280 280 277 280 275 285 285 275 287 285 287 290 287 290 290 287 240	0
26593886	43812	D009422	False	2	From @GeneSrc$ to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and @DiseaseTgt$ . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila @GeneSrc$ gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in @DiseaseTgt$ ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 90|92 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 283 274|283 283 286 283 286 286 283 239	0
26593886	43812	D000853	False	2	From @GeneSrc$ to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between @DiseaseTgt$ and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila @GeneSrc$ gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or @DiseaseTgt$ are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 89 87|89 89 92 89 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 258 258 244 247 247 247 242 247 251 251 247 255 255 253 251|253|255 258 258 240 261 261 258 261 261 265 263 265 261 258 258 272 272 258 274 272 277 277 274 277 272 282 282 272 284 282 284 287 284 287 287 284 239	0
26593886	351	D000544	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( @GeneSrc$ ) leading to the hypothesis that cataracts could be used as " biomarkers " for @DiseaseTgt$ . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 50 47|50 10 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	1415	D000544	False	6	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for @DiseaseTgt$ . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , @GeneSrc$ ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 50 47|50 10 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	1414	D019636	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in @DiseaseTgt$ ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. @GeneSrc$ , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 274 274|261 277 277 274 277 274 282 282 274 284 282 284 287 284 287 287 284 240	0
26593886	5080	D009422	True	0	From eyeless to neurological diseases . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and @DiseaseTgt$ . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian @GeneSrc$ gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that @GeneSrc$ is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( @GeneSrc$ ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in @DiseaseTgt$ ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 90|92 83 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 283 274|283 283 286 283 286 286 283 239	0
26593886	1414	D020271	False	7	From eyeless to @DiseaseTgt$ . Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that cataracts could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian Pax6 gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that Pax6 is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( Pax6 ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. @GeneSrc$ , Crybb2 ) .	1 1 3 1|3 1 6 9 9 9 9 12 12 9 16 16 16 12 19 19 16 21 19 21 24 21 21 19 29 29 19 31 29 33 31 33 31 38 38 35 43 43 43 43 38 46 46 43 46 50 50 46 9 57 57 55 57 57 82 63 60 63 60 63 57 65 63 65 65 65 65 65 72 65 72 72 65 65 82 82 82 82 82 82 84 82 86 84 89 89 86 89 92 89 82 96 96 99 99 99 99 101 99 103 101 103 103 110 110 110 110 99 112 110 99 115 130 119 119 119 115 124 124 124 124 119 129 129 129 129 119 130 133 133 130 137 137 137 133 140 140 137 130 143 144 130 147 147 144 147 153 153 152 153 147 156 156 153 158 153 158 158 130 164 164 167 167 167 167 172 172 172 172 167 175 175 172 178 178 175 178 182 182 179 185 185 182 167 188 189 189 192 192 189 194 189 194 209 199 199 209 202 202 199 202 199 206 207 209 209 195 209 209 213 209 213 213 213 213 217 217 222 222 209 226 226 226 222 230 230 230 226 209 189 235 235 239 237 239 239 239 239 260 260 244 247 247 247 242 247 251 251 247 257 257 253 253 257 251 260 260 240 263 263 260 263 263 267 265 267 263 260 260 274 274 260 276 274 279 279 276 279 274 284 284 274 286 284 286 289 286 289 289 286 239	0
26593886	5080	D002386	False	3	From eyeless to neurological diseases . Age-related @DiseaseTgt$ are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins , but also other proteins including amyloids ( Abeta ) leading to the hypothesis that @DiseaseTgt$ could be used as " biomarkers " for Alzheimer disease . Even if this hypothesis was rejected by David Beebe 's last paper ( Bei et al. , Exp . Eye Res . , 2015 ) , it is a fascinating aspect to look for commonalities between eye diseases and neurological disorders . In this review , I discuss such commonalities between eye and brain mainly from a developmental point of view . The finding of the functional homology of the Drosophila eyeless gene with the mammalian @GeneSrc$ gene marks a first highlight in the developmental genetics of the eye - this result destroyed the " dogma " of the different evolutionary routes of eye development in flies and mammals . The second highlight was the finding that @GeneSrc$ is also involved in the development of the forebrain supporting the pleiotropic role of many genes . These findings opened a new avenue for research showing that a broad variety of transcription factors , but also structural proteins are involved both , in eye and brain development as well as into the maintenance of the functional integrity of the corresponding tissue(s ) . In this review recent findings are summarized demonstrating that genes whose mutations have been identified first to be causative for congenital or juvenile eye disorders are also involved in regenerative processes and neurogenesis ( @GeneSrc$ ) , but also in neurodegenerative diseases like Parkinson ( e.g. Pitx3 ) or in neurological disorders like Schizophrenia ( e.g. Crybb1 , Crybb2 ) .	1 1 4 4 1 1 7 10 10 10 10 13 13 10 17 17 17 13 20 20 17 22 20 22 25 22 22 20 30 30 20 32 30 34 32 34 32 39 39 36 44 44 44 44 39 47 47 44 47 51 51 47 10 58 58 56 58 58 83 64 61 64 61 64 58 66 64 66 66 66 66 66 73 66 73 73 66 66 83 83 83 83 83 83 85 83 87 85 90 90 87 90 93 90 83 97 97 100 100 100 100 102 100 104 102 104 104 111 111 111 111 100 113 111 100 116 131 120 120 120 116 125 125 125 125 120 130 130 130 130 120 131 134 134 131 138 138 138 134 141 141 138 131 144 145 131 148 148 145 148 154 154 153 154 148 157 157 154 159 154 159 159 131 165 165 168 168 168 168 173 173 173 173 168 176 176 173 179 179 176 179 183 183 180 186 186 183 168 189 190 190 193 193 190 195 190 195 210 200 200 210 203 203 200 203 200 207 208 210 210 196 210 210 214 210 214 214 214 214 218 218 223 223 210 227 227 227 223 231 231 231 227 210 190 236 236 240 238 240 240 240 240 261 261 245 248 248 248 243 248 252 252 248 258 258 254 254 258 252 261 261 241 264 264 261 264 264 268 266 268 264 261 261 275 275 261 277 275 280 280 277 280 275 285 285 275 287 285 287 290 287 290 290 287 240	0
19715727	6657	D019636	False	2	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , @GeneSrc$ , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after @DiseaseTgt$ and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	6657	D010300	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , @DiseaseTgt$ , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , @GeneSrc$ , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 25|30 30 34 34 30 34 30 38 30 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	4684	D020521	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including @DiseaseTgt$ , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , @GeneSrc$ , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	4440	D000070642	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and @DiseaseTgt$ . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , @GeneSrc$ , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32|38 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	4440	D000544	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , @DiseaseTgt$ and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , @GeneSrc$ , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 32|34 34 32 38 32 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6657	D009410	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . @DiseaseTgt$ is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , @GeneSrc$ , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 16|20 20 20 20 20 24 24 24 20 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 20 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	6658	D009422	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many @DiseaseTgt$ , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , @GeneSrc$ , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 24 24 24|21 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 21 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	5080	D009410	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . @DiseaseTgt$ is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and @GeneSrc$ . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 16|20 20 20 20 20 24 24 24 20 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 20 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	4440	D009410	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . @DiseaseTgt$ is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , @GeneSrc$ , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 16|20 20 20 20 20 24 24 24 20 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 20 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	10763	D009422	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many @DiseaseTgt$ , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as @GeneSrc$ , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 24 24 24|21 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 21 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	6658	D000544	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , @DiseaseTgt$ and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , @GeneSrc$ , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 32|34 34 32 38 32 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	4684	D009410	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . @DiseaseTgt$ is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , @GeneSrc$ , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 16|20 20 20 20 20 24 24 24 20 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 20 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	6657	D009422	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many @DiseaseTgt$ , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , @GeneSrc$ , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 24 24 24|21 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 21 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	6656	D009422	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many @DiseaseTgt$ , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , @GeneSrc$ , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 24 24 24|21 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 21 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	6658	D009410	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . @DiseaseTgt$ is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , @GeneSrc$ , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 16|20 20 20 20 20 24 24 24 20 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 20 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	10763	D020521	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including @DiseaseTgt$ , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as @GeneSrc$ , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	4684	D000544	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , @DiseaseTgt$ and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , @GeneSrc$ , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 32|34 34 32 38 32 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	10763	D000070642	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and @DiseaseTgt$ . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as @GeneSrc$ , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32|38 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6656	D009410	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . @DiseaseTgt$ is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , @GeneSrc$ , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 16|20 20 20 20 20 24 24 24 20 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 20 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	4684	D009422	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many @DiseaseTgt$ , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , @GeneSrc$ , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 24 24 24|21 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 21 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	5080	D010300	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , @DiseaseTgt$ , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and @GeneSrc$ . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 25|30 30 34 34 30 34 30 38 30 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	5080	D019636	False	2	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and @GeneSrc$ . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after @DiseaseTgt$ and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	6658	D019636	False	2	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , @GeneSrc$ , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after @DiseaseTgt$ and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	5080	D000544	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , @DiseaseTgt$ and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and @GeneSrc$ . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 32|34 34 32 38 32 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6656	D000544	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , @DiseaseTgt$ and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , @GeneSrc$ , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 32|34 34 32 38 32 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6657	D000544	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , @DiseaseTgt$ and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , @GeneSrc$ , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 32|34 34 32 38 32 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6657	D000070642	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and @DiseaseTgt$ . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , @GeneSrc$ , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32|38 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	10763	D010300	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , @DiseaseTgt$ , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as @GeneSrc$ , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 25|30 30 34 34 30 34 30 38 30 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6656	D010300	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , @DiseaseTgt$ , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , @GeneSrc$ , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 25|30 30 34 34 30 34 30 38 30 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	5080	D000070642	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and @DiseaseTgt$ . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and @GeneSrc$ . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32|38 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6656	D019636	False	2	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , @GeneSrc$ , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after @DiseaseTgt$ and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	4440	D010300	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , @DiseaseTgt$ , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , @GeneSrc$ , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 25|30 30 34 34 30 34 30 38 30 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	4440	D019636	False	2	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , @GeneSrc$ , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after @DiseaseTgt$ and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	6658	D020521	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including @DiseaseTgt$ , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , @GeneSrc$ , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	10763	D009410	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . @DiseaseTgt$ is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as @GeneSrc$ , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 16|20 20 20 20 20 24 24 24 20 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 20 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	6656	D000070642	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and @DiseaseTgt$ . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , @GeneSrc$ , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32|38 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	10763	D000544	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , @DiseaseTgt$ and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as @GeneSrc$ , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 32|34 34 32 38 32 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	4684	D019636	False	2	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , @GeneSrc$ , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after @DiseaseTgt$ and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	4684	D010300	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , @DiseaseTgt$ , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , @GeneSrc$ , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 25|30 30 34 34 30 34 30 38 30 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6657	D020521	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including @DiseaseTgt$ , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , @GeneSrc$ , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	5080	D020521	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including @DiseaseTgt$ , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and @GeneSrc$ . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	4440	D020521	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including @DiseaseTgt$ , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , @GeneSrc$ , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	4440	D009422	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many @DiseaseTgt$ , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , @GeneSrc$ , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 24 24 24|21 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 21 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	4684	D000070642	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and @DiseaseTgt$ . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , @GeneSrc$ , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32|38 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	6658	D000070642	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and @DiseaseTgt$ . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , @GeneSrc$ , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32|38 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	5080	D009422	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many @DiseaseTgt$ , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and @GeneSrc$ . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 24 24 24|21 24 27 24 27 31 29 24 31 35 35 31 35 31 39 31 21 44 44 44 52 47 47 44 49 47 49 52 52 54 52 56 54 59 59 56 59 59 64 64 54 64 64 66 66 64 71 69 75 75 75 71 52 79 79 79 81 79 84 84 81 87 87 84 91 91 91 84 94 94 91 79 101 101 101 98 98 105 105 105 105 105 107 105 109 107 112 112 107 114 112 114 114 121 121 121 121 112 121 125 125 107 130 130 130 130 125 105 135 135 135 141 141 139 139 141 141 141 143 141 145 148 145 145 143 148 152 150 148 152 152 152 152 152 152 152 152 152 152 152 152 152 152 152 141 171 171 172 172 174 172 179 177 179 179 174 179 182 179 172 172 186 187 172 189 187 191 189 193 191 198 198 198 198 191 200 198 200 200 202 202 200 172 208 209 209 213 210 210 209 216 216 213 221 221 221 221 213 223 221 226 226 221 228 226 228 228 228 233 226 221 221 238 238 235 241 241 238 243 238 246 246 243 209	0
19715727	6656	D020521	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including @DiseaseTgt$ , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , @GeneSrc$ , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
19715727	6658	D010300	False	4	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , @DiseaseTgt$ , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as Nestin , Sox1 , Sox2 , @GeneSrc$ , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after neurodegeneration and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 25|30 30 34 34 30 34 30 38 30 21 43 43 43 51 46 46 43 48 46 48 51 51 53 51 55 53 58 58 55 58 58 63 63 53 63 63 65 65 63 70 68 74 74 74 70 51 78 78 78 80 78 83 83 80 86 86 83 90 90 90 83 93 93 90 78 100 100 100 97 97 104 104 104 104 104 106 104 108 106 111 111 106 113 111 113 113 120 120 120 120 111 120 124 124 106 129 129 129 129 124 104 134 134 134 140 140 138 138 140 140 140 142 140 144 147 144 144 142 147 151 149 147 151 151 151 151 151 151 151 151 151 151 151 151 151 151 151 140 170 170 171 171 173 171 178 176 178 178 173 178 181 178 171 171 185 186 171 188 186 190 188 192 190 197 197 197 197 190 199 197 199 199 201 201 199 171 207 208 208 212 209 209 208 215 215 212 220 220 220 220 212 222 220 225 225 220 227 225 227 227 227 232 225 220 220 237 237 234 240 240 237 242 237 245 245 242 208	0
19715727	10763	D019636	False	2	A method for rapid derivation and propagation of neural progenitors from human embryonic stem cells . Neuronal loss is a common feature of many neurological disorders , including stroke , Parkinson 's disease , Alzheimer 's disease and traumatic brain injury . Human embryonic stem cell (hESC)-derived neural progenitors ( NPs ) may provide new ways of treatment for several diseases and injuries in the brain , as well as enhance our understanding of early human development . Here we report a method for rapid generation of proliferating NPs from feeder free cultures of undifferentiated hESCs . In this rapid and simple protocol , NPs are derived by seeding undifferentiated hESC on adherent surfaces of laminin or gelatine with normal hESC culturing medium and with the addition of basic fibroblast growth factor . After the first passage , adherent monolayer progenitors are derived that express early neuroectodermal and progenitor markers , such as @GeneSrc$ , Sox1 , Sox2 , Sox3 , Internexin , Musashi-1 , NCAM , and Pax6 . This novel protocol renders hESCs suitable for large scale progenitor production and long-term propagation , and the progenitors have the capacity to differentiate in vitro into all three neural lineages ( neurons , astrocytes and oligodendrocytes ) . This method allows rapid , cost-efficient production of expandable progenitors that may be a source of cells for the restoration of cellular and functional loss after @DiseaseTgt$ and/or provide a useful source of progenitor cells for studying early brain development .	1 1 4 4 1 4 4 9 9 4 14 14 14 14 4 1 17 21 21 21 21 21 25 25 25 21 25 28 25 28 32 30 25 32 36 36 32 36 32 40 32 21 45 45 45 53 48 48 45 50 48 50 53 53 55 53 57 55 60 60 57 60 60 65 65 55 65 65 67 67 65 72 70 76 76 76 72 53 80 80 80 82 80 85 85 82 88 88 85 92 92 92 85 95 95 92 80 102 102 102 99 99 106 106 106 106 106 108 106 110 108 113 113 108 115 113 115 115 122 122 122 122 113 122 126 126 108 131 131 131 131 126 106 136 136 136 142 142 140 140 142 142 142 144 142 146 149 146 146 144 149 153 151 149 153 153 153 153 153 153 153 153 153 153 153 153 153 153 153 142 172 172 173 173 175 173 180 178 180 180 175 180 183 180 173 173 187 188 173 190 188 192 190 194 192 199 199 199 199 192 201 199 201 201 203 203 201 173 209 210 210 214 211 211 210 217 217 214 222 222 222 222 214 224 222 227 227 222 229 227 229 229 229 234 227 222 222 239 239 236 242 242 239 244 239 247 247 244 210	0
32867562	693122	D000544	False	2	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , @GeneSrc$ , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	406921	D000544	True	0	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( @GeneSrc$ , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . @GeneSrc$ plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . @GeneSrc$ and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	1
32867562	2353	D000544	False	2	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( @GeneSrc$ , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	407010	D000544	False	1	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , @GeneSrc$ , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	100302255	D000544	False	2	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( @GeneSrc$ , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 73 71|73 73 77 77 73 73 73 73 73 73 73 73 87 87 73 73 68 68 93 93 90 95 93 95 101 97 101 101 95 95 105 105 90 109 109 109 90 67 113 113 115 115 115 118 118 115 121 121 118 123 121 123 123 123 123 123 121 121 133 133 130 133 136 133 133 133 140 133 143 143 118 143 143 115 148 148 151 151 148 153 148 155 156 153 148 159 148 161 159 164 164 161 166 164 166|167 148 177 169 169 169 169 175 173 177 177 179 177 177 182 177 184 182 187 187 184 177 213 193 193 193 189 195 193 195 195 195 195 195 195 195 195 195 195 209 209 209 195 213 213 213 213 213 216 213 216 220 220 217 213 226 222 222 222 226 226 226 230 228 230 230 226 237 237 237 226 239 237 239 243 243 239 246 246 243 226 249 251 251 251 255 255 253 251 255 255 259 260 255 262 255 251 267 267 267 267 270 270 267 273 273 270 273 277 277 274 277 281 281 277 267 284 286 286 286 288 286 292 292 292 288 295 295 292 292 298 288 302 302 302 298 304 298 286	0
32867562	627	D000544	False	2	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and @GeneSrc$ ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . @GeneSrc$ and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	1385	D000544	False	2	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , @GeneSrc$ , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	4137	D000544	True	0	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating @GeneSrc$ protein levels and is important for preventing @GeneSrc$ protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	1
32867562	6622	D000544	False	3	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and @GeneSrc$ , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	407011	D000544	False	1	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , @GeneSrc$ ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	23405	D000544	False	1	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and @GeneSrc$ , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	2624	D000544	False	3	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by @GeneSrc$ , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	1958	D000544	False	2	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , hsa-miR-361 - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , @GeneSrc$ , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32867562	494323	D000544	False	2	Music-listening regulates human microRNA expression . Music-listening and performance have been shown to affect human gene expression . In order to further elucidate the biological basis of the effects of music on the human body , we studied the effects of music-listening on gene regulation by sequencing microRNAs of the listeners ( Music Group ) and their controls ( Control Group ) without music exposure . We identified upregulation of six microRNAs ( hsa-miR-132 - 3p , @GeneSrc$ - 5p , hsa-miR-421 , hsa-miR-23a-3p , hsa-miR-23b-3p , hsa-miR-25 - 3p ) and downregulation of two microRNAs ( hsa-miR-378a-3p , hsa-miR-16 - 2 - 3p ) in Music Group with high musical aptitude . Some upregulated microRNAs were reported to be responsive to neuronal activity ( miR-132 , miR-23a , miR-23b ) and modulators of neuronal plasticity , CNS myelination , and cognitive functions like long-term potentiation and memory . miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes @DiseaseTgt$ . miR-132 and DICER , upregulated after music-listening , protect dopaminergic neurons and are important for retaining striatal dopamine levels . Some of the transcriptional regulators ( FOS , CREB1 , JUN , EGR1 , and BDNF ) of the upregulated microRNAs were immediate early genes and top candidates associated with musical traits . BDNF and SNCA , co-expressed and upregulated in music-listening and music-performance , are both are activated by GATA2 , which is associated with musical aptitude . Several miRNAs were associated with song-learning , singing , and seasonal plasticity networks in songbirds . We did not detect any significant changes in microRNA expressions associated with music education or low musical aptitude . Our data thereby show the importance of inherent musical aptitude for music appreciation and for eliciting the human microRNA response to music-listening .	1 1 4 4 1 1 11 6 6 11 11 11 13 11 16 16 13 11 22 18 22 22 37 25 25 22 28 28 25 30 28 34 34 34 28 22 37 37 39 37 41 39 44 44 39 46 37 46 50 50 47 53 53 50 53 50 57 50 60 60 57 60 64 64 46 37 67 67 67 71 71 68 75 75 75 71 75 79 79 75 75 75 75 75 75 75 75 89 89 75 75 68 68 95 95 92 97 95 97 103 99 103 103 97 97 107 107 92 111 111 111 92 67 115 115 117 117 117 120 120 117 123 123 120 125 123 125 125 125 125 125 123 123 135 135 132 135 138 135 135 135 142 135 145 145 120 145 145 117 150 150 153 153 150 155 150 157 158 155 150 161 150 163 161 166 166 163 168 166 168|169 150 179 171 171 171 171 177 175 179 179 181 179 179 184 179 186 184 189 189 186 179 215 195 195 195 191 197 195 197 197 197 197 197 197 197 197 197 197 211 211 211 197 215 215 215 215 215 218 215 218 222 222 219 215 228 224 224 224 228 228 228 232 230 232 232 228 239 239 239 228 241 239 241 245 245 241 248 248 245 228 251 253 253 253 257 257 255 253 257 257 261 262 257 264 257 253 269 269 269 269 272 272 269 275 275 272 275 279 279 276 279 283 283 279 269 286 288 288 288 290 288 294 294 294 290 297 297 294 294 300 290 304 304 304 300 306 300 288	0
32485097	6647	D019636	True	0	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer 's disease . @DiseaseTgt$ are a growing burden , and there is an urgent need for better biomarkers for diagnosis , prognosis , and treatment efficacy . Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid ( CSF ) . Alzheimer 's disease ( AD ) patients have higher CSF levels of tau , but we lack knowledge of systems-wide changes of CSF protein levels that accompany AD . Here , we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts . From three independent studies ( 197 individuals ) , we characterize differences in proteins by AD status ( > 1,000 proteins , CV < 20 % ) . Proteins with previous links to @DiseaseTgt$ such as tau , @GeneSrc$ , and PARK7 differed most strongly by AD status , providing strong positive controls for our approach . CSF proteome changes in Alzheimer 's disease prove to be widespread and often correlated with tau concentrations . Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study . Machine learning suggests clinical utility of this proteomic signature .	1 5 4 4 1 5 7 5 11 11 11 7 5 13|17 17 17 17 17 17 17 21 17 24 24 21 27 27 24 29 27 29 29 29 29 35 29 21 41 37 37 41 43 43 43 47 47 47 43 50 50 47 52 50 52 43 57 57 61 59 57 59 62 62 65 65 62 67 65 62 62 71 62 71 75 75 72 79 78 79 75 81 79 81 71 87 87 87 87 92 90 92 92 95 94 95 87 99 99 99 87 101 99 105 105 105 99 87 110 110 110 117 113 113 110 113 117 117 117 117 120 118 123 123 117 127 127 127 123 127 130 127 132 127 127 117 149 138 138 135 140 138 143 141 140 143 143 143 143 149 149 151 149 154 154 149 149 149 159 157 156 162 162 156 149 166 166 171 170 170 170 166 171 174 174 171 174 174 174 180 180 177 171 184 184 186 186 186 190 190 188 186 193 193 190 193 197 197 193 186 200 201 201 203 201 207 207 207 203 201	0
32485097	6647	D000544	True	0	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of @DiseaseTgt$ . Neurodegenerative diseases are a growing burden , and there is an urgent need for better biomarkers for diagnosis , prognosis , and treatment efficacy . Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid ( CSF ) . @DiseaseTgt$ ( @DiseaseTgt$ ) patients have higher CSF levels of tau , but we lack knowledge of systems-wide changes of CSF protein levels that accompany @DiseaseTgt$ . Here , we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts . From three independent studies ( 197 individuals ) , we characterize differences in proteins by @DiseaseTgt$ status ( > 1,000 proteins , CV < 20 % ) . Proteins with previous links to neurodegeneration such as tau , @GeneSrc$ , and PARK7 differed most strongly by @DiseaseTgt$ status , providing strong positive controls for our approach . CSF proteome changes in @DiseaseTgt$ prove to be widespread and often correlated with tau concentrations . Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study . Machine learning suggests clinical utility of this proteomic signature .	1 5 4 4 1 5 7 5 9 9|7 5 12 16 16 16 16 16 16 16 20 16 23 23 20 26 26 23 28 26 28 28 28 28 34 28 20 40 36 36 40 42 42 42 46 46 46 42 49 49 46 51 49 51 42 54|58 56 54 56 59 59 62 62 59 64 62 59 59 68 59 68 72 72 69 76 75 76 72 78 76 78 68 84 84 84 84 89 87 89 89 92 91 92 84 96 96 96 84 98 96 102 102 102 96 84 107 107 107 114 110 110 107 110 114 114 114 114 117 115 120 120 114 124 124 124 120 124 127 124 129 124 124 114 146 135 135 132 137 135 140 138 137 140 140 140 140 146 146 148 146 151 151 146 146 146 156 154 153 159 159 153 146 163 163 166 165 163|165 166 169 169 166 169 169 169 175 175 172 166 179 179 181 181 181 185 185 183 181 188 188 185 188 192 192 188 181 195 196 196 198 196 202 202 202 198 196	0
32485097	4137	D000544	True	0	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of @DiseaseTgt$ . Neurodegenerative diseases are a growing burden , and there is an urgent need for better biomarkers for diagnosis , prognosis , and treatment efficacy . Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid ( CSF ) . @DiseaseTgt$ ( @DiseaseTgt$ ) patients have higher CSF levels of @GeneSrc$ , but we lack knowledge of systems-wide changes of CSF protein levels that accompany @DiseaseTgt$ . Here , we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts . From three independent studies ( 197 individuals ) , we characterize differences in proteins by @DiseaseTgt$ status ( > 1,000 proteins , CV < 20 % ) . Proteins with previous links to neurodegeneration such as @GeneSrc$ , SOD1 , and PARK7 differed most strongly by @DiseaseTgt$ status , providing strong positive controls for our approach . CSF proteome changes in @DiseaseTgt$ prove to be widespread and often correlated with @GeneSrc$ concentrations . Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study . Machine learning suggests clinical utility of this proteomic signature .	1 5 4 4 1 5 7 5 9 9|7 5 12 16 16 16 16 16 16 16 20 16 23 23 20 26 26 23 28 26 28 28 28 28 34 28 20 40 36 36 40 42 42 42 46 46 46 42 49 49 46 51 49 51 42 54|58 56 54 56 59 59 62 62 59 64 62 59 59 68 59 68 72 72 69 76 75 76 72 78 76 78 68 84 84 84 84 89 87 89 89 92 91 92 84 96 96 96 84 98 96 102 102 102 96 84 107 107 107 114 110 110 107 110 114 114 114 114 117 115 120 120 114 124 124 124 120 124 127 124 129 124 124 114 146 135 135 132 137 135 140 138 137 140 140 140 140 146 146 148 146 151 151 146 146 146 156 154 153 159 159 153 146 163 163 166 165 163|165 166 169 169 166 169 169 169 175 175 172 166 179 179 181 181 181 185 185 183 181 188 188 185 188 192 192 188 181 195 196 196 198 196 202 202 202 198 196	0
32485097	11315	D000544	True	0	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of @DiseaseTgt$ . Neurodegenerative diseases are a growing burden , and there is an urgent need for better biomarkers for diagnosis , prognosis , and treatment efficacy . Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid ( CSF ) . @DiseaseTgt$ ( @DiseaseTgt$ ) patients have higher CSF levels of tau , but we lack knowledge of systems-wide changes of CSF protein levels that accompany @DiseaseTgt$ . Here , we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts . From three independent studies ( 197 individuals ) , we characterize differences in proteins by @DiseaseTgt$ status ( > 1,000 proteins , CV < 20 % ) . Proteins with previous links to neurodegeneration such as tau , SOD1 , and @GeneSrc$ differed most strongly by @DiseaseTgt$ status , providing strong positive controls for our approach . CSF proteome changes in @DiseaseTgt$ prove to be widespread and often correlated with tau concentrations . Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study . Machine learning suggests clinical utility of this proteomic signature .	1 5 4 4 1 5 7 5 9 9|7 5 12 16 16 16 16 16 16 16 20 16 23 23 20 26 26 23 28 26 28 28 28 28 34 28 20 40 36 36 40 42 42 42 46 46 46 42 49 49 46 51 49 51 42 54|58 56 54 56 59 59 62 62 59 64 62 59 59 68 59 68 72 72 69 76 75 76 72 78 76 78 68 84 84 84 84 89 87 89 89 92 91 92 84 96 96 96 84 98 96 102 102 102 96 84 107 107 107 114 110 110 107 110 114 114 114 114 117 115 120 120 114 124 124 124 120 124 127 124 129 124 124 114 146 135 135 132 137 135 140 138 137 140 140 140 140 146 146 148 146 151 151 146 146 146 156 154 153 159 159 153 146 163 163 166 165 163|165 166 169 169 166 169 169 169 175 175 172 166 179 179 181 181 181 185 185 183 181 188 188 185 188 192 192 188 181 195 196 196 198 196 202 202 202 198 196	0
32485097	4137	D019636	True	0	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer 's disease . @DiseaseTgt$ are a growing burden , and there is an urgent need for better biomarkers for diagnosis , prognosis , and treatment efficacy . Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid ( CSF ) . Alzheimer 's disease ( AD ) patients have higher CSF levels of @GeneSrc$ , but we lack knowledge of systems-wide changes of CSF protein levels that accompany AD . Here , we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts . From three independent studies ( 197 individuals ) , we characterize differences in proteins by AD status ( > 1,000 proteins , CV < 20 % ) . Proteins with previous links to @DiseaseTgt$ such as @GeneSrc$ , SOD1 , and PARK7 differed most strongly by AD status , providing strong positive controls for our approach . CSF proteome changes in Alzheimer 's disease prove to be widespread and often correlated with @GeneSrc$ concentrations . Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study . Machine learning suggests clinical utility of this proteomic signature .	1 5 4 4 1 5 7 5 11 11 11 7 5 13|17 17 17 17 17 17 17 21 17 24 24 21 27 27 24 29 27 29 29 29 29 35 29 21 41 37 37 41 43 43 43 47 47 47 43 50 50 47 52 50 52 43 57 57 61 59 57 59 62 62 65 65 62 67 65 62 62 71 62 71 75 75 72 79 78 79 75 81 79 81 71 87 87 87 87 92 90 92 92 95 94 95 87 99 99 99 87 101 99 105 105 105 99 87 110 110 110 117 113 113 110 113 117 117 117 117 120 118 123 123 117 127 127 127 123 127 130 127 132 127 127 117 149 138 138 135 140 138 143 141 140 143 143 143 143 149 149 151 149 154 154 149 149 149 159 157 156 162 162 156 149 166 166 171 170 170 170 166 171 174 174 171 174 174 174 180 180 177 171 184 184 186 186 186 190 190 188 186 193 193 190 193 197 197 193 186 200 201 201 203 201 207 207 207 203 201	0
32485097	11315	D019636	True	0	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer 's disease . @DiseaseTgt$ are a growing burden , and there is an urgent need for better biomarkers for diagnosis , prognosis , and treatment efficacy . Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid ( CSF ) . Alzheimer 's disease ( AD ) patients have higher CSF levels of tau , but we lack knowledge of systems-wide changes of CSF protein levels that accompany AD . Here , we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts . From three independent studies ( 197 individuals ) , we characterize differences in proteins by AD status ( > 1,000 proteins , CV < 20 % ) . Proteins with previous links to @DiseaseTgt$ such as tau , SOD1 , and @GeneSrc$ differed most strongly by AD status , providing strong positive controls for our approach . CSF proteome changes in Alzheimer 's disease prove to be widespread and often correlated with tau concentrations . Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study . Machine learning suggests clinical utility of this proteomic signature .	1 5 4 4 1 5 7 5 11 11 11 7 5 13|17 17 17 17 17 17 17 21 17 24 24 21 27 27 24 29 27 29 29 29 29 35 29 21 41 37 37 41 43 43 43 47 47 47 43 50 50 47 52 50 52 43 57 57 61 59 57 59 62 62 65 65 62 67 65 62 62 71 62 71 75 75 72 79 78 79 75 81 79 81 71 87 87 87 87 92 90 92 92 95 94 95 87 99 99 99 87 101 99 105 105 105 99 87 110 110 110 117 113 113 110 113 117 117 117 117 120 118 123 123 117 127 127 127 123 127 130 127 132 127 127 117 149 138 138 135 140 138 143 141 140 143 143 143 143 149 149 151 149 154 154 149 149 149 159 157 156 162 162 156 149 166 166 171 170 170 170 166 171 174 174 171 174 174 174 180 180 177 171 184 184 186 186 186 190 190 188 186 193 193 190 193 197 197 193 186 200 201 201 203 201 207 207 207 203 201	0
34428276	4137	D009410	False	1	Amyloid-beta toxicity modulates @GeneSrc$ phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of @GeneSrc$ protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and @GeneSrc$ hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced @DiseaseTgt$ , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in @GeneSrc$ hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of @GeneSrc$ at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and @GeneSrc$ pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	1869	D000544	False	1	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and @GeneSrc$ , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates @GeneSrc$ , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both @GeneSrc$ and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	2931	D000544	False	3	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of @GeneSrc$ , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to @GeneSrc$ activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	18508	D000544	False	1	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of @GeneSrc$ protects against amyloid-beta peptide-induced neuronal death , suggesting that @GeneSrc$ is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of @GeneSrc$ and c-Myb , while @GeneSrc$ is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , @GeneSrc$ directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and @GeneSrc$ , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	18508	D003643	True	0	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of @GeneSrc$ protects against amyloid-beta peptide-induced neuronal death , suggesting that @GeneSrc$ is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of @GeneSrc$ and c-Myb , while @GeneSrc$ is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , @GeneSrc$ directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors c-Myb and @GeneSrc$ , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	18508	D009410	True	0	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of @GeneSrc$ protects against amyloid-beta peptide-induced @DiseaseTgt$ , suggesting that @GeneSrc$ is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of @GeneSrc$ and c-Myb , while @GeneSrc$ is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , @GeneSrc$ directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and @GeneSrc$ , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	5080	D009410	False	1	Amyloid-beta toxicity modulates tau phosphorylation through the @GeneSrc$ signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that @GeneSrc$ , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced @DiseaseTgt$ , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	5080	D064420	True	0	Amyloid-beta @DiseaseTgt$ modulates tau phosphorylation through the @GeneSrc$ signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that @GeneSrc$ , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta @DiseaseTgt$ pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	2931	D003643	True	0	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of @GeneSrc$ , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors c-Myb and PAX6 , leading to @GeneSrc$ activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	5080	D003643	False	4	Amyloid-beta toxicity modulates tau phosphorylation through the @GeneSrc$ signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that @GeneSrc$ , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	2931	D064420	False	2	Amyloid-beta @DiseaseTgt$ modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta @DiseaseTgt$ pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of @GeneSrc$ , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to @GeneSrc$ activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	4137	D003643	True	0	Amyloid-beta toxicity modulates @GeneSrc$ phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of @GeneSrc$ protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and @GeneSrc$ hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in @GeneSrc$ hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of @GeneSrc$ at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and @GeneSrc$ pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	351	D003643	False	2	@GeneSrc$ toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between @GeneSrc$ plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that @GeneSrc$ peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of @GeneSrc$ cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between @GeneSrc$ and tau hyperphosphorylation . Downregulation of PAX6 protects against @GeneSrc$ peptide-induced neuronal death , suggesting that PAX6 is a key executor of the @GeneSrc$ toxicity pathway . Mechanistically , @GeneSrc$ upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	5925	D064420	False	3	Amyloid-beta @DiseaseTgt$ modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta @DiseaseTgt$ pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	4137	D064420	True	0	Amyloid-beta @DiseaseTgt$ modulates @GeneSrc$ phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of @GeneSrc$ protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and @GeneSrc$ hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta @DiseaseTgt$ pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in @GeneSrc$ hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of @GeneSrc$ at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and @GeneSrc$ pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	5925	D003643	True	0	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	5925	D009410	False	3	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced @DiseaseTgt$ , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	1869	D064420	False	1	Amyloid-beta @DiseaseTgt$ modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and @GeneSrc$ , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta @DiseaseTgt$ pathway . Mechanistically , amyloid-beta upregulates @GeneSrc$ , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both @GeneSrc$ and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	5080	D000544	True	0	Amyloid-beta toxicity modulates tau phosphorylation through the @GeneSrc$ signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that @GeneSrc$ , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	351	D064420	True	0	@GeneSrc$ @DiseaseTgt$ modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between @GeneSrc$ plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that @GeneSrc$ peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of @GeneSrc$ cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between @GeneSrc$ and tau hyperphosphorylation . Downregulation of PAX6 protects against @GeneSrc$ peptide-induced neuronal death , suggesting that PAX6 is a key executor of the @GeneSrc$ @DiseaseTgt$ pathway . Mechanistically , @GeneSrc$ upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	4602	D003643	True	0	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and @GeneSrc$ , while Pax6 is a direct target for both E2F1 and its downstream target @GeneSrc$ . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors @GeneSrc$ and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	4137	D000544	True	0	Amyloid-beta toxicity modulates @GeneSrc$ phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of @GeneSrc$ protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between amyloid-beta and @GeneSrc$ hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in @GeneSrc$ hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of @GeneSrc$ at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and @GeneSrc$ pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	2931	D009410	False	2	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced @DiseaseTgt$ , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of @GeneSrc$ , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to @GeneSrc$ activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	18508	D064420	True	0	Amyloid-beta @DiseaseTgt$ modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of @GeneSrc$ protects against amyloid-beta peptide-induced neuronal death , suggesting that @GeneSrc$ is a key executor of the amyloid-beta @DiseaseTgt$ pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of @GeneSrc$ and c-Myb , while @GeneSrc$ is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , @GeneSrc$ directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and @GeneSrc$ , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	4602	D000544	False	2	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and @GeneSrc$ , while Pax6 is a direct target for both E2F1 and its downstream target @GeneSrc$ . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors @GeneSrc$ and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	351	D000544	True	0	@GeneSrc$ toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between @GeneSrc$ plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that @GeneSrc$ peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of @GeneSrc$ cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between @GeneSrc$ and tau hyperphosphorylation . Downregulation of PAX6 protects against @GeneSrc$ peptide-induced neuronal death , suggesting that PAX6 is a key executor of the @GeneSrc$ toxicity pathway . Mechanistically , @GeneSrc$ upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	5925	D000544	False	4	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of @DiseaseTgt$ , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with @DiseaseTgt$ and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 30 16 16 13 16 19 16 19 24 24 24 13 26 24|26 24 30 30 30 30 33 34 34 38 37 38 34 40 38 44 44 44 40 44 48 48 44 48 49 48 38 38 55 53 58 58 55 34 72 72 64 64 72 64 70 70 70 70 65 72 72 72 77 77 77 77 97 97 79 83 83 79 83 86 84 86 89 86 92 92 83 94 92 79 97 77 100 100 97 102 100 104 102|104 102 109 109 109 102 97 97 97 115 115 112 117 112 117 117 117 77 125 124 122 125 130 130 130 130 125 125 125 138 138 138 138 138 132 143 143 143 143 138 125 148 148 148 148 148 148 148 154 154 151 156 154 156 156 148 165 165 165 165 165 148 168 168 165 168 173 172 173 168 148 179 179 179 179 179 179 182 180 182 185 182 185 189 189 186 189 193 193 189 179 179 197 179 199 197 201 197 201 201 203 201 179 208 211 211 211 211 218 214 218 216 214 216 211 221 221 218 223 218 226 226 223 226 227 227 223 218 234 234 231 234 237 234 218 218 242 242 239 245 245 242 211	0
34428276	351	D009410	True	0	@GeneSrc$ toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between @GeneSrc$ plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that @GeneSrc$ peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of @GeneSrc$ cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between @GeneSrc$ and tau hyperphosphorylation . Downregulation of PAX6 protects against @GeneSrc$ peptide-induced @DiseaseTgt$ , suggesting that PAX6 is a key executor of the @GeneSrc$ toxicity pathway . Mechanistically , @GeneSrc$ upregulates E2F1 , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both E2F1 and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	4602	D009410	False	1	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced @DiseaseTgt$ , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and @GeneSrc$ , while Pax6 is a direct target for both E2F1 and its downstream target @GeneSrc$ . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors @GeneSrc$ and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	1869	D009410	False	1	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and @GeneSrc$ , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced @DiseaseTgt$ , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates @GeneSrc$ , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both @GeneSrc$ and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal death signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 133 133 133 129|133 129 129 141 141 141 141 141 135 146 146 146 146 141 129 151 151 151 151 151 151 151 157 157 154 159 157 159 159 151 168 168 168 168 168 151 171 171 168 171 176 175 176 171 151 182 182 182 182 182 182 185 183 185 188 185 188 192 192 189 192 196 196 192 182 182 200 182 202 200 204 200 204 204 206 204 182 211 214 214 214 214 221 217 221 219 217 219 214 224 224 221 226 221 229 229 226 229 230 230 226 221 237 237 234 237 240 237 221 221 245 245 242 248 248 245 214	0
34428276	1869	D003643	True	0	Amyloid-beta toxicity modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and @GeneSrc$ , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta toxicity pathway . Mechanistically , amyloid-beta upregulates @GeneSrc$ , followed by the induction of PAX6 and c-Myb , while Pax6 is a direct target for both @GeneSrc$ and its downstream target c-Myb . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include @GeneSrc$ modulate neuronal @DiseaseTgt$ signals by activating downstream transcription factors c-Myb and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
34428276	4602	D064420	False	1	Amyloid-beta @DiseaseTgt$ modulates tau phosphorylation through the PAX6 signalling pathway . The molecular link between amyloid-beta plaques and neurofibrillary tangles , the two pathological hallmarks of Alzheimer 's disease , is still unclear . Increasing evidence suggests that amyloid-beta peptide activates multiple regulators of cell cycle pathways , including transcription factors CDKs and E2F1 , leading to hyperphosphorylation of tau protein . However , the exact pathways downstream of amyloid-beta-induced cell cycle imbalance are unknown . Here , we show that PAX6 , a transcription factor essential for eye and brain development which is quiescent in adults , is increased in the brains of patients with Alzheimer 's disease and in APP transgenic mice , and plays a key role between amyloid-beta and tau hyperphosphorylation . Downregulation of PAX6 protects against amyloid-beta peptide-induced neuronal death , suggesting that PAX6 is a key executor of the amyloid-beta @DiseaseTgt$ pathway . Mechanistically , amyloid-beta upregulates E2F1 , followed by the induction of PAX6 and @GeneSrc$ , while Pax6 is a direct target for both E2F1 and its downstream target @GeneSrc$ . Furthermore , PAX6 directly regulates transcription of GSK-3beta , a kinase involved in tau hyperphosphorylation and neurofibrillary tangles formation , and its phosphorylation of tau at Ser356 , Ser396 and Ser404 . In conclusion , we show that signalling pathways that include CDK/pRB/E2F1 modulate neuronal death signals by activating downstream transcription factors @GeneSrc$ and PAX6 , leading to GSK-3beta activation and tau pathology , providing novel potential targets for pharmaceutical intervention .	1 2 2 4 2 9 9 9 9 2 2 13 13 32 16 16 13 16 19 16 19 24 24 24 13 28 28 28 24 24 32 32 32 32 35 36 36 40 39 40 36 42 40 46 46 46 42 46 50 50 46 50 51 50 40 40 57 55 60 60 57 36 74 74 66 66 74 66 72 72 72 72 67 74 74 74 79 79 79 79 99 99 81 85 85 81 85 88 86 88 91 88 94 94 85 96 94 81 99 79 102 102 99 104 102 108 108 108 104 104 113 113 113 104 99 99 99 119 119 116 121 116 121 121 121 79 129 128 126 129 134 134 134 134 129 129 129 142 142 142 142 142 136 147 147 147 147 142 129 152 152 152 152 152 152 152 158 158 155 160 158 160 160 152 169 169 169 169 169 152 172 172 169 172 177 176 177 172 152 183 183 183 183 183 183 186 184 186 189 186 189 193 193 190 193 197 197 193 183 183 201 183 203 201 205 201 205 205 207 205 183 212 215 215 215 215 222 218 222 220 218 220 215 225 225 222 227 222 230 230 227 230 231 231 227 222 238 238 235 238 241 238 222 222 246 246 243 249 249 246 215	0
31462605	351	D064420	True	0	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( @GeneSrc$ ) causes neurotoxicity and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by @GeneSrc$ . When @GeneSrc$ and DDC had been preincubated for 3 h , the aggregation of @GeneSrc$ was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on @GeneSrc$ @DiseaseTgt$ . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect @GeneSrc$ neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of @GeneSrc$ and inhibits neuronal death induced by @GeneSrc$ , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 87 87 87 87 87 87 87 87 87 83 87 85 83 87 72 51 92 92 92 92 94 92 96 94 100 100 100 94 100 103 101 92 111 111 106 106 111 111 122 114 114 111 122 117 122 119 117 122 122 122 122 126 126 129 129 129 129 132 132 129 135 135 132 138 138 132 129 146 142 140 145 145 140 146 148 146 151 151 148 153 151 153 146 146 159 159 146 162 162 159 166 166 166 162 146 173 173 173 173 173 173 176 176 173 178 173 181 181 178 173 184 185 185 188 188 185 190 188 192 190 188 188 196 194 196 199 197 188 188 204 204 188 207 207 204 213 210 213 213 213 188 216 216 213 185	0
31462605	3162	D003072	False	6	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and @DiseaseTgt$ in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of @GeneSrc$ ( @GeneSrc$ ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 27|25 31 31 31 25 33 31 33 24 37 40 40 40 40 43 43 40 45 43 40 50 50 50 50 63 63 54 52 54 52 58 52 61 61 58 52 50 65 63 68 68 65 71 71 63 86 86 86 86 86 86 86 86 86 82 86 84 82 86 71 50 91 91 91 91 93 91 95 93 99 99 99 93 99 102 100 91 110 110 105 105 110 110 121 113 113 110 121 116 121 118 116 121 121 121 121 125 125 128 128 128 128 131 131 128 134 134 131 137 137 131 128 145 141 139 144 144 139 145 147 145 149 147|149 151 149 151 145 145 157 157 145 160 160 157 164 164 164 160 145 171 171 171 171 171 171 174 174 171 176 171 179 179 176 171 182 183 183 186 186 183 188 186 190 188 186 186 194 192 194 197 195 186 186 202 202 186 205 205 202 211 208 211 211 211 186 214 214 211 183	0
31462605	3162	D009410	False	1	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical @DiseaseTgt$ induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of @GeneSrc$ ( @GeneSrc$ ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect Abeta-induced @DiseaseTgt$ under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits @DiseaseTgt$ induced by Abeta , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 87 87 87 87 87 87 87 87 87 83 87 85 83 87 72 51 92 92 92 92 94 92 96 94 99 99 99|94 99 102 100 92 110 110 105 105 110 110 121 113 113 110 121 116 121 118 116 121 121 121 121 125 125 128 128 128 128 131 131 128 134 134 131 137 137 131 128 145 141 139 144 144 139 145 147 145 149 147|149 151 149 151 145 145 157 157 145 160 160 157 164 164 164 160 145 171 171 171 171 171 171 173 171|173 175 171 178 178 175 171 181 182 182 185 185 182 187 185 189 187 185 185 191|192 192 195 193 185 185 200 200 185 203 203 200 209 206 209 209 209 185 212 212 209 182	0
31462605	351	D000544	True	0	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( @GeneSrc$ ) causes neurotoxicity and cognitive impairment in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress is closely related to the pathogenesis of @DiseaseTgt$ . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by @GeneSrc$ . When @GeneSrc$ and DDC had been preincubated for 3 h , the aggregation of @GeneSrc$ was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on @GeneSrc$ cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect @GeneSrc$ neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of @GeneSrc$ and inhibits neuronal death induced by @GeneSrc$ , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 30 30|25 32 30 32 24 36 39 39 39 39 42 42 39 44 42 39 49 49 49 49 62 62 53 51 53 51 57 51 60 60 57 51 49 64 62 67 67 64 70 70 62 85 85 85 85 85 85 85 85 85 81 85 83 81 85 70 49 90 90 90 90 92 90 94 92 98 98 98 92 98 101 99 90 109 109 104 104 109 109 120 112 112 109 120 115 120 117 115 120 120 120 120 124 124 127 127 127 127 130 130 127 133 133 130 136 136 130 127 144 140 138 143 143 138 144 146 144 149 149 146 151 149 151 144 144 157 157 144 160 160 157 164 164 164 160 144 171 171 171 171 171 171 174 174 171 176 171 179 179 176 171 182 183 183 186 186 183 188 186 190 188 186 186 194 192 194 197 195 186 186 202 202 186 205 205 202 211 208 211 211 211 186 214 214 211 183	1
31462605	3162	D020258	False	6	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced @DiseaseTgt$ in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes @DiseaseTgt$ and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of @GeneSrc$ ( @GeneSrc$ ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 87 87 87 87 87 87 87 87 87 83 87 85 83 87 72 51 92 92 92 92 94 92 96 94 100 100 100 94 100 103 101 92 111 111 106 106 111 111 122 114 114 111 122 117 122 119 117 122 122 122 122 126 126 129 129 129 129 132 132 129 135 135 132 138 138 132 129 146 142 140 145 145 140 146 148 146 150 148|150 152 150 152 146 146 158 158 146 161 161 158 165 165 165 161 146 172 172 172 172 172 172 175 175 172 177 172 180 180 177 172 183 184 184 187 187 184 189 187 191 189 187 187 195 193 195 198 196 187 187 203 203 187 206 206 203 212 209 212 212 212 187 215 215 212 184	0
31462605	3162	D064420	False	1	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced @DiseaseTgt$ . Treatment with DDC for 24 h increased the expression of @GeneSrc$ ( @GeneSrc$ ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 87 87 87 87 87 87 87 87 87 83 87 85 83 87 72 51 92 92 92 92 94 92 96 94 100 100 100 94 100 103 101 92 111 111 106 106 111 111 122 114 114 111 122 117 122 119 117 122 122 122 122 126 126 129 129 129 129 132 132 129 135 135 132 138 138 132 129 146 142 140 145 145 140 146 148 146 150 148|150 152 150 152 146 146 158 158 146 161 161 158 165 165 165 161 146 172 172 172 172 172 172 175 175 172 177 172 180 180 177 172 183 184 184 187 187 184 189 187 191 189 187 187 195 193 195 198 196 187 187 203 203 187 206 206 203 212 209 212 212 212 187 215 215 212 184	0
31462605	4780	D003072	False	2	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and @DiseaseTgt$ in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the @GeneSrc$ @GeneSrc$ response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the @GeneSrc$ pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the @GeneSrc$ pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 27|25 31 31 31 25 33 31 33 24 37 40 40 40 40 43 43 40 45 43 40 50 50 50 50 63 63 54 52 54 52 58 52 61 61 58 52 50 65 63 68 68 65 71 71 63 81 81 81 81 77 81 79 77 81 71 50 86 86 86 86 88 86 90 88 94 94 94 88 94 97 95 86 105 105 100 100 105 105 116 108 108 105 116 111 116 113 111 116 116 116 116 120 120 123 123 123 123 126 126 123 129 129 126 132 132 126 123 140 136 134 139 139 134 140 142 140 145 145 142 147 145 147 140 140 153 153 140 156 156 153 160 160 160 156 140 167 167 167 167 167 167 170 170 167 172 167 175 175 172 167 178 179 179 182 182 179 184 182 186 184 182 182 190 188 190 193 191 182 182 198 198 182 201 201 198 207 204 207 207 207 182 210 210 207 179	0
31462605	4780	D000544	False	1	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and cognitive impairment in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress is closely related to the pathogenesis of @DiseaseTgt$ . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the @GeneSrc$ @GeneSrc$ response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the @GeneSrc$ pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the @GeneSrc$ pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 30 30|25 32 30 32 24 36 39 39 39 39 42 42 39 44 42 39 49 49 49 49 62 62 53 51 53 51 57 51 60 60 57 51 49 64 62 67 67 64 70 70 62 80 80 80 80 76 80 78 76 80 70 49 85 85 85 85 87 85 89 87 93 93 93 87 93 96 94 85 104 104 99 99 104 104 115 107 107 104 115 110 115 112 110 115 115 115 115 119 119 122 122 122 122 125 125 122 128 128 125 131 131 125 122 139 135 133 138 138 133 139 141 139 144 144 141 146 144 146 139 139 152 152 139 155 155 152 159 159 159 155 139 166 166 166 166 166 166 169 169 166 171 166 174 174 171 166 177 178 178 181 181 178 183 181 185 183 181 181 189 187 189 192 190 181 181 197 197 181 200 200 197 206 203 206 206 206 181 209 209 206 178	0
31462605	351	D009410	True	0	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( @GeneSrc$ ) causes neurotoxicity and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical @DiseaseTgt$ induced by @GeneSrc$ . When @GeneSrc$ and DDC had been preincubated for 3 h , the aggregation of @GeneSrc$ was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on @GeneSrc$ cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect @GeneSrc$ @DiseaseTgt$ under any of these conditions . These results suggest that DDC prevents the aggregation of @GeneSrc$ and inhibits @DiseaseTgt$ induced by @GeneSrc$ , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 87 87 87 87 87 87 87 87 87 83 87 85 83 87 72 51 92 92 92 92 94 92 96 94 99 99 99|94 99 102 100 92 110 110 105 105 110 110 121 113 113 110 121 116 121 118 116 121 121 121 121 125 125 128 128 128 128 131 131 128 134 134 131 137 137 131 128 145 141 139 144 144 139 145 147 145 150 150 147 152 150 152 145 145 158 158 145 161 161 158 165 165 165 161 145 172 172 172 172 172 172 174 172|174 176 172 179 179 176 172 182 183 183 186 186 183 188 186 190 188 186 186 192|193 193 196 194 186 186 201 201 186 204 204 201 210 207 210 210 210 186 213 213 210 183	0
31462605	3162	D000544	False	5	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and cognitive impairment in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress is closely related to the pathogenesis of @DiseaseTgt$ . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of @GeneSrc$ ( @GeneSrc$ ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 30 30|25 32 30 32 24 36 39 39 39 39 42 42 39 44 42 39 49 49 49 49 62 62 53 51 53 51 57 51 60 60 57 51 49 64 62 67 67 64 70 70 62 85 85 85 85 85 85 85 85 85 81 85 83 81 85 70 49 90 90 90 90 92 90 94 92 98 98 98 92 98 101 99 90 109 109 104 104 109 109 120 112 112 109 120 115 120 117 115 120 120 120 120 124 124 127 127 127 127 130 130 127 133 133 130 136 136 130 127 144 140 138 143 143 138 144 146 144 148 146|148 150 148 150 144 144 156 156 144 159 159 156 163 163 163 159 144 170 170 170 170 170 170 173 173 170 175 170 178 178 175 170 181 182 182 185 185 182 187 185 189 187 185 185 193 191 193 196 194 185 185 201 201 185 204 204 201 210 207 210 210 210 185 213 213 210 182	0
31462605	351	D003072	True	0	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( @GeneSrc$ ) causes neurotoxicity and @DiseaseTgt$ in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by @GeneSrc$ . When @GeneSrc$ and DDC had been preincubated for 3 h , the aggregation of @GeneSrc$ was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on @GeneSrc$ cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect @GeneSrc$ neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of @GeneSrc$ and inhibits neuronal death induced by @GeneSrc$ , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 27|25 31 31 31 25 33 31 33 24 37 40 40 40 40 43 43 40 45 43 40 50 50 50 50 63 63 54 52 54 52 58 52 61 61 58 52 50 65 63 68 68 65 71 71 63 86 86 86 86 86 86 86 86 86 82 86 84 82 86 71 50 91 91 91 91 93 91 95 93 99 99 99 93 99 102 100 91 110 110 105 105 110 110 121 113 113 110 121 116 121 118 116 121 121 121 121 125 125 128 128 128 128 131 131 128 134 134 131 137 137 131 128 145 141 139 144 144 139 145 147 145 150 150 147 152 150 152 145 145 158 158 145 161 161 158 165 165 165 161 145 172 172 172 172 172 172 175 175 172 177 172 180 180 177 172 183 184 184 187 187 184 189 187 191 189 187 187 195 193 195 198 196 187 187 203 203 187 206 206 203 212 209 212 212 212 187 215 215 212 184	1
31462605	4780	D064420	False	1	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the @GeneSrc$ @GeneSrc$ response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced @DiseaseTgt$ . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the @GeneSrc$ pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the @GeneSrc$ pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 82 82 82 82 78 82 80 78 82 72 51 87 87 87 87 89 87 91 89 95 95 95 89 95 98 96 87 106 106 101 101 106 106 117 109 109 106 117 112 117 114 112 117 117 117 117 121 121 124 124 124 124 127 127 124 130 130 127 133 133 127 124 141 137 135 140 140 135 141 143 141 146 146 143 148 146 148 141 141 154 154 141 157 157 154 161 161 161 157 141 168 168 168 168 168 168 171 171 168 173 168 176 176 173 168 179 180 180 183 183 180 185 183 187 185 183 183 191 189 191 194 192 183 183 199 199 183 202 202 199 208 205 208 208 208 183 211 211 208 180	0
31462605	4780	D020258	False	2	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced @DiseaseTgt$ in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes @DiseaseTgt$ and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the @GeneSrc$ @GeneSrc$ response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the @GeneSrc$ pathway . However , DDC did not affect Abeta-induced neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits neuronal death induced by Abeta , and although it activates the @GeneSrc$ pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 82 82 82 82 78 82 80 78 82 72 51 87 87 87 87 89 87 91 89 95 95 95 89 95 98 96 87 106 106 101 101 106 106 117 109 109 106 117 112 117 114 112 117 117 117 117 121 121 124 124 124 124 127 127 124 130 130 127 133 133 127 124 141 137 135 140 140 135 141 143 141 146 146 143 148 146 148 141 141 154 154 141 157 157 154 161 161 161 157 141 168 168 168 168 168 168 171 171 168 173 168 176 176 173 168 179 180 180 183 183 180 185 183 187 185 183 183 191 189 191 194 192 183 183 199 199 183 202 202 199 208 205 208 208 208 183 211 211 208 180	0
31462605	351	D020258	True	0	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced @DiseaseTgt$ in Primary Cortical Neurons . Amyloid beta protein ( @GeneSrc$ ) causes @DiseaseTgt$ and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical neuronal death induced by @GeneSrc$ . When @GeneSrc$ and DDC had been preincubated for 3 h , the aggregation of @GeneSrc$ was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on @GeneSrc$ cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the Nrf2-ARE pathway . However , DDC did not affect @GeneSrc$ neuronal death under any of these conditions . These results suggest that DDC prevents the aggregation of @GeneSrc$ and inhibits neuronal death induced by @GeneSrc$ , and although it activates the Nrf2-ARE pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 87 87 87 87 87 87 87 87 87 83 87 85 83 87 72 51 92 92 92 92 94 92 96 94 100 100 100 94 100 103 101 92 111 111 106 106 111 111 122 114 114 111 122 117 122 119 117 122 122 122 122 126 126 129 129 129 129 132 132 129 135 135 132 138 138 132 129 146 142 140 145 145 140 146 148 146 151 151 148 153 151 153 146 146 159 159 146 162 162 159 166 166 166 162 146 173 173 173 173 173 173 176 176 173 178 173 181 181 178 173 184 185 185 188 188 185 190 188 192 190 188 188 196 194 196 199 197 188 188 204 204 188 207 207 204 213 210 213 213 213 188 216 216 213 185	1
31462605	4780	D009410	True	0	Protective Effect of Green Perilla-Derived Chalcone Derivative DDC on Amyloid beta Protein-Induced Neurotoxicity in Primary Cortical Neurons . Amyloid beta protein ( Abeta ) causes neurotoxicity and cognitive impairment in Alzheimer 's disease ( AD ) . Oxidative stress is closely related to the pathogenesis of AD . We have previously reported that 2',3'-dihydroxy-4',6'-dimethoxychalcone ( DDC ) , a component of green perilla , enhances cellular resistance to oxidative damage through the activation of the @GeneSrc$ @GeneSrc$ response element ( ARE ) pathway . Here , we investigated the effects of DDC on cortical @DiseaseTgt$ induced by Abeta . When Abeta and DDC had been preincubated for 3 h , the aggregation of Abeta was significantly suppressed . In this condition , we found that DDC provided a neuroprotective action on Abeta-induced cytotoxicity . Treatment with DDC for 24 h increased the expression of heme oxygenase-1 ( HO-1 ) , and this was controlled by the activation of the @GeneSrc$ pathway . However , DDC did not affect Abeta-induced @DiseaseTgt$ under any of these conditions . These results suggest that DDC prevents the aggregation of Abeta and inhibits @DiseaseTgt$ induced by Abeta , and although it activates the @GeneSrc$ pathway , this mechanism is less involved its neuroprotective effect .	1 1 7 7 7 7 7 1 12 10 11 12 1 16 16 16 12 1 20 20 24 22 20 22 24 24 25 28 25 32 32 32 25 34 32 34 24 38 41 41 41 41 44 44 41 46 44 41 51 51 51 51 64 64 55 53 55 53 59 53 62 62 59 53 51 66 64 69 69 66 72 72 64 82 82 82 82 78 82 80 78 82 72 51 87 87 87 87 89 87 91 89 94 94 94|89 94 97 95 87 105 105 100 100 105 105 116 108 108 105 116 111 116 113 111 116 116 116 116 120 120 123 123 123 123 126 126 123 129 129 126 132 132 126 123 140 136 134 139 139 134 140 142 140 145 145 142 147 145 147 140 140 153 153 140 156 156 153 160 160 160 156 140 167 167 167 167 167 167 169 167|169 171 167 174 174 171 167 177 178 178 181 181 178 183 181 185 183 181 181 187|188 188 191 189 181 181 196 196 181 199 199 196 205 202 205 205 205 181 208 208 205 178	0
17508937	1351	D009369	True	0	Small-scale immunopurification of cytochrome c oxidase for a high-throughput multiplexing analysis of enzyme activity and amount . @GeneSrc$ ( cytochrome c oxidase ) deficiency is one of the main causes of genetic mitochondrial disease and presents with multiple phenotypes , depending on whether the causative mutation exists in a mitochondrial or nuclear gene and on whether it involves an altered catalytic or structural component or an assembly factor for this membrane-embedded 13-subunit enzyme complex . @GeneSrc$ deficiency is routinely observed in AD ( Alzheimer 's disease ) , although there is continuing debate about whether this is a causative or a secondary consequence of the condition . Altered levels of @GeneSrc$ and reduced oxidative phosphorylation capacity have been reported in other common diseases , including @DiseaseTgt$ , and are seen as unwanted side effects in a number of drug treatments , particularly with antiretroviral and antibiotic treatments . Here , we introduce a simple , rapid , high-throughput 96-well plate protocol that uses a multiplex approach to determine the amount and activity of @GeneSrc$ , which should find widespread use in evaluating the above diseases and in drug safety studies . Importantly , the method uses very small amounts of cell material or tissue and does not require the isolation of mitochondria . We show the utility of this approach by example of the analysis of fibroblasts from patients with @GeneSrc$ activity deficiency and the effect of the antiretroviral drug ddC ( 2',3'-dideoxycytidine ) on the biogenesis of the enzyme .	1 1 5 5 5 1 10 10 10 10 1 13 13 10 13 13 1 23 23 23 21 23 23 25 25 25 29 29 29 25 33 33 33 29 25 25 38 38 35 25 46 46 46 45 45 46 25 52 52 52 49 49 46 52 57 57 57 46 60 60 57 60 60 60 63 67 67 60 73 73 73 73 73 60 25 76 79 79 79 79 81 79 85 85 83 81 85 79 90 90 79 92 90 98 98 98 98 98 92 98 102 102 98 105 105 102 79 108 112 110 108 110 112 115 115 112 118 118 112 122 122 122 118 122 125 122 118 118 129 118 133 133 133 129 136 136 129 139 139 136 139 146 146 146 143 143 129 112 151 151 151 151 160 160 155 153 155 155 160 160 151 162 160 165 165 162 167 165 169 167 169 169 173 169 173 177 177 169 179 177 181 179 184 184 181 184 189 188 189 184 151 195 195 194 195 195 197 198 195 201 201 198 201 201 195 207 207 195 209 207 211 209 195 214 214 216 214 219 219 216 221 216 224 224 221 226 224 228 226 232 232 232 228 228 235 226 240 240 240 240 235 242 240 242 246 246 216 249 249 246 214	0
17508937	1351	D000544	True	0	Small-scale immunopurification of cytochrome c oxidase for a high-throughput multiplexing analysis of enzyme activity and amount . @GeneSrc$ ( cytochrome c oxidase ) deficiency is one of the main causes of genetic mitochondrial disease and presents with multiple phenotypes , depending on whether the causative mutation exists in a mitochondrial or nuclear gene and on whether it involves an altered catalytic or structural component or an assembly factor for this membrane-embedded 13-subunit enzyme complex . @GeneSrc$ deficiency is routinely observed in @DiseaseTgt$ ( @DiseaseTgt$ ) , although there is continuing debate about whether this is a causative or a secondary consequence of the condition . Altered levels of @GeneSrc$ and reduced oxidative phosphorylation capacity have been reported in other common diseases , including cancer , and are seen as unwanted side effects in a number of drug treatments , particularly with antiretroviral and antibiotic treatments . Here , we introduce a simple , rapid , high-throughput 96-well plate protocol that uses a multiplex approach to determine the amount and activity of @GeneSrc$ , which should find widespread use in evaluating the above diseases and in drug safety studies . Importantly , the method uses very small amounts of cell material or tissue and does not require the isolation of mitochondria . We show the utility of this approach by example of the analysis of fibroblasts from patients with @GeneSrc$ activity deficiency and the effect of the antiretroviral drug ddC ( 2',3'-dideoxycytidine ) on the biogenesis of the enzyme .	1 1 5 5 5 1 10 10 10 10 1 13 13 10 13 13 1 23 23 23 21 23 23 25 25 25 29 29 29 25 33 33 33 29 25 25 38 38 35 25 46 46 46 45 45 46 25 52 52 52 49 49 46 52 57 57 57 46 60 60 57 60 60 60 63 67 67 60 73 73 73 73 73 60 25 76 79 79 79 79 81 79 83 83|81 83 79 88 88 79 90 88 96 96 96 96 96 90 96 100 100 96 103 103 100 79 106 110 108 106 108 110 113 113 110 116 116 110 120 120 120 116 120 123 120 116 116 127 116 131 131 131 127 134 134 127 137 137 134 137 144 144 144 141 141 127 110 149 149 149 149 158 158 153 151 153 153 158 158 149 160 158 163 163 160 165 163 167 165 167 167 171 167 171 175 175 167 177 175 179 177 182 182 179 182 187 186 187 182 149 193 193 192 193 193 195 196 193 199 199 196 199 199 193 205 205 193 207 205 209 207 193 212 212 214 212 217 217 214 219 214 222 222 219 224 222 226 224 230 230 230 226 226 233 224 238 238 238 238 233 240 238 240 244 244 214 247 247 244 212	0
17508937	1351	D030342	True	0	Small-scale immunopurification of cytochrome c oxidase for a high-throughput multiplexing analysis of enzyme activity and amount . @GeneSrc$ ( cytochrome c oxidase ) deficiency is one of the main causes of @DiseaseTgt$ and presents with multiple phenotypes , depending on whether the causative mutation exists in a mitochondrial or nuclear gene and on whether it involves an altered catalytic or structural component or an assembly factor for this membrane-embedded 13-subunit enzyme complex . @GeneSrc$ deficiency is routinely observed in AD ( Alzheimer 's disease ) , although there is continuing debate about whether this is a causative or a secondary consequence of the condition . Altered levels of @GeneSrc$ and reduced oxidative phosphorylation capacity have been reported in other common diseases , including cancer , and are seen as unwanted side effects in a number of drug treatments , particularly with antiretroviral and antibiotic treatments . Here , we introduce a simple , rapid , high-throughput 96-well plate protocol that uses a multiplex approach to determine the amount and activity of @GeneSrc$ , which should find widespread use in evaluating the above diseases and in drug safety studies . Importantly , the method uses very small amounts of cell material or tissue and does not require the isolation of mitochondria . We show the utility of this approach by example of the analysis of fibroblasts from patients with @GeneSrc$ activity deficiency and the effect of the antiretroviral drug ddC ( 2',3'-dideoxycytidine ) on the biogenesis of the enzyme .	1 1 5 5 5 1 10 10 10 10 1 13 13 10 13 13 1 23 23 23 21 23 23 25 25 25 29 29 29 25 31 29|31 25 25 36 36 33 25 44 44 44 43 43 44 25 50 50 50 47 47 44 50 55 55 55 44 58 58 55 58 58 58 61 65 65 58 71 71 71 71 71 58 25 74 77 77 77 77 79 77 83 83 81 79 83 77 88 88 77 90 88 96 96 96 96 96 90 96 100 100 96 103 103 100 77 106 110 108 106 108 110 113 113 110 116 116 110 120 120 120 116 120 123 120 116 116 127 116 131 131 131 127 134 134 127 137 137 134 137 144 144 144 141 141 127 110 149 149 149 149 158 158 153 151 153 153 158 158 149 160 158 163 163 160 165 163 167 165 167 167 171 167 171 175 175 167 177 175 179 177 182 182 179 182 187 186 187 182 149 193 193 192 193 193 195 196 193 199 199 196 199 199 193 205 205 193 207 205 209 207 193 212 212 214 212 217 217 214 219 214 222 222 219 224 222 226 224 230 230 230 226 226 233 224 238 238 238 238 233 240 238 240 244 244 214 247 247 244 212	1
9074397	1813	D000544	True	0	D2 dopamine receptor A1 allele in @DiseaseTgt$ and aging . BACKGROUND : The apolipoprotein E4 ( APOE*4 ) allele is a major risk factor for the common forms of late-onset @DiseaseTgt$ ( @DiseaseTgt$ ) , but does not account for all the genetic variation in late-onset @DiseaseTgt$ ; hence , other genetic markers must be examined . The @GeneSrc$ ( @GeneSrc$ allele is associated with abnormal brain function and decreased DRD2s . These receptors are decreased in hippocampus and amygdala in @DiseaseTgt$ , and allele frequencies may vary with age . OBJECTIVE : To study APOE and @GeneSrc$ genotypes in patients with @DiseaseTgt$ and cognitively intact controls of varying ages . DESIGN : The @GeneSrc$ and APOE genotypes were examined in 832 unrelated white subjects , including 554 patients with @DiseaseTgt$ ( 486 sporadic ; 68 familial ) and 278 controls . Logistic regressions tested A1 allele effects on disease status and age , and @GeneSrc$ linkage with @DiseaseTgt$ was investigated in 60 families with late-onset @DiseaseTgt$ . SETTING : University medical centers . SUBJECTS : Patients ( mean + /- SD age , 74.6 + /- 8.1 years ; range , 52 - 98 years ) had probable @DiseaseTgt$ , according to standard consensus diagnostic criteria ; controls ( mean + /- SD age , 69.2 + /- 8.6 years ; range , 50 - 93 years ) were cognitively intact . MAIN OUTCOME MEASURES : Disease status , age , and @GeneSrc$ linkage with @DiseaseTgt$ . RESULTS : No association between the @GeneSrc$ and APOE alleles was found , and the presence of the A1 allele did not increase the risk for @DiseaseTgt$ . There was also no evidence of linkage between @GeneSrc$ and @DiseaseTgt$ . Age analyses , including both patients and controls , indicated a decrease in A1 allele frequency with age . CONCLUSIONS : The A1 allele does not contribute to @DiseaseTgt$ risk , alone or in combination with the APOE*4 allele . The DRD2 A1 allele frequencies decrease with age in both patients and controls . Thus , studies of @GeneSrc$ disease association need to control for age .	4 4 4 4 4 6 4|6 6 6 4 10 10 18 18 18 18 18 18 23 23 23 23 23 10 27 27 27 23 30 30 27|30 32 30 32 23 23 38 38 23 43 43 43 43 38 46 46 43 10 55 55 52 52 55 55 55 10 10 61 61 61 61 63 63 63 67 67 67 63 63 63 69 63 73 75 75 75 77 75 77 77 81 75 75 75 85 87 87 75 89 87 87 91 91 94 91 98 95 95 94 100 94 102 100 100 105 106 100 109 109 106 91 111 111 114 119 114 114 114 119 111 124 124 124 124 119 124 128 128 124 130 128 133 133 128 133 136 133 136 133 140 133 111 143 144 144 147 147 144 150 150 147 150 150 150 150 156 150 158 156 160 144 163 163 160 166 166 163 144 168 168 172 172 168 168 174 174 197 178 176 178 176 182 176 176 176 176 176 188 176 176 176 190 194 194 195 190 176 174 199 197 197 206 201 206 205 206 197 206 206 210 208 210 197 214 231 214 214 216 214 220 214 220 220 222 226 226 227 220 220 231 231 231 231 235 235 235 235 238 235 238 238 238 238 244 238 246 238 235 248 248 251 259 254 254 251 254 254 254 259 248 259 259 263 270 267 267 267 263 270 270 259 272 270 274 272 248 277 277 277 280 277 282 280 284 282 284 284 277 289 297 289 293 293 289 293 293 289 297 299 297 303 303 303 299 305 299 297 307 307 311 311 314 314 314 307 317 317 314 317 320 317 322 317 326 326 326 322 307 332 332 332 332 333 333 335 333 338 338 333 338 338 333 349 349 349 348 348 348 344 349 351 349 353 351 349	0
9074397	348	D000544	True	0	D2 dopamine receptor A1 allele in @DiseaseTgt$ and aging . BACKGROUND : The @GeneSrc$ ( @GeneSrc$ ) allele is a major risk factor for the common forms of late-onset @DiseaseTgt$ ( @DiseaseTgt$ ) , but does not account for all the genetic variation in late-onset @DiseaseTgt$ ; hence , other genetic markers must be examined . The D2 dopamine receptor ( DRD2 ) A1 allele is associated with abnormal brain function and decreased DRD2s . These receptors are decreased in hippocampus and amygdala in @DiseaseTgt$ , and allele frequencies may vary with age . OBJECTIVE : To study @GeneSrc$ and DRD2 genotypes in patients with @DiseaseTgt$ and cognitively intact controls of varying ages . DESIGN : The DRD2 and @GeneSrc$ genotypes were examined in 832 unrelated white subjects , including 554 patients with @DiseaseTgt$ ( 486 sporadic ; 68 familial ) and 278 controls . Logistic regressions tested A1 allele effects on disease status and age , and DRD2 linkage with @DiseaseTgt$ was investigated in 60 families with late-onset @DiseaseTgt$ . SETTING : University medical centers . SUBJECTS : Patients ( mean + /- SD age , 74.6 + /- 8.1 years ; range , 52 - 98 years ) had probable @DiseaseTgt$ , according to standard consensus diagnostic criteria ; controls ( mean + /- SD age , 69.2 + /- 8.6 years ; range , 50 - 93 years ) were cognitively intact . MAIN OUTCOME MEASURES : Disease status , age , and DRD2 linkage with @DiseaseTgt$ . RESULTS : No association between the DRD2 and @GeneSrc$ alleles was found , and the presence of the A1 allele did not increase the risk for @DiseaseTgt$ . There was also no evidence of linkage between DRD2 and @DiseaseTgt$ . Age analyses , including both patients and controls , indicated a decrease in A1 allele frequency with age . CONCLUSIONS : The A1 allele does not contribute to @DiseaseTgt$ risk , alone or in combination with the @GeneSrc$ allele . The DRD2 A1 allele frequencies decrease with age in both patients and controls . Thus , studies of DRD2 disease association need to control for age .	4 4 4 4 4 6 4|6 6 6 4 10 10 17 17 17 17 17 22 22 22 22 22 10 26 26 26 22 29 29 26|29 31 29 31 22 22 37 37 22 42 42 42 42 37 45 45 42 10 54 54 51 51 54 54 54 10 10 64 64 64 64 64 64 64 64 66 66 66 70 70 70 66 66 66 72 66 76 78 78 78 80 78 80 80 84 78 78 78 88 90 90 78 92 90 90 94 94 97 94 101 98 98 97 103 97 105 103 103 108 109 103 112 112 109 94 114 114 117 122 117 117 117 122 114 127 127 127 127 122 127 131 131 127 133 131 136 136 131 136 139 136 139 136 143 136 114 146 147 147 150 150 147 153 153 150 153 153 153 153 159 153 161 159 163 147 166 166 163 169 169 166 147 171 171 175 175 171 171 177 177 200 181 179 181 179 185 179 179 179 179 179 191 179 179 179 193 197 197 198 193 179 177 202 200 200 209 204 209 208 209 200 209 209 213 211 213 200 217 234 217 217 219 217 223 217 223 223 225 229 229 230 223 223 234 234 234 234 238 238 238 238 241 238 241 241 241 241 247 241 249 241 238 251 251 254 262 257 257 254 257 257 257 262 251 262 262 266 273 270 270 270 266 273 273 262 275 273 277 275 251 280 280 280 283 280 285 283 287 285 287 287 280 292 300 292 296 296 292 296 296 292 300 302 300 306 306 306 302 308 302 300 310 310 314 314 317 317 317 310 320 320 317 320 323 320 325 320 329 329 329 325 310 335 335 335 335 336 336 338 336 341 341 336 341 341 336 352 352 352 351 351 351 347 352 354 352 356 354 352	1
35328025	51142	C564048	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as @GeneSrc$ , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	2629	C564048	True	0	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the @GeneSrc$ gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	1
35328025	1639	D010300	False	1	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , @GeneSrc$ , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	23400	D010300	False	1	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as @GeneSrc$ , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	25793	D010302	True	0	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , @GeneSrc$ , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	1
35328025	55737	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and @GeneSrc$ ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	26020	C564048	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , @GeneSrc$ , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	65018	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , @GeneSrc$ and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	25793	D010300	False	1	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , @GeneSrc$ , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	54832	D010302	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and @GeneSrc$ . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	65018	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , @GeneSrc$ and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	1
35328025	8867	D010300	False	1	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and @GeneSrc$ . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	26020	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , @GeneSrc$ , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	1639	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , @GeneSrc$ , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	8867	D010302	True	0	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and @GeneSrc$ . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	1
35328025	6622	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( @GeneSrc$ , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	8398	D010302	True	0	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , @GeneSrc$ , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	1
35328025	51142	D010302	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as @GeneSrc$ , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	2629	D010302	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the @GeneSrc$ gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	2629	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the @GeneSrc$ gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	1
35328025	29058	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , @GeneSrc$ , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	23400	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as @GeneSrc$ , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	11315	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and @GeneSrc$ ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	1
35328025	120892	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , @GeneSrc$ , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	6622	D010302	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( @GeneSrc$ , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	1
35328025	5071	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( @GeneSrc$ , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	7384	D010302	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , @GeneSrc$ , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	120892	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , @GeneSrc$ , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	1
35328025	55737	D010302	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and @GeneSrc$ ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	11315	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and @GeneSrc$ ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	65018	D010302	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , @GeneSrc$ and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	29058	C564048	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , @GeneSrc$ , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	7384	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , @GeneSrc$ , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	23400	D010302	True	0	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as @GeneSrc$ , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	1
35328025	9829	D010302	True	0	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , @GeneSrc$ , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	1
35328025	54832	C564048	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and @GeneSrc$ . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	6622	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( @GeneSrc$ , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	8398	D010300	False	1	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , @GeneSrc$ , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	1639	D010302	True	0	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , @GeneSrc$ , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	1
35328025	8867	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and @GeneSrc$ . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	8398	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , @GeneSrc$ , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	25793	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , @GeneSrc$ , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	26020	D010302	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , @GeneSrc$ , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	54832	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and @GeneSrc$ . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	120892	D010302	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , @GeneSrc$ , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	55737	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and @GeneSrc$ ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	1
35328025	5071	D010302	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( @GeneSrc$ , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	7384	C564048	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , @GeneSrc$ , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	11315	D010302	False	2	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and @GeneSrc$ ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	29058	D010302	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex @DiseaseTgt$ may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , @GeneSrc$ , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 128 128 128 124 122 140 140 135 132 132 140 140 140 140 140 140 142 140 145 143 142 145 145 145 145 145 145 145 145 145 145 145 140 165 165 161 165 165 165 165 165 169 169 167 165 169 173 171 169 173 173 173 173 173 173 173 173 173 165 187 187 187 187 189 187 192 192 189 196 196 196 189 196 199 187 201 199 201 208 208 208 205 208 202 208 211 199 215 215 215 211 199 199 219 199 222 222 219 187 225 225 232 230 230 228 232 232 225 234 232 234 234 234 232 232 241 239 244 244 241 246 244 248 246 250 248 246 246 255 255 252 225	0
35328025	5071	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( @GeneSrc$ , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	1
35328025	51142	D010300	True	0	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , DNAJC6 , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as @GeneSrc$ , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35328025	9829	C564048	False	1	Monogenic Parkinson 's Disease : Genotype , Phenotype , Pathophysiology , and Genetic Testing . Parkinson 's disease may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established Parkinson 's disease genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for Parkinson 's disease , and there have been major developments for @DiseaseTgt$ . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , @GeneSrc$ , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in Parkinson 's disease , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two Parkinson 's disease genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic Parkinson 's disease is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 3 1 3 3 3 5 5 7 7 5 5 5 5 3 17 17 20 20 20 20 25 25 24 25 20 27 25 27 33 33 32 30 25 35 33 20 20 42 41 41 38 20 45 45 42 42 49 49 52 52 52 52 55 55 52 58 58 52 60 58 60 60 60 60 60 60 71 71 68 68 60 52 77 77 74 77 78 78 81 81 78 83 81 83 83 83 83 83 83 81 93 93 81 95 93 95 95 97 97 95 78 113 113 113 108 108 108 104 113 113 113 113 113 117 117 115 113 113 113 122 122 113 124 122 126 126|124 122 138 138 133 130 130 138 138 138 138 138 138 140 138 143 141 140 143 143 143 143 143 143 143 143 143 143 143 138 163 163 159 163 163 163 163 163 167 167 165 163 167 171 169 167 171 171 171 171 171 171 171 171 171 163 185 185 185 185 187 185 190 190 187 194 194 194 187 194 197 185 199 197 199 206 206 206 203 206 200 206 209 197 213 213 213 209 197 197 217 197 220 220 217 185 223 223 230 228 228 226 230 230 223 232 230 232 232 232 230 230 239 237 242 242 239 244 242 246 244 248 246 244 244 253 253 250 223	0
35328025	9829	D010300	False	1	Monogenic @DiseaseTgt$ : Genotype , Phenotype , Pathophysiology , and Genetic Testing . @DiseaseTgt$ may be caused by a single pathogenic variant ( monogenic ) in 5 - 10 % of cases , but investigation of these disorders provides valuable pathophysiological insights . In this review , we discuss each genetic form with a focus on genotype , phenotype , pathophysiology , and the geographic and ethnic distribution . Well-established @DiseaseTgt$ genes include autosomal dominant forms ( SNCA , LRRK2 , and VPS35 ) and autosomal recessive forms ( PRKN , PINK1 and DJ1 ) . Furthermore , mutations in the GBA gene are a key risk factor for @DiseaseTgt$ , and there have been major developments for X-linked dystonia parkinsonism . Moreover , atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2 , DCTN1 , @GeneSrc$ , FBXO7 , PLA2G6 , and SYNJ1 . Furthermore , numerous genes have recently been implicated in @DiseaseTgt$ , such as CHCHD2 , LRP10 , TMEM230 , UQCRC1 , and VPS13C . Additionally , we discuss the role of heterozygous mutations in autosomal recessive genes , the effect of having mutations in two @DiseaseTgt$ genes , the outcome of deep brain stimulation , and the role of genetic testing . We highlight that monogenic @DiseaseTgt$ is influenced by ethnicity and geographical differences , reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes .	1 1 1 1 3 3 5 5 3 3 3 3 1 13|16 16 16 16 21 21 20 21 16 23 21 23 29 29 28 26 21 31 29 16 16 38 37 37 34 16 41 41 38 38 45 45 48 48 48 48 51 51 48 54 54 48 56 54 56 56 56 56 56 56 67 67 64 64 56 48 71 70|71 72 72 75 75 72 77 75 77 77 77 77 77 77 75 87 87 75 89 87 89 89 91 91 89 72 107 107 107 102 102 102 98 107 107 107 107 107 109 107|109 107 107 114 114 107 116 114 120 120 120 116 114 132 132 127 124 124 132 132 132 132 132 132 134 132 137 135 134 137 137 137 137 137 137 137 137 137 137 137 132 157 157 153 157 157 157 157 157 159 159|157 159 163 161 159 163 163 163 163 163 163 163 163 163 157 177 177 177 177 179 177 182 182 179 186 186 186 179 186 189 177 191 189 191 196 196 195|196 192 196 199 189 203 203 203 199 189 189 207 189 210 210 207 177 213 213 218 216 216|218 218 213 220 218 220 220 220 218 218 227 225 230 230 227 232 230 234 232 236 234 232 232 241 241 238 213	0
35986530	57526	D012640	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	57526	D020521	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	1000	D004827	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	0
35986530	6324	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6323	D008881	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	2566	D004827	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	0
35986530	2566	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6326	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	57526	D030342	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6324	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6324	D004827	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	0
35986530	57526	D004827	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	1
35986530	1000	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	1000	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	1000	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	2566	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	1000	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6326	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6324	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6812	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6812	D004827	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	0
35986530	6326	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6812	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6323	D000544	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6326	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6326	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6326	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6812	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6812	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	57526	D000544	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	1000	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6326	D004827	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	0
35986530	6812	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6324	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6323	D030342	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	2566	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	57526	D008881	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6324	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6323	D012640	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6323	D009422	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	2566	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and @GeneSrc$ , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	1000	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	6323	D004827	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	1
35986530	57526	D000069279	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6324	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6326	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , @GeneSrc$ , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6324	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in @GeneSrc$ , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	6323	D020521	False	4	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	1000	D000544	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and @DiseaseTgt$ . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and @GeneSrc$ have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 45|38 38 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D009422	False	3	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	348980	D030342	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of @DiseaseTgt$ . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 98 96|98 91 101 103 103 104 112 107 107 104 112 112 112 112 112 116 116 116 112 112 112 120 121 127 123 121 127 127 127 112 131 131 131 127 112 134 158 158 158 138 136 138 138 138 138 138 138 148 148 148 138 148 148 150 150 150 150 148 158 158 158 161 161 158 158 168 168 168 168 168 175 168 172 172 168 175 175 175 175 184 184 181 179 184 184 184 184 186 184 188 186 184 196 196 193 196 196 196 196 198 196 201 201 198 203 201 203 206 204 196 209 211 211 211 214 214 211 217 217 214 221 218 221 217 221 221 223 223 225 223 227 227 223 211 234 234 236 236 236 240 240 240 236 243 243 240 236 246 236 249 249 246 236 254 254 254 266 257 257 254 259 257 254 264 264 264 254 266 266 268 266 272 272 272 268 275 275 272 268 268 279 277 281 277 281 284 282 266	0
35986530	6812	D008881	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after @DiseaseTgt$ , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	348980	D020521	False	5	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , @DiseaseTgt$ , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 169 169 169 169 169 176 169 173 173 169 176 176 176 176 185 185 182 180 185 185 185 185 187 185 189 187 185 197 197 194 197 197 197 197 199 197 202 202 199 204 202 204 207 205 197 210 212 212 212 215 215 212 218 218 215 222 219 222 218 222 222 224 224 226 224 228 228 224 212 235 235 237 237 237 241 241 241 237 244 244 241 237 247 237 250 250 247 237 255 255 255 267 258 258 255 260 258 255 265 265 265 255 267 267 269 267 273 273 273 269 276 276 273 269 269 280 278 282 278 282 285 283 267	0
35986530	348980	D004827	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , @DiseaseTgt$ is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of @DiseaseTgt$ that are reported in children ; one of them is @DiseaseTgt$ . It is a neurological disorder of infants ' outset during the first year of life . @DiseaseTgt$ is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The @DiseaseTgt$ drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 54 52|54 57 57 52 59 57 50 64 63 61 65 65|50 50 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 83|88 88 88 87 88 88 88 93 92 93 88 96 96 93 88 99 101 101 102 110 105 105 102 110 110 110 110 110 114 114 114 110 110 110 118 119 125 121 119 125 125 125 110 129 129 129 125 110 132 156 156 156 136 134 136 136 136 136 136 136 146 146 146 136 146 146 148 148 148 148 146 156 156 156 159 159 156 156 166 166 166 166 166 173 166 170 170 166 173 173 173 173 182 182 179 177 182 182 182 182 184 182 186 184 182 194 194 191 194 194 194 194 196 194 199 199 196 201 199 201 204 202 194 207 209 209 209 212 212 209 215 215 212 219 216 219 215 219 219 221 221 223 221 225 225 221 209 232 232 234 234 234 238 238 238 234 241 241 238 234 244 234 247 247 244 234 252 252 252 264 255 255 252 257 255 252 262 262 262 252 264 264 266 264 270 270 270 266 273 273 270 266 266 277 275 279 275 279 282 280 264	0
35986530	348980	D000069279	False	1	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , @GeneSrc$ , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6323	D000069279	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the @GeneSrc$ gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a @DiseaseTgt$ and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 38 26 26 28 38 38 38 38 36 36 38 38 38 40 38 40 40 40 38 47 45 38 38 50 50 52 50 55 55 52 58 58 52 60 58 50 65 64 62 67 67 50 50 73 73 73 73 73 77 77 75 73 81 81 81 73 83 81 73 86 91 91 91 90 91 91 91 96 95 96 91 99 99 96 91 102 104 104 105 113 108 108 105 113 113 113 113 113 117 117 117 113 113 113 121 122 128 124 122 128 128 128 113 132 132 132 128 113 135 159 159 159 139 137 139 139 139 139 139 139 149 149 149 139 149 149 151 151 151 151 149 159 159 159 162 162 159 159 167 167 167 174|167 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0
35986530	6812	D012640	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of @DiseaseTgt$ . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent neurological disorder after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a neurological disorder of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the PCDH19 gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , @GeneSrc$ , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant @DiseaseTgt$ . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of @DiseaseTgt$ and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 17 17|15 0 24 19 24 24 24 36 24 24 26 36 36 36 36 34 34 36 36 36 38 36 38 38 38 36 45 43 36 36 48 48 50 48 53 53 50 56 56 50 58 56 48 63 62 60 65 65 48 48 71 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 273 271|273 267 267 277 275 279 275 279 282 280 265	0
35986530	57526	D009422	False	2	Genetics of Dravet Syndrome and its Targeted Therapy by Nanomedicine : A Roadmap for Future Treatment of Drug Resistant Seizures . According to the World Health Organization ( WHO ) , epilepsy is the 4th most prevalent @DiseaseTgt$ after migraine , stroke , and Alzheimer 's disease . There are numerous types of epileptic syndrome that are reported in children ; one of them is Dravet syndrome . It is a @DiseaseTgt$ of infants ' outset during the first year of life . Dravet syndrome is a genetically determined syndrome and the most studied form of genetic epilepsy . Nearly 70 - 80 % of its cases are due to genetic alterations in the SCN1A gene , and almost 16 % of cases are due to variations in the @GeneSrc$ gene . Besides that , mutations in SCN1B , SCN2A , and GABRG2 , including some novel genes , STXBP1 , HCN1 , and CDH2 have been observed in DS patients . It is a drug-resistant epileptic syndrome and its complete removal is still challenging . So , novel therapeutic techniques are being used to treat drug-resistant seizures . Recently , new strategies have been made to improve the neuron-specific targeting of AEDs encapsulated by nanocarriers . The nanocarriers will have a major contribution to nano-neuro medicines such as drug delivery , neuroimaging , neuroprotection , neurosurgery , and neuroregeneration . The nanotechnology-mediated techniques also have a fantastic success rate in gene therapy , as reported in recent years . The anti-epileptic drug delivery with the help of nanoparticles , at the targeted position , makes them applicable for the possible treatment of drug-resistant seizures and gives new hope to patients affected with it .	0 3 3 0 3 7 7 3 9 7 0 12 0 15 15 12 19 19 19 15 0 26 21 26 26 26 37 26 26 28 37 37 37 37 36 36 37 37 39 37 39 39 39 37 46 44 37 37 49 49 51 49 54 54 51 57 57 51 59 57 49 64 63 61 66 66 49 49 71 71 71 71 75 75 73 71 79 79 79 71 81 79 71 84 89 89 89 88 89 89 89 94 93 94 89 97 97 94 89 100 102 102 103 111 106 106 103 111 111 111 111 111 115 115 115 111 111 111 119 120 126 122 120 126 126 126 111 130 130 130 126 111 133 157 157 157 137 135 137 137 137 137 137 137 147 147 147 137 147 147 149 149 149 149 147 157 157 157 160 160 157 157 167 167 167 167 167 174 167 171 171 167 174 174 174 174 183 183 180 178 183 183 183 183 185 183 187 185 183 195 195 192 195 195 195 195 197 195 200 200 197 202 200 202 205 203 195 208 210 210 210 213 213 210 216 216 213 220 217 220 216 220 220 222 222 224 222 226 226 222 210 233 233 235 235 235 239 239 239 235 242 242 239 235 245 235 248 248 245 235 253 253 253 265 256 256 253 258 256 253 263 263 263 253 265 265 267 265 271 271 271 267 274 274 271 267 267 278 276 280 276 280 283 281 265	0